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ABSTRACT 
 
Since the pioneering works by E. P. Kennedy, E. H. Fischer, E. G. Krebs, E. W. 
Sutherland and W. D. Wosilait in 1950s [Cohen P., 2002], protein phospho-
rylation has stayed one of the most thoroughly studied and discussed topics of 
the natural sciences. Protein kinases, the enzymes catalyzing phosphorylation 
have been termed “the machines of life” for being involved in most processes of 
cell regulation; the aberrant signalling of protein kinases has been connected to 
a variety of diseases, including cancer, diabetes, and asthma. Consequently, an 
increasing amount of effort has been focussed on the investigation and impli-
cation of mechanisms responsible for the regulation of protein kinase activity, 
giving stimulus for the intense development of protein kinase inhibitors. 
  This thesis describes the focussed design and synthesis of a family of protein 
kinase inhibitors represented by conjugates of adenosine analogues and 
arginine-rich peptides (ARCs) targeted to the basophilic protein kinases. 
Structure-affinity relationship studies as well as crystallographic evidence have 
been used to guide the development process to yield new generations of ARC-
inhibitors, with most efficient compounds expressing subnanomolar affinity and 
tunable selectivity towards protein kinases of the AGC-group, including cyclic 
nucleotide-dependent protein kinases, pharmacologically important protein 
kinase B and Rho-dependent protein kinase. The remarkable inhibitory pro-
perties of ARCs in combination with their proteolytic stability and ability to 
penetrate the cell plasma membrane have enabled the successful application of 
ARC-1059 in vasoconstriction experiments via targeting cAMP/PKA and 
cGMP/PKG pathways in isolated rat arteries, which confirmed the potential of 
bisubstrate inhibitor strategy as a whole.  
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LITERATURE OVERVIEW 
 
1. Protein kinases 
 
1.1. General features 
 
Protein kinases (PKs) are enzymes that catalyze the phosphorylation reaction, 
i.e., the transfer of a -phosphoryl group from a donor (nucleotide, usually ATP 
[Bostrom et al., 2009; Shugar, 1996]) to an acceptor molecule (protein/peptide 
substrate) (Figure 1). As a result of phosphoryl transfer, a negative charge is 
incorporated into the hydroxyl-bearing side-chain of a Ser, Thr or Tyr residue of 
the substrate [Pinna and Ruzzene, 1996], and this relatively small change in the 
chemical composition of the prosphorylated amino acid triggers massive re-
arrangement of its neighboring microenvironment [Steichen et al., 2010]. The 
phosphorylation reaction thus serves as a molecular switch, causing a change of 
the protein substrate conformation and rendering its ability to participate in a 
variety of cellular processes, ranging from differentiation, transcription and 
apoptosis to  cytoskeletal rearrangement, cell movement and responsiveness to 
extracellular stimuli [Manning B. D. and Cantley, 2007; Shabb, 2001]. 
 
 
Figure 1. Scheme of protein phosphorylation. PK, protein kinase; PP, protein phosphatase. 
 
 
The spatiotemporal control of activity of PKs themselves is performed by seve-
ral mechanisms, including expression within a certain stage of cell cycle 
[Murray A. W., 2004], localization in  subcellular compartments [Tasken and 
Aandahl, 2004], positive or negative feedback-loops, etc. PKs participate in 
large intracellular information currents, all of them leading to a certain outcome 
event involving the examples provided below: 
  repetitive autophosphorylation and phosphorylation steps (i.e., PK cascades 
[Chang and Karin, 2001]);  
  intertwined signaling of PKs and protein phosphatases (PP, enzymes cata-
lyzing the hydrolytic removal of phosphoryl groups from protein substrates) 
[Pidoux and Tasken, 2010];  
  conjunction of PK functioning with gradients of activating secondary mes-
sengers or ligands [Wilson L. S. et al., 2008]. 
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Not surprisingly, taking advantage of the phosphorylation reaction as such and 
PKs as its catalyzing ’machinery’ for the sustainment of life is utilized through-
out the nature, both by prokaryotic [Leonard et al., 1998] and eukaryotic 
organisms [Lee J. and Rudd, 2002; Miranda-Saavedra et al., 2007]. In humans, 
518 PKs are encoded in genome, of which 40 are atypical and 50 predicted to 
be catalytically inactive due to the lack of at least one of the conserved catalytic 
residues [Hanks, 2003; Manning G. et al., 2002]. The efforts to systematize the 
set of human PKs (termed human kinome) on the basis of sequence comparison 
of PK catalytic and other domains, biological functions, and a similar classi-
fication of kinomes of other organisms, have resulted in generation of phylo-
genic maps, where PKs are divided into groups, families, and subfamilies 
[Invitrogen
TM Human Kinome Map; Kinnings and Jackson, 2009; Manning G. 
et al., 2002]. The main phylogenic groups of PKs are as follows [Manning G. et 
al., 2002; Parsons et al., 2005]:  
  AGC (containing members of PKA, PKG, and PKC families, which are 
often activated by second messengers and mostly phosphorylate substrates 
rich in basic amino acid residues);  
  CAMK (calcium/calmodulin-dependent PKs, which also frequently 
phosphorylate substrates rich in basic amino acid residues);  
  CMGC (containing members of CDK, MAPK, GSK3, and CLK families, 
which often phosphorylate substrates rich in Pro residues);  
  CK1 (casein kinase 1 family, which preferably phosphorylate motifs rich in 
acidic residues);  
  STE (homologs of yeast Sterile 7, Sterile 11, and Sterile 20 kinases, 
including PKs involved in MAPK activation and related kinases);  
  TK (tyrosine kinases, including receptor TKs and non-receptor TKs);  
  TKL (tyrosine kinase-like PKs, which share high domain similarity with 
TKs, but are Ser/Thr kinases). 
 
 
1.2. AGC-group PKs 
 
The term AGC-group was introduced by Steven Hanks and Tony Hunter in 
1995 to delimit PKs that share a high similarity of primary amino acid sequence 
in their catalytic kinase domains with cAMP-dependent PK (PKA), cGMP-
dependent PK (PKG), and protein kinase C (PKC) [Hanks and Hunter, 1995]. In 
humans, AGC-group contains 60 PKs, whereas the majority of members pos-
sess several isoforms and splice variants, further enhancing the diversity of this 
group. 
  Representatives of the AGC-group are activated downstream of a wide range 
of extracellular stimuli, and several levels of activity (i.e., basal, partial, or full) 
may exist, tuned through a variety of mechanisms. The full activation is usually 
acquired via the two following mechanisms: 14 
  (auto)phosphorylation of the two highly conserved regulatory motifs (the 
activation loop located inside the catalytic core and the hydrophobic motif 
positioned in a non-catalytic region following the kinase domain) [Smith J. 
A. et al., 1996; Steichen et al., 2010];  
  binding of one or more low-molecular weight messenger molecules (i.e., 
cyclic nucleotides, phospholipids, phosphoinositides, or members of Rho 
GTPase family) to the regulatory domain of PK [Liu P. et al., 2009; Poppe et 
al., 2008; Somlyo and Somlyo, 2000].  
In several cases, divalent cations (Mg
2+, Ca
2+) are also required for the catalytic 
functioning [Herberg et al., 1999; Lin X. et al., 2005]. 
  The majority of PKs of the AGC-group are the basophilic Ser/Thr PKs, 
meaning that they phosphorylate substrates on side-chains of Ser or Thr 
residues preferably flanked by basic amino acids (Lys or Arg; (Table 1) [Pearce 
et al., 2010]. Due to the similar consensus sequences of substrates, several 
AGC-group PKs can phosphorylate the same protein in vivo (i.e., PKB, RSK, 
PKA, PKC and S6K isoforms phosphorylate the same Ser residue at the N-
terminus of glycogen synthase kinase 3 [Frame and Cohen, 2001]), such cross-
reactivity demonstrating the importance and the scope of confluence in PK 
pathways. 
 
 
Table 1. Examples of substrate consensus sequences of AGC-group members (adapted 
from Pearce et al., 2010). 
 
Protein kinase Substrate consensus sequence 
a
PKAc  Arg-Arg-Xaa-Ser/Thr-Hyd
PKB  Arg-Xaa-Arg-Xaa-Xaa-Ser/Thr-Hyd
PKC (for isoform )  Arg-Lys-Xaa-Ser/Thr-Xaa-Arg/Lys
PKG  Arg/Lys2…3-Xaa-Ser/Thr
ROCK  Arg/Lys-Arg/Lys-Xaa-Ser/Thr
S6K  Arg/Lys-Xaa-Arg-Xaa-Xaa-Ser/Thr 
a The phosphorylatable residue (i.e., position P0) is indicated in bold; Hyd, amino acid 
with bulky hydrophobic side-chain; Xaa, any amino acid 
 
 
A brief review about the members of AGC-group within the scope of studies of 
the given thesis is given below. 
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1.2.1. PKA 
 
Since the beginning of the human kinome research era, PKA has been one of 
the most extensively studied PKs, both due to the importance of its signaling 
throughout the body systems and its attractive features as a model kinase (high 
expression and purification yield, good crystallization properties, activation by a 
comparatively uncomplicated mechanism, etc).  
  PKA is one of the major downstream effectors of the secondary messenger 
cAMP, and the “classical” PKA activation cascade involves several steps 
linking an extracellular event with an intracellular outcome (Figure 2; [Skal-
hegg et al., 2005]). Binding of a ligand to the extracellular part of a Gs-protein 
coupled receptor triggers conformational change, which is translated to the 
intracellular Gs-protein, causing substitution of GTP for GDP in the latter and 
subsequent dissociation of the activated Gs-protein into an -subunit and a -
heterodimer [Nelson et al., 2000]. The -subunit of Gs subsequently binds to 
and activates a member of adenylate cyclase (AC) family of transmembrane 
proteins, comprising nine closely related isoforms in mammals; alternatively, 
ACs can be directly activated by small-molecular weight compounds (i.e., 
forskolin) [Hanoune and Defer, 2001]. ACs then catalyze the conversion of 
ATP to cAMP, which in turn triggers several downstream events including the 
activation of the cyclic nucleotide-binding proteins PKA and EPAC [Cheng X. 
et al., 2008].  
  The PKA holoenzyme consists of two regulatory and two catalytic subunits; 
when cAMP binds cooperatively to the regulatory subunits of the PKA holo-
enzyme (two cAMP molecules per  regulatory subunit), the latter dissociates 
into a dimer of regulatory subunits (PKAr) and two catalytic subunits (PKAc) 
that represent the active form of PKA. It should be noted, however, that in order 
to become catalytically active, PKAc also requires phosphorylation at Thr197 
(performed by PDK1 in vivo) and autophosphorylation at Ser338.  
  In normal tissues, the ratio of the PKAr:PKAc molar concentrations is 
relatively constant, being kept close to unity [Hofmann et al., 1977]. Both 
regulatory and catalytic subunits of PKA are expressed as a variety of isoforms: 
PKArI, PKArI(with a molecular weight of 43–47 kDa), PKArIIand 
PKArII(molecular weight of 49–55 kDa), or PKAc, PKAc, PKAc, and 
PRKX (with a molecular weight of 40 kDa), respectively [Diskar et al., 2007; 
Skallhegg et al., 1998]. The two classes of PKA holoenzymes are designated 
type I and type II according to the type of regulatory subunits; the apparent 
activation constant of PKA holoenzymes type I by cAMP is 110 nM, while for 
PKA holoenzymes type II it is 180 nM [Diskar et al., 2007]. 16 
 
Figure 2. General scheme of PKAc activation and intracellular targeting. AC, adenylate 
cyclase; GPCR, G-protein coupled receptor; PDE, phosphodiestherase; PP, protein 
phosphatase. 
 
 
The region of PKAc where the regulatory subunits bind, partially coincides with 
the substrate-binding site of PKAc, and the regulatory subunits also contain the 
PKAc substrate consensus sequence [Taylor et al., 2008]. Indeed, PKArII 
subunits are autophosphorylated by PKAc, while PKArI subunits contain Ala 
moiety instead of the phosphorylatable Ser or Thr residue and are therefore not 
autophosphorylated [Smith C. M. et al., 1999]. Interestingly, the apparent acti-
vation constant of PKA holoenzymes containing phosphorylated PKArII is 
higher (340 nM) than for the non-phosphorylated form [Diskar et al., 2007]. 
Another difference between type I and type II subunits lies in the fact that 
PKArI subunits require the presence of MgATP for the tight binding to PKAc 
whereas PKArII do not; this phenomenon has also been attributed to the pre-
sence or absence of the phosphorylatable residue in the composition of the 
regulatory subunit [Skalhegg et al., 2005]. Overall, it has been demonstrated 
that the PKA holoenzyme type I is more sensitive to perturbations in the active 
site cleft and fixes PKAc in fully closed conformation that requires MgATP 
[Skalhegg et al., 2005]. Moreover, the alanine residue in the P0
1 position of 
                                                            
1  P0 position indicates the phosphorylatable residue of the substrate protein/peptide, 
or a residue corresponding to the phosphorylatable residue in the peptide substrate-
mimicking inhibitor. Positions of amino acids residing to the N-terminus of the 
substrate from the phosphorylatable residue are designated as P-1, P-2, etc., and the 
positions of amino acids residing to the C-terminus of the substrate as P+1, P+2, etc. 
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PKArI prevents complete dissociation of the PKA holoenzyme type I in the 
presence of cAMP in vivo (however, the affinity of PKArI towards PKAc is 
reduced almost 100-fold in the presence of cAMP)[Anand et al., 2010]. The 
PKA holoenzyme type II, on the other hand, is less sensitive towards changes in 
the catalytic core, and the autophosphorylated form of RII enables PKAc to 
adopt a half-closed conformation; upon activation with cAMP, the PKA 
holoenzyme type II becomes fully dissociated [Skalhegg et al., 2005]. 
The intracellular compartmentalization of the PKA holoenzyme is controlled 
by association of the regulatory subunits with A-kinase anchoring proteins 
(AKAPs) [Dibenedetto et al., 2008; Pidoux and Tasken, 2010]. Primarily, only 
RII-targeting AKAPs have been identified, hence the PKA holoenzyme type I 
was regarded mainly cytoplasmic; however, AKAPs for RI have also been 
subsequently discovered [Huang L. J. et al., 1997; Tasken and Aandahl, 2004]. 
Overall, AKAP family is represented in mammals by over 50 members; all of 
them contain a domain for binding PKAr subunits and a domain for directing the 
PKA holoenzyme-AKAP complex to subcellular structures, membranes, or 
organelles [Beene and Scott, 2007]. Moreover, AKAPs uphold the constitution of 
localized pools of cAMP-signalling, as in addition to PKA holoenzyme, AKAPs 
may bear binding domains also for phosphodiesterases (PDEs), which degrade 
cAMP, and even for PPs, which perform dephosphorylation [Pidoux and Tasken, 
2010]. In some cases, the complexity of such pools of cAMP-signalling is further 
enhanced by negative feedback loops triggered by cross-activation of PDEs (i.e., 
PDE3B, PDE4D3), deactivation of Gs protein-coupled receptors (i.e., D1-
dopamine receptor) or even conversion of Gs to Gi (i.e., in case of 2- adrenergic 
receptor) via PKAc-catalyzed phosphorylation [Shabb, 2001].  
PKAc dissociated from the holoenzyme may be located in the cytosol, or 
may enter the nucleus by passive diffusion through the pores in the nuclear 
envelope [Harootunian et al., 1993]. The re-location of PKAc back to the 
cytosol is mediated by the family of heat-stable protein kinase inhibitors (PKIs) 
[Wen  et al., 1995]. PKIs are proteins comprising 70...75 amino acids and 
consisting of two domains: an N-terminal protein kinase inhibition domain 
mimicking the substrate consensus sequence of PKAc, and a C-terminal nuclear 
export signal [Dalton and Dewey, 2006]. The nuclear export signal that is 
located within residues 37–46 of PKI contains several hydrophobic leucine 
residues; in PKAc-unbound state of PKI, these residues are 'masked' and PKI 
moves freely between the cytosol and the nucleus [Dalton and Dewey, 2006]. 
Upon binding of PKI kinase inhibitory domain to PKAc, the nuclear export 
signal of PKI becomes exposed, and the PKAc-PKI complex is transported back 
to the cytosol, where PKI further acts as a potent endogenous PKAc inhibitor. 
The latter function of PKI becomes especially important if reduction of PKAc 
activity in the presence of cAMP is required, as PKI does not  contain a cAMP-
binding domain and retains its inhibitory functions in the conditions where 
PKAr subunits are “switched off”. 
In the recent years, an increasing number of studies have provided evidence 
for another endogenous way of inhibition of PKAc that is retained in the 18 
presence of cAMP and is performed by the complex of nuclear factor-B 
(NFB) with the unphosphorylated form of its natural inhibitor (IB). The exact 
mechanism of this PKAc inhibition is unknown, although it has been suggested 
that IB masks the ATP-binding site of PKAc [Zhong et al., 1997]. The 
phosphorylation of IB catalyzed by IB kinase (stimulated by lipopolysaccha-
rides or by vasoactive peptides), by ROCK or by MEKK1 triggers proteosomal 
degradation of pIB and thus causes the release of active PKAc [Dulin et al., 
2001; Ma Y. et al., 2005; Profirovic et al., 2005; Sriwai et al., 2008]. 
PKA is an ubiquitous PK, being expressed in high concentration in several 
tissues (i.e., skeletal, cardiac, smooth muscle, adipose, brain, endocrine tissue, 
etc.); consequently, PKAc phosphorylates a large variety of substrates localized 
either in the cytosol, in the nucleus, or even in the extracellular environment in 
vivo [Shabb, 2001]. Historically, PKAc was discovered as an enzyme sti-
mulating glycogenolysis in muscle by phosphorylating cytosolic phosphorylase 
kinase, which in turn activates glycogen phosphorylase and thus triggers con-
version of glycogen to glucose-1-phosphate [Walsh et al., 1968]; PKAc further 
contributes to glycogenolysis by deactivating phosphorylation of glycogen 
synthase at Ser5 [Shabb, 2001]. PKAc also regulates metabolic processes in the 
liver by inhibition of glycolysis via deactivation of fructose-2,6-bisphosphatase 
and pyruvate kinase by PKAc-catalyzed phosphorylation at Ser32 and at Ser12, 
respectively [Shabb, 2001]. 
One of the most widely known PKA pathways in the nucleus involves 
phosphorylation of the cAMP response element-binding protein (CREB) at 
Ser133; in certain conditions, however, the phosphorylation of the same site can 
be performed by PKB [Du and Montminy, 1998], and phosphorylation of other 
sites (required for full activation of CREB) by Raf, MEK, or PKC [Johannessen 
and Moens, 2007]. Analogically, PKAc phosphorylates at Ser117 the homo-
logous CRE modulator (CREM) [Rosenberg et al., 2002]. Phosphorylated 
CREB (pCREB) binds subsequently the CREB-binding protein (CBP) that is a 
general transcriptional co-activator, and this interaction results in stimulation of 
the transcription [Rosenberg et al., 2002]. Similarly, transcription is activated as 
a result of PKAc-catalyzed phosphorylation of NF-B; however, PKAc may 
also inhibit transcriptional activity, as exemplified by PKAc-catalyzed de-
activating phosphorylation of the NFAT3 isoform [Shabb, 2001].  
The ubiquitous functions of PKAc also involve destabilization of actin 
cytoskeleton, and suppression of apoptosis; additionally, there are several 
tissue-specific physiological tasks, such as stimulation of lipolysis in adipose 
tissue, regulation of ion conductance and cardiovascular relaxation in smooth 
muscle, inhibition of platelet aggregation, inhibition of antigen-induced B- and 
T-cell activation, etc. [Shabb, 2001, Skalhegg et al., 2005, Hofmann et al., 
2009]. 
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1.2.2. PKG 
 
Along with PKA, another closely related member of the cyclic nucleotide-
dependent PK family is PKG (Figure 3), which represents one of the major 
effectors in the cGMP signaling. Mammals possess two PKG genes termed 
PKGI and PKGII [Hofmann et al., 2000; Smolenski et al., 1998], whereas 
PKGI is mainly located in the cytoplasm and PKGII is usually myristylated and 
anchored to the plasma membrane [Vaandrager et al., 2005]. The holoenzyme 
of PKGI is formed by N-terminal dimerization of monomeric chains; a mono-
meric chain has a molecular weight of 76 kDa and consists of several domains, 
including the N-terminal dimerization domain, autoinhibitory domain, regula-
tory domain carrying cGMP-binding sites, and catalytic domain bearing ATP- 
and protein/peptide substrate-binding sites [Hofmann et al., 2009].  
In the absence of cGMP, the PKGI holoenzyme is maintained in the basal 
state by association of the autoinhibitory domain of each monomer with the 
substrate-binding site located in the catalytic domain of the same chain; the 
basal activity of PKGI is surprisingly high, constituting 10% of the maximal 
activity, and it may be even more enhanced by autophosphorylation [Scholten et 
al., 2008]. According to the mass-spectrometric studies, PKGI has at least two 
major autophosphorylation sites, Thr516 in the activation loop and Thr84 in the 
N-terminal part of the protein, whereas more Ser/Thr sites within the amino acid 
region 26–84 have also been identified [Alverdi et al., 2008].  
 
 
 
 
Figure 3. Comparison of sequences of PKAc and PKGI. The catalytically important 
regions of PKs are coloured, the catalytic domain of PKGI is gray. 
 
 
PKAc [Bos taurus], PubMed NP_777009 
  1 mgnaaaakkg seqesvkefl akakedflkk wenpaqntah ldqferiktl gtgsfgrvml 
 61 vkhmetgnhy amkildkqkv vklkqiehtl nekrilqavn fpflvklefs fkdnsnlymv 
121 meyvpggemf shlrrigrfs epharfyaaq ivltfeylhs ldliyrdlkp enllidqqgy 
181 iqvtdfgfak rvkgrtwtlc gtpeylapei ilskgynkav dwwalgvliy emaagyppff 
241 adqpiqiyek ivsgkvrfps hfssdlkdll rnllqvdltk rfgnlkngvn diknhkwfat 
301 tdwiaiyqrk veapfipkfk gpgdtsnfdd yeeeeirvsi nekcgkefse f 
 
PKGI [Bos taurus], PubMed CAA70155 
  1 mseleedfak ilmlkeerik elekrlseke eeiqelkrkl hkcqsvlpvp sthigprttr 
 61 aqgisaepqt yrsfhdlrqa frkftksers kdlikeaild ndfmknlels qiqeivdcmy 
121 pveygkdsci ikegdvgslv yvmedgkvev tkegvklctm gpgkvfgela ilynctrtat 
181 vktlvnvklw aidrqcfqti mmrtglikht eymeflksvp tfqslpeeil skladvleet 
241 hyengeyiir qgargdtffi iskgkvnvtr edspnedpvf lrtlgkgdwf gekalqgedv 
301 rtanviaaea vtclvidrds fkhliggldd vsnkayedae akakyeaeaa ffanlklsdf 
361 niidtlgvgg fgrvelvqlk seesktfamk ilkkrhivdt rqqehirsek qimqgahsdf 
421 ivrlyrtfkd skylymlmea clggelwtil rdrgsfedst trfytacvve afaylhskgi 
481 iyrdlkpenl ildhrgyakl vdfgfakkig fgkktwtfcg tpeyvapeii lnkghdisad 
541 ywslgilmye lltgsppfsg pdpmktynii lrgidmiefp kkiaknaanl ikklcrdnps 
601 erlgnlkngv kdiqkhkwfe gfnweglrkg tltppiipsv asptdtsnfd sfpedndepp 
661 pddnsgwdid f 20 
PKGI is expressed in two splice variants, PKGI and PKGI that differ only in 
the 80–100 N-terminal amino acids; however, these structural variations cause 
substantial alterations of the cGMP binding pattern. While PKGI comprises a 
high- and a low-affinity cGMP-binding site (KD values towards cGMP of 
10 nM and 150 nM, respectively) interconnected by the positive cooperativity, 
PKGI has two low-affinity binding sites [Landgraf and Hofmann, 1989; Smith 
J. A. et al., 2000]. Both PKGI splice variants bind cGMP with ca 100-fold se-
lectivity over cAMP, as compared to only 50-fold selectivity of PKAr subunits 
towards cAMP over cGMP [Shabb and Corbin, 1992].  
  Analogically to cAMP/PKA pathway, the cGMP-PKGI signaling involves 
several positive and negative feedback loops connected to the production of 
cGMP from GTP, which might be connected either to the extracellular or to the 
intracellular event. In the first case, binding of natriuretic peptides to the 
transmembrane receptors NPRA and NPRB triggers receptor dimerization and 
induction of the intrinsic guanylyl cyclase (GC) activity, causing rapid increase 
in the intracellular cGMP concentration [Schultz et al., 1989; Wilson E. M. and 
Chinkers, 1995]. Importantly, activation of GC activity also requires phospho-
rylation of NPRA and NPRB prior to the ligand binding, and recent studies 
have shown that this phophorylation is catalyzed by PKGI [Airhart et al., 2003]. 
The second mechanism of cGMP production involves NO-induced activation of 
the soluble guanylyl cyclase (sGC); dependent on the level of NO production, 
sGC may function via tonic or via acute signaling mode, correspondingly 
resulting in long-lasting low-level cGMP production or in sharp burst of cGMP 
concentration [Cary et al., 2005].  
  The main responsibility for the amplitude and duration of the cGMP effect is 
controlled by the cyclic nucleotide phosphodiesterase PDE5, which selectively 
transforms cGMP into GMP. Interestingly, cGMP serves not only as a substrate 
but also as an activator of PDE5 [Rybalkin et al., 2003], whereas the longer-
lasting activation of PDE5 is achieved via PKGI-catalyzed phosphorylation at 
Ser92 [Rybalkin et al., 2002]; most likely, the former mechanism is utilized for 
cleavage of sharp burst of cGMP, whereas the latter is more important for the 
tonic dissimilation. The quick cleavage of local high gradients of cGMP neces-
sitates co-localization of GCs, PKGI, and PDE5; while in case of cAMP/PKA 
pathway the co-localization is achieved with the aid of AKAPs, the cor-
responding putative G-kinase anchoring proteins (GKAPs) have also been 
recently reported [Wilson L. S. et al., 2008]. Another way for the compart-
mentalization of PKG signaling is the association of the latter with cGMP-
producing NPRA or NPRB [Airhart et al., 2003], or the interaction of PKGI via 
its N-terminal leucine zipper domain with various substrates, including 
inositol(1,4,5)triphosphate (IP3) receptor-associated substrate (IRAG) [Desch et 
al., 2010; Schlossmann et al., 2000]. Interestingly, the latter is also responsible 
for the prevention of PKGI (but not PKGI) translocation to the nucleus in 
some cell types and suppression of PKGIβ transcriptional activity [Casteel et 
al., 2008]. 21 
  In the organism, PKGI is not as abundant as PKA, and is primarily found in 
the smooth muscles, platelets, lung, and cerebellum; PKGII, on the other hand 
prevails in the secretory epithelium of small intestine, juxta-glomerular cells, 
adrenal cortex, and several brain nuclei [Hofmann et al., 2009]. Despite notable 
variations in the amino acid composition of the C-terminal fragments ATP-
binding cleft and the surrounding loops, both cyclic nucleotide-dependent PKs 
have preference towards the similar substrate consensus sequences, and in some 
cases may phosphorylate the same substrates in vivo [Kumar and Walsh, 2002; 
Murthy  et al., 2003; Wood J. S. et al., 1996]. One of the most important 
physiological examples of tight confluence between cGMP/PKGI and cAMP/ 
PKA pathways is represented by the relaxation of vascular smooth muscle tone 
[Kuroki et al., 2007; Murthy, 2006; Muzaffar et al., 2008; Sanchez et al., 2008].  
  Smooth muscle contraction requires phosphorylation of Ser19 on the 20 kDa 
regulatory light chain of myosin II (MLC20); the initial contraction is performed 
by Ca
2+/calmodulin-dependent myosin light-chain kinase (MLCK) as a response 
to increase in concentration of cytosolic Ca
2+ [Murthy, 2006; Wooldridge et al., 
2004]. The mobilization of Ca
2+ is performed by several pathways, i.e., by IP3-
induced Ca
2+ release via IP3 receptors (IP3R-I)/Ca
2+ channels, or by arachidonic 
acid- and cyclic ADP ribose-induced Ca
2+ release via ryanodine receptors/Ca
2+ 
channels [Murthy, 2006]. As the initial rise of Ca
2+ concentration is rapidly 
dissipated and MLCK becomes inactivated, a Ca
2+-independent protein kinase 
is required to sustain the phosphorylation state of MLC20. Whereas this protein 
kinase has not yet been unambiguously identified (although ZIP kinase has been 
suggested as a candidate), it has been demonstrated that the sustained 
contraction is uphold by RhoA/Rho kinase (ROCK) pathway that prevents the 
dephosphorylation of MLC20 by MLC phosphatase (MYPT) [Murthy, 2006; 
Puetz et al., 2009]. All of the aforementioned pathways may be blocked by the 
cyclic nucleotide-dependent PKs, which impede the initial contraction (Scheme 
1) as well as sustained contraction of smooth muscle (Scheme 2) [Frei et al., 
2009; Wooldridge et al., 2004].  
  Other related functions of PKGI involve cardiac and vascular remodeling; 
additionally, PKGI mediates anti-aggregatory effect in platelets, regulates 
several processes in central nervous system, and transcriptional activity in some 
cellular systems [Hofmann et al., 2009]. PKGII, on the other hand, regulates 
gastrointestinal secretion, reduces renin secretion in juxta-glomerular cells, and 
is essential for the bone development [Hofmann et al., 2009]. 22 
 
 
Scheme 1. Relaxation of the initial (i.e., Ca
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Scheme 2. Relaxation of the sustained (i.e., Ca
2+-independent) contraction by PKGI and 
PKAc. 
 
 
1.2.3. ROCK 
 
A member of the AGC-group triggering physiological responses that often 
oppose those of cyclic nucleotides is ROCK, the principal mediator of the 
signaling pathways initiated by members of the Ras homolog gene family of 
small GTPases (RhoA or RhoE). ROCK has two isoforms, ROCK-I (ROCK) 
and ROCK-II (ROCK) that share 64% net sequence homology and possess a 
molecular weight of 160 kDa (Figure 4); both isoforms are activated by RhoA, 
but only ROCK-I may be activated by RhoE [Hahmann and Schroeter, 2010; 
LoGrasso and Feng, 2009]. In organism, ROCK is ubiquitously expressed, 
whereas ROCK-I is more prominent in lung, liver, spleen, kidneys, and testes, 
and ROCK-II expression is elevated in brain and heart [Hahmann and 
Schroeter, 2010].  
ROCK comprises several domains, starting from the N-terminal kinase 
domain (where isoforms exhibit 89% homology) followed by the coiled-coil 
domain, Rho-binding (RB) domain, and finally the C-terminal pleckstrin 
homology (PH) domain split into two halves by an internal cysteine-rich (C1) 
domain [Jacobs et al., 2006]. The crystallographic studies suggest that ROCK 
forms a head-to-head homodimer through N-terminal extension [Yamaguchi et 
al., 2006a; Yamaguchi et al., 2006b], whereas in the inactive state, the RB and 
the PH-C1 domains of ROCK sequester its N-terminal kinase domain and thus 
suppress its catalytic activity [Amano et al., 1999].  
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Figure 4. Domains of human ROCK-I and ROCK-II isoforms (adapted from Olson, 
2008). Percentage reflects the sequence homology; RBD, Rho-binding domain. 
 
 
The activation of ROCK does not require (auto)phosphorylation at any site of 
the kinase, but necessitates recruitment of both RhoA and ROCK to the plasma 
membrane, which is comprised as a result of a sequence of intracellular events. 
RhoA is a monomeric G-protein active when bound to GTP and inactive when 
bound to GDP [Somlyo and Somlyo, 2000]. In a resting state, the inactive form 
(RhoA-GDP) is stabilized by complexation with guanine nucleotide disso-
ciation inhibitor (GDI); upon activation by guanine nucleotide exchange factors 
that stimulate GDP to GTP exchange on RhoA, RhoA-GTP dissociates from the 
complex with GDI and translocates to the plasma membrane [Somlyo and 
Somlyo, 2000].  
  The localization of ROCK, on the other hand, is regulated by its PH-C1 
domains. Interestingly, the ROCK PH domain lacks the signature phosphoino-
sitide-binding motif found in typical lipid-binding PH domains, and the ROCK 
C1 domain does not contain the diacylglycerol/phorbol ester binding pocket 
found in the canonical C1 domains [Wen et al., 2008]. Instead, the folding pat-
tern of ROCK PH-C1 domains exposes the unconventional positively charged 
surface that is responsible for the attachment of ROCK to the negatively 
charged membrane bilayers (possibly via the recognition of phosphatidylino-
sitol-3,4,5-triphosphates, PtdInsP3) [Wen et al., 2008].  
  Binding of RhoA-GTP to ROCK interferes with the interaction of the ROCK 
N-terminal kinase domain with the C-terminal RB and the PH-C1 domains, 
resulting in a gain of catalytic activity [Jacobs et al., 2006]. The RhoA/ROCK 
pathway has been especially thoroughly investigated in the context of regulation 
of smooth muscle contraction, where it opposes the effect of cAMP/PKA and 
cGMP/PKG pathways. As pointed out before, ROCK mediates phosphorylation 
of the regulatory subunit of MYPT1 at Thr696; as a result of this phospho-
rylation, MYPT1 dissociates from the catalytic subunit of the MLC phospha-
tase, and the phosphatase activity is reduced [Fukata et al., 2001]. Furthermore, 
ROCK contributes to the sustained contraction of smooth muscle by catalyzing 
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phosphorylation of ZIPK, a kinase that enables preservation of the phospho-
rylated state of MLC20 in the absence of Ca
2+ [Murthy, 2006].   
  The down-regulation of MYPT1 and closely related MYPT2 activity by 
ROCK is also important for the remodeling of actin cytoskeleton inside the 
cells, as the sustainment of phosphorylated state of MLC20 enables the latter to 
interact with filamentous actin (F-actin) [Fukata et al., 2001]. An additional 
mechanism contributing to the ROCK-mediated actin-myosin contractile force 
generation is ROCK-catalyzed phosphorylation of LIM kinase (LIMK); LIMK 
in turn phosphorylates the ADF/cofilin family of proteins, and thus blocks their 
actin-depolymerizing activity [Maekawa et al., 1999]. Other non-muscle cell 
functions regulated by RhoA/ROCK pathways involve contraction of endo-
thelial cells, aggregation of platelets, neurite retraction, formation of microvilli, 
membrane ruffling and cell migration, etc [LoGrasso and Feng, 2009; Mulder et 
al., 2004; Nakayama et al., 2005; Olson, 2008; Paul et al., 1999]. 
 
 
1.2.4. PKB 
 
Another PK sharing high percent of sequence homology with PKA and PKG 
within the catalytic domain is PKB (Akt). PKB is expressed as three isoforms, 
PKB (Akt1), PKB (Akt2), and PKB (Akt3), which all possess similar 
structure, consisting of an N-terminal PH domain, a central catalytic domain, 
and a small C-terminal regulatory domain [Liu P. et al., 2009; Manning B. D. 
and Cantley, 2007].  
  PKB activation relies on a variety of mechanisms Figure 5):  
  firstly, activation of PKB (similarly to PKA) is connected with the extra-
cellular event, through the receptor (i.e., insulin receptor, growth factor 
receptors, GPCRs) -> phosphoinositide-3-kinase (PI3K) -> phosphatidy-
linositol(3,4,5)triphosphate (PtdInsP3) pathway [Dilly and Rajala, 2008; 
Shah B. H. et al., 2006];  
  secondly, the subcellular localization of PKB is of crucial importance, as its 
activation is performed at the membrane via utilization of PtdInsP3 (similarly 
to ROCK, S6K1, p90RSK, and PKC isoforms) [Currie et al., 1999; Liu P. et 
al., 2009]; 
  thirdly, PKB serves as an example of phosphorylation cascade, as PKB is a 
substrate protein for another kinase, 3-phosphoinositide-dependent protein 
kinase 1 (PDK1) [Calleja et al., 2007]; 
  finally, full activation of PKB involves phosphorylation by mammalian 
target of rapamycin (mTOR), which is in turn one of the downstream targets 
of PKB itself [Facchinetti et al., 2008; Sarbassov et al., 2005; Toker, 2008]. 
The intracellular analyses proved the existence of a cytosolic pre-activation 
complex with PKB bound to PDK1, whereas the intramolecular interactions 
between the PH domain and the catalytic domain of PKB cause the absence of 
catalytic activity of the latter [Calleja et al., 2007]. Binding of PtdInsP3 to 
PDK1 and to the PH domain of PKB leads to the recruitment of PDK1-PKB 26 
complex to the cell membrane, and induces a conformational change that 
relieves the autoinhibition within PKB molecule [Calleja et al., 2007]. The 
activation loop of the PKB catalytic domain released from the intramolecular 
interaction becomes accessible for phosphorylation at Thr308 (PKB numbe-
ring) catalyzed by PDK1, whereas it has been demonstrated that the interaction 
of PDK1 with PtdInsP3 enhances the rate at which PDK1 activates PKB [Currie 
et al., 1999].  
  Importantly, the phosphorylated PKB may dissociate from the membrane 
and retain its active conformation when functioning in cytosol; still, the full 
activation requires another phosphorylation at Ser473 (PKB numbering) in the 
hydrophobic motif of the C-terminal tail [Sarbassov et al., 2005]. The exact role 
of this phosphorylation has not been resolved yet, and it has been even proposed 
that phosphorylation at Ser473 precedes the phosphorylation at Thr308 and 
contributes to the recognition of PKB by PDK1 [Sarbassov et al., 2005]. The 
PK catalyzing phosphorylation at Ser473 has not been unequivocally identified, 
and a number of candidates have been proposed including PKC isoform 2, 
DNA-dependent protein kinase, and PKB itself; however, most studies have 
pointed out the importance of mTOR complex 2 (mTORC2) in this process [Liu 
P. et al., 2009]. mTORC2 consists of mTOR bound to the rapamycin-insensitive 
companion of mTOR (rictor) and several other mTOR-interacting proteins; 
according to the in vitro studies, mTORC2 directly phosphorylates PKB on 
Ser473 and also facilitates Thr308 phosphorylation by PDK1 [Sarbassov et al., 
2005; Toker, 2008]. It has also been suggested that mTORC2 is responsible for 
the phosphorylation of PKB at its turn motif (Thr450 in PKB). This 
phosphorylation occurs probably during or shortly after the synthesis of PKB, 
and is required for the facilitation of carboxyl-terminal folding and for the 
stabilization of the newly synthesized PKB by interactions of phosphorylated 
Thr450 with the conserved basic residues in the kinase domain [Facchinetti et 
al., 2008]. 
PKB itself has a colossal amount of protein substrates, whereas the first PKB 
target identified in cells was glycogen synthase kinase 3 (GSK3) [Cross et al., 
1995]. PKB phosphorylates GSK3 at a highly conserved N-terminal Ser residue 
(Ser21 in GSK3, Ser9 in GSK3), and this phosphorylation triggers inacti-
vation of GSK3 resulting in stimulation of glycogen synthesis, promotion of 
lipid production, and in loss of GSK3 proapoptotic function [Frame and Cohen, 
2001; Manning B. D. and Cantley, 2007; Yang J. et al., 2002]. Recent data, 
however, suggests that in the absence of PKB, GSK3 may also be phospho-
rylated at the same Ser by other representatives of the AGC-group, i.e. ribo-
somal protein S6 kinase 1 (S6K1), PKAc, or the most downstream kinase of 
the classical mitogen-activated protein kinase (MAPK) cascade called MAPK-
activated protein kinase-1 (MAPKAP-K1 or RSK) [Frame and Cohen, 2001; 
Zhang H. H. et al., 2006]. 
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Figure 5. General scheme of PKB activation and feedback loops. RTK, receptor 
tyrosine kinase; p85, the regulatory subunit of PI3K. 
  
 
PKB is also a principal upstream regulator of crucial intracellular processes 
responsible for cell survival, growth, proliferation, angiogenesis, metabolism, 
and probably cell migration and invasion [Manning B. D. and Cantley, 2007]. 
Interestingly, the PKB-catalyzed phosphorylation often serves for ‘switching 
off’ the functioning of its downstream targets; for example, the PKB-catalyzed 
phosphorylation of tuberous sclerosis 2 protein (TSC2), a component of the 
TSC1-TSC2 complex, inhibits the GTPase-activating protein function of TSC1-
TSC2 and thus stimulates the GTP-loading of RheB, which in turn potently 
activates mTOR [Toker, 2008]. In this way, PKB attenuates the inhibitory 
effects of the TSC1-TSC2 complex on the mTOR complexes mTORC1 and 
mTORC2, and thus creates two important feedback loops, as mTORC2 acts as 
PKB activator (positive feedback), while mTORC1 has been demonstrated to 
inhibit PKB (negative feedback) [Huang J. and Manning, 2009]. 
 
 
1.3. PKs in disease 
 
While the normal functioning of PKs is essential for the sustainment of life of 
an organism, the errors at DNA-level (i.e., mutations of PK-encoding genes) or 
faults of PK expression, activation or feedback loops are connected to a variety 
of diseases [Chico et al., 2009; Knight et al., 2010; Manning B. D. and Cantley, 
2007]. Probably the most explored group of diseases that are caused by dere-
gulation of PKs is cancer. Within last decades, PKs and their direct activators 
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have evolved as the most frequently mutated oncogenes and tumor suppressors, 
thus representing the major path of signaling by which cancer cells evade 
normal physiological constraints on growth and survival [Zhang J. et al., 2009]. 
Moreover, some PKs expressed in tumor or in the surrounding tissues contri-
bute to disease progression as a result of their normal functioning by enabling 
tumor to acquire possibilities for angiogenesis and metastases [Knight et al., 
2010]. Whereas the identification of PKs contributing to tumor development 
and/or survival is a continuous process aided by the development of RNA-
interference techniques and performance of large-scale forward and reverse 
genetic screens, the currently well-known examples of oncogenic PKs involve 
the following kinases [García-Echeverria et al., 2000; Keri et al., 2006; Knight 
et al., 2010; Zhang J. et al., 2009]: 
  receptor tyrosine kinases – i.e., BCR-Abl in chronic myeloid leukaemia, 
EGFR in lung, head, neck, pancreatic and colourectal cancers, HER2 in 
breast cancer, VEGFR-2 in ovarian and kidney cancers, and PDGFR in a 
variety of tumors; 
  STE kinases, MAPK pathway PKs – i.e., BRAF, MEK1 and MEK2 in 
ovarian and colourectal cancers;  
  PI3K pathway PKs (including AGC-group) – i.e., PKB in a variety of 
tumors. 
The consequences of PK malfunctioning are also tightly connected with another 
large group of diseases – central nervous system (CNS) disorders [Chico et al., 
2009], although unveiling the role of PK in the CNS has been largely obstructed 
by the specific properties of the tissue itself (i.e., existence of blood-brain-
barrier). Interestingly, in case of CNS disorders the major 'culprits' are not   
represented by Tyr-kinases (as in case of cancers) but by Ser/Thr kinases from 
different groups [Chico et al., 2009; Keri et al., 2006; Virdee et al., 2007]:  
  CMGC-group – i.e., GSK3 involved in a vast spectrum of disorders 
involving Alzheimer's and Parkinson's diseases, depression, HIV-associated 
dementia, traumatic brain injury, etc.;  
  STE-group – i.e., MAPK in Alzheimer's and Parkinson's diseases, cerebral 
ischaemia, spinal cord and traumatic brain injuries, etc.; 
  AGC-group – i.e., PKC and ROCK, both in Alzheimer's disease, cerebral 
ischaemia and vasospasm, and additionally,  ROCK in multiple sclerosis and 
epilepsy; 
  CAMK-group – i.e., DAPK in acute brain injury and Alzheimer's disease. 
The increased activity of a PK in the diseased tissue is in several cases 
accompanied by the increase of the concentration of the same PK in periferal 
tissues, i.e., body fluids. For instance, elevated levels of extracellular PKAc 
(ECPKA) and ECPKA autoantibodies have been detected in blood serum 
samples of patients with different malignant tumors (especially prostate, blad-
der, breast, and colon cancers) [Nesterova et al., 2006]. Moreover, the valu-
ability of ECPKA as a biomarker is not limited with diagnosis of cancer, but 
also allows monitoring and prognosis, as the good correlation between con-
centration of ECPKA and stage of disease or success of anti-cancer therapy has 29 
been demonstrated in recent tests [Wang H. et al., 2007]. Another PK suggested 
as a biomarker for cancers (i.e., melanoma) according to the studies of xeno-
graft mouse models is PKC [Kang et al., 2009]; moreover, the latter may also 
serve as a biomarker for Alzheimers disease, in parallel with other PKC 
isozymes [Barry et al., 2010]. 
  The examples mentioned above clearly illustrate that PKs belong to both, 
disease-associated and disease-modifying category of proteins, this fact 
rendering substantial interest in PKs as potential biological targets for pharma-
ceutical industry.  Importantly, in order to be classified as a therapeutic target, a 
protein should also be termed ‘druggable’, i.e. it should possess a well-defined 
binding site capable of development of multiple strong and specific interactions 
with a small drug molecule [Hopkins and Groom, 2002]. PKs fulfill the 
druggability requirement by virtue of incorporation of at least one suitable site 
represented by the ATP-binding site, and therefore belong to ca 3000 thera-
peutic targets that comprise the ‘human druggable genome’ (which also 
includes GPCRs, nuclear hormone receptors, ion channels, metallopeptidases, 
proteases, PDEs, etc) [Hajduk et al., 2005]. On the other hand, it should be kept 
in mind that therapeutic targets might also be represented by bacterial, viral, 
fungal or parasitic enzymes (as in case of malarial PKs) [Doerig et al., 2010].  
According to the currently reported state-of-the-art, there are only ca 330 
targets that bind approved drugs, 270 encoded by the human genome and 60 
belonging to pathogenic organisms; therefore, a vast majority of putative 
therapeutic targets remains to be explored [Landry and Gies, 2008]. In case of 
PKs, the difficulties for drug development rise not only due to the intrinsic 
complexity of PK signaling, but also due to the susceptibility of several thera-
peutically important PKs to mutations that trigger resistance towards drug 
candidates designed to interfere with the non-mutated target [Krishnamurty and 
Maly, 2010]. It is therefore evident that the discovery of novel compounds able 
to interact with and suppress the activity of the disease-modifying PKs remains 
of utmost importance. Consequently, there is also a strong requirement for 
methods enabling assessment of PK inhibitors, exploration of PK structure, 
functions and regulation mechanisms, and determination of protein kinase 
activity (i.e., for PKs serving as biomarkers).  
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2. Protein kinase inhibitors 
 
2.1. General features 
 
Within the last 10 years, the development of PK inhibitors as potential drug 
candidates has become the major goal of pharmaceutical industry, with 1871 
currently undergoing or completed clinical studies considering inhibition of PKs 
[Cohen P., 2010; Fedorov et al., 2010; NIH Clinical Trials Homepage]. Further-
more, the field of application of PK inhibitors is not limited with pharmacy 
only. PK inhibitors may serve as valuable „devices“ for studying signaling of 
PKs and other up- and downstream cellular systems connected to PK activation 
and catalysis (i.e., GPCRs, transcription factors) in vivo and in living cells/tis-
sues, but also for in vitro biochemical assays aiming at surveillance of PK 
functioning and its modulation in simplified systems. 
  Dependent on the presumptive field of application, the development of PK 
inhibitors may focus attention on the achievement and improvement of different 
properties of the compounds. In 1997, Lipinski formulated a set of physico-
chemical parameter ranges (often referred to as “Rule-of-Five”, ROF; Tabel 2) 
that were associated with 90% of orally active drugs that achieved phase II 
status [Lipinski et al., 1997]. Basically, ROF and its further extensions state 
characteristics that should be fulfilled for the compounds that are under 
development as oral drugs, in order to reduce the number of compounds 
entering the clinical trials by exclusion of the “unsuitable” candidates already at 
the stage of design and preliminary selection.  
 
 
Table 2. Rule-of-Five and its extensions 
 
„Rule-of-Five“ 
a  Extensions
  Molecular weight ≤ 500 
  log P ≤ 5 
  Number of H-bond donors ≤ 5 
  Number of H-bond acceptors ≤ 10
  Polar surface area ≤ 140 A
2  
o  or sum of H-bond donors and 
acceptors ≤ 12 
  Number of rotatable bonds ≤ 10 
a No more than one violation is allowed; log P, octanol-water partition coefficient. 
 
 
Despite the wide popularity of ROF criteria, it should be kept in mind that ROF 
applies only for orally administered compounds absorbed by passive mecha-
nisms, and is hence not valid for immunotherapeutic vaccines, antisense techno-
logies, and other novel biologic therapies [Grant, 2009; Keller et al., 2006]. 
Moreover, several exceptions to ROF have been reported, i.e., those represented 
by natural compounds [Clardy and Walsh, 2004]. Last but not least, a com-
pound fulfilling the ROF criteria is not automatically an efficient drug, as ROF 
criteria do not take most of the issues of pharmacokinetics (i.e., bioavailability, 
generation and excretion of metabolites, etc) and pharmacodynamics (i.e., drug 
affinity and selectivity, therapeutic window, drug cytotoxicity and toxicity of 
metabolites, etc) into consideration [Chico et al., 2009]. 31 
2.2. Characteristics and general principles  
of design of PK inhibitors 
 
2.2.1. Affinity and inhibitory potency 
 
Several of the previously mentioned properties of inhibitors cannot be reliably 
predicted at the initial stages of development, and sometimes are also not of 
major concern for PK inhibitors developed for biochemical assays in vitro; still, 
the high affinity (and high inhibitory potency) of an inhibitor towards its 
biological target is a primary goal for nearly all applications.  
  The affinity of a reversible ligand (i.e., inhibitor, substrate, co-factor, etc.) 
towards an enzyme may mathematically be expressed as the equilibrium dis-
sociation constant (KD) of the complex consisting of the enzyme and the ligand 
(Equation 1A, 1B). Low dissociation constant value
2 means low susceptibility 
of the complex for dissociation and hence good affinity of the ligand towards 
the given enzyme. 
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Equation 1. (A) KD, dissociation constant of the enzyme-ligand complex; [E], equilib-
rium concentration of free enzyme; [L], equilibrium concentration of free ligand; [EL], 
equilibrium concentration of the enzyme-ligand complex. (B) Et, total concentration of 
enzyme; Lt, total concentration of ligand.  
 
 
According to the basic principles of thermodynamics, an equilibrium constant 
of a reaction is related to the change of standard free energy of the reaction ac-
cording to (Equation 2A). As association reaction (i.e., binding of ligand) is the 
reverse process of the dissociation reaction, the relationship between the change 
of standard free energy of ligand binding (G
0
B) and the equilibrium constant of 
the dissociation reaction (KD) is expressed according to Equation 2B.  
  The change of standard free energy of binding (G
0
B) is a sum of enthalpic 
and entropic terms (Equation 2C). Like any other spontaneous process, the 
binding of ligand to the enzyme takes place only in case of negative free energy 
of binding; therefore, the lower H
0
B and the higher S
0
B, the more negative is 
                                                            
2  In biochemistry, all constants are by convention expressed as dissociation constants, 
and differently from physical chemistry not divided by standard concentration C0 (1 
mol/L); therefore, according Equation 1, biochemical constants usually possess a 
dimension [mol/L]. However, for mathematical equations containing logarithms of 
constants (i.e., Equation 2), the division of corresponding constant by standard 
concentration is by default performed, and the dimensionless constant is then subjected 
to logarithm transformation. 32 
G
0
B for the given reaction and the higher is the affinity of the inhibitor towards 
the given enzyme. 
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  − ∆    
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Equation 2. (A) G
0, change of standard free energy of a reaction; R, universal gas 
constant; T, absolute temperature; K, equilibrium constant of the reaction. (B) G
0
B, 
change of standard free energy of binding. (C) H
0
B, change of standard enthalpy of 
binding; S
0
B, change of standard entropy of binding. 
 
 
 
While H
0
B decreases with an increasing number of favorable interactions in 
the system consisting of an inhibitor, an enzyme, and solvent, the increasing 
value of S
0
B reflects the rising amount of degrees of freedom. It is therefore 
evident that in several cases, enthalpic and entropic terms of inhibitor binding 
can compensate each other (i.e., strong interactions between inhibitor and 
enzyme associated with low H
0
B cause ordering of both enzyme and inhibitor 
molecules and thus low S
0
B), resulting in zero G
0
B and extremely low affinity 
of the inhibitor [Bissantz et al., 2010]. Still, in other cases one of the G
0
B 
components may strongly outweigh another, triggering fully enthalpy- or fully 
entropy-driven binding.  
  While the affinity of a PK-targeted compound reflects the ability of the latter 
to bind to its target, the inhibitory potency characterizes its ability to block the 
phosphorylation reaction catalyzed by the PK of interest and thus cause 
reduction of the speed of formation of the phosphorylated product. According to 
the Michaelis-Menten kinetics [Segel, 1993], the initial velocity v0 of one-
substrate reaction (Scheme 3) reflects the change in concentration of reaction 
product in time (Equation 3A). The initial velocity might be expressed as 
Equation 3B, whereas the concentration of free enzyme [E] is expressed as 
Equation 3C and an additional criterion [S] >> Et is fulfilled, hence the reaction 
occurs at quasi-steady-state conditions ([ES] = const). 
 
 
Scheme 3. Mono-substrate enzymatic reaction with formation of one product. 
   33 
 
   =
 [ ]
  
 
   =
   ∙    ∙[   ]
[ ] +     +   
  
  [ ] =    −[     ]  
A  B C 
 
Equation 3. (A) v0, initial velocity; [P], concentration of product; t, time. (B) [S], con-
centration of substrate. (C) [E], concentration of free enzyme; [ES], concentration of the 
enzyme-substrate complex. 
 
 
The member k2·Et is usually designated as the maximal velocity of an enzyme-
catalyzed reaction (vmax); in order to compare different enzymatic reactions, the 
term turnover number is introduced, reflecting maximal catalytic activity of an 
enzyme. Turnover number is equal to the number of substrate molecules 
converted into product by enzyme per unit of time when the enzyme is fully 
saturated with substrate (Equation 4A); for different enzymes, kcat may 
generally range from 1 s
−1 to 10000 s
−1 [Nelson et al., 2000]. The member (k–1 + 
k2)/k1 in Equation 3B is termed Michaelis constant (Km); mathematically, the Km 
value is equal to the concentration of substrate enabling achievement of half of 
the maximal velocity of the reaction. Given the fact that several enzymatic 
reactions may occur at physiological conditions where [S] << Km, the Equation 
3B might be rewritten as Equation 4B; hence, the reaction resembles the bi-
molecular reaction with pseudo-second order rate constant k2/Km. In case of 
most efficient enzymes, the value of the latter ratio is close to the diffusion limit 
(in the range of 10
9 M
−1 s
−1) [Nelson et al., 2000]. 
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Equation 4. (A) kcat, turnover number; vmax, maximum velocity. (B) Km, Michaelis-
Menten constant. 
 
 
The inhibition of one-substrate reaction may be realized via several ways, 
including competitive, uncompetitive, and mixed mechanism of inhibition 
versus the substrate (Scheme 4), whereas the equation for inhibition constant Ki 
is dependent on the inhibition mechanism; only in case of competitive in-
hibition, the Ki may be expressed analogically to KD [Segel, 1993]. The initial 
velocity of an inhibited reaction (v0
Inh) is correspondingly be expressed as 
Equation 5A, Equation 5B, or Equation 5C (in case if both [S] and [I] are re-
markably larger than Et). The comparison of the latter Equations with Equation 
3B shows that in case of competitive inhibition, vmax is kept constant but the Km 
value of the substrate is changed (the concentration of the substrate enabling 34 
achievement of half of vmax at a fixed concentration of inhibitor is termed Km
app, 
Equation 6A). In case of uncompetitive inhibition, both Km and vmax are different 
from the non-inhibited reaction Equation 7A and 7B; the maximum velocity of 
the inhibited reaction at a fixed concentration of inhibitor is termed vmax
app). 
Both parameters are changed also in case of mixed inhibition (Equation 8A and 
8B); however, if  equals to ’, the inhibition mechanism is termed non-
competitive and only vmax is changed as compared to the non-inhibited reaction 
[Segel, 1993]. 
 
 
A  B C 
 
Scheme 4. Mechanisms of inhibition of a one-substrate reaction. (A) Competitive 
inhibition. (B) Uncompetitive inhibition. (C) Non-competitive inhibition. 
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Equation 5. The initial velocities of the inhibited reactions. (A) Competitive inhibition; 
Km
app, apparent Michaelis-Menten constant. (B) Uncompetitive inhibition; vmax
app, 
apparent maximum velocity. (C) Mixed inhibition. 
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Equation 6. Parameters of the competitive inhibition. [I], concentration of an inhibitor; 
Ki, inhibition constant. 
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Equation 7. Parameters of the uncompetitive inhibition. 
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Equation 8. Parameters of the mixed inhibition. 
 
 
In experiments where the detailed mechanism of inhibition is not of primary 
interest, it is convenient to introduce a quantity that reflects the potency of an 
inhibitor at the given assay conditions. The most popular of such quantities is 
IC50, which is mathematically equal to the concentration of an inhibitor that 
causes 50% reduction of the reaction velocity as compared to that of non-
inhibited reaction (i.e., if [I] = IC50, then v0
Inh = 0.5 v0) [Segel, 1993]. In case of 
competitive inhibition, the IC50 value may be re-calculated to obtain Ki value 
according to the Cheng-Prusoff equation (Equation 9); however, it should be 
kept in mind that the latter is valid only in the assay conditions presupposed by 
Michaelis-Menten kinetics (i.e., if [S] >> Et and [I] >> Et) [Cheng Y. and 
Prusoff, 1973]. 
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Equation 9. Cheng-Prusoff equation. 
 
 
In case of bisubstrate reactions (as in case of PKs, where ATP is a co-substrate 
and the  phosphorylatable protein/peptide serves as a substrate), the reaction 
scheme is substantially more complicated. Studies with PKAc have shown that 
the preferred order of substrate binding is ATP-first [Kong and Cook, 1988; 
Lew et al., 1997b], and that the rate-limiting step of the reaction is generally not 
the phosphoryl transfer, but the dissociation of the co-product ADP (or the 
conformational change of PK associated with this dissociation) [Lew et al., 
1997b; Zhou J. and Adams, 1997]. The latter fact was also confirmed in studies 
with ROCK [Futer et al., 2006]. Hence, the simplified reaction pathway may be 
depicted as Scheme 5, and the general expression for the reciprocal initial 
velocity of the reaction is then given as Equation 10, whereas the members 0, 
1, 2, and 12 are calculated according to Equation 11A, 11B, 11C, and 11D, 
respectively [Dalziel and Dickinson, 1966].  
 
 
 
Scheme 5. Bisubstrate enzymatic reaction with formation of two products and ordered 
mechanism of substrate binding and product dissociation. 
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Equation 10. The reciprocal initial velocity of the bisubstrate reaction corresponding to  
Scheme 5; [S1] and [S2] are the concentrations of substrates. 
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Equation 11. Parameters of the constants from Equation 10. 
 
 
Consequently, inhibition of the bisubstrate reaction can also occur via several 
routes, and it is substantially more convenient to use the IC50 value instead of 
calculating the true inhibition constant values by resolving complicated models 
of inhibition. Still, in case if the inhibition mechanism versus ATP or versus 
protein/peptide substrate is of primary interest, it is frequently established by 
fixation of concentration of a (co-)substrate, and measurement of the rate of the 
PK-catalyzed reaction at varied concentration of the other (co-)substrate [Segel, 
1993]. The latter curve is then repeated at several fixed concentrations of an 
inhibitor, and the relative shift of the inhibited curves as compared to the non-
inhibited curve (i.e., the increase of Km
app of the varied (co-)substrate at the 
growing concentration of the inhibitor) can be used to determine the inhibition 
mechanism. The true inhibition constant Ki of the inhibitor is then calculated 
from a double logarithmic Schild plot (for competitive inhibitors, see Equation 
6B), or from the IC50 of the inhibitor according to the Cheng-Prusoff equation in 
case if competitive inhibition mechanism is established versus the (co-)substrate 
[Segel, 1993].  
 
 
2.2.2. Rational design of PK inhibitors 
 
The structure-aided development of PK inhibitors aims at pinpointing the 
crucial interactions between an inhibitor and a PK that need to be satisfied to 
achieve high efficiency of inhibitor binding, while being aware of flexibility of 
both inhibitor and PK molecules and the role of desolvation effects during 
inhibitor binding [Pratt et al., 2004]. This goal is achieved by implementation of 
wealth of structural data considering PKs and their complexes resolved by 
crystallographic studies, NMR, in silico analysis and homology modeling, etc.  37 
  Probably the most important specific interactions for biomolecular recogni-
tion processes are hydrogen bonds, including strong “classical” H-bonds (i.e., 
NH or OH as a donor and C=O as an acceptor) and weak H-bonds (i.e., CH as a 
donor and C=O as an acceptor, or NH as a donor and -system as an acceptor) 
[Bissantz et al., 2010]. The bond distances and angular preferences of H-bonds 
follow strict rules, and apart from the nature of atoms forming the bond and 
from geometric parameters, the strength of a hydrogen bond is dependent on the 
neighboring atoms (i.e., in some systems H-bonds with suboptimal geometries 
might be stabilized by flanking partners) [Bissantz et al., 2010]. However, as 
formation of strong H-bond also implies high desolvation costs for both the 
donor and the acceptor, the net free energy gain may be minimal; hence, the 
molecular design of inhibitors should primarily aim at identification of H-bond 
donors and acceptors in the enzyme that are positioned in the clefts with 
decreased solvent accessibility. 
The charge-assisted H-bonds (salt-bridges) between an inhibitor and a kinase 
should yield stronger interactions than those provided by neutral hydrogen 
bonds by virtue of the coulombic force component. However, in case of 
solvent-exposed salt-bridges, little gain in net free energy may be expected, as 
the free energy of salt-bridge formation has to exceed the solvatation free 
energies of both, donor and the acceptor, which are initially strongly hydrated 
[Luo R. et al., 1999]. Still, (partially) buried charged protein residues represent 
the extremely important spots for the structure-aided inhibitor design. 
Several studies have demonstrated that the structural parameter of an 
inhibitor correlating best with its affinity towards an enzyme is the area of 
hydrophobic surface of the inhibitor buried upon binding to the enzyme [Engh 
and Bossemeyer, 2002; Vallone et al., 1998]. The magnitude of this hydropho-
bic effect may be up to 125 J/(mol·Å
2), with particularly large gains in binding 
energy obtained in cases where a non-polar ligand optimally occupies a 
hydrophobic narrow and poorly solvated pocket of protein [Southall et al., 
2002]. A separate group of hydrophobic interactions is represented by aryl-aryl 
interactions, where side-chains of aromatic amino acids of an enzyme form 
edge-to-face (T-shaped) or face-to-face (parallel) - interactions with aromatic 
fragments of an inhibitor; aryl-aryl interactions may additionally profit from 
charge transfer, if formed between an electron-rich and an electron-poor 
substituted aromatic system [Bissantz et al., 2010]. Importantly, the majority of 
hydrophobic interactions between an enzyme and an inhibitor should also be 
entropically favorable. The presence of a hydrophobic solute causes ordering of 
surrounding water molecules, whereas the association of two hydrophobic 
solutes results in formation of water “cage” with smaller ordered surface area 
than the sum of ordered surface areas of “cages” for initial solutes [Bissantz et 
al., 2010]. 
The structure-aided design of inhibitors represents one of two branches of a 
general strategy termed rational design. The other branch of this strategy is 
ligand-based design (or analogue-design [Zhang J. et al., 2009]), taking advan-
tage of published lead compounds (the “templates”, or “privileged structures” 38 
[Keri  et al., 2006]) and selected features of catalytic cores of enzymes. 
Historically, several inhibitors with moderate to high affinity towards PKs have 
also been discovered as a result of screening of large collections of random 
compound (libraries) with intention to test a vast variety of different structures 
independently on their binding mode or mechanism [Lam et al., 2003]. How-
ever, this approach has now mostly been claimed ineffective due to large 
overhead costs and relatively low outcome; instead, the design of focused 
libraries has become popular, consisting of compounds derived from scaffolds 
of well-known potent inhibitors and targeted to certain sites of enzyme known 
to ensure development of strong interactions (i.e., ATP-binding site of PKs). 
Recently, several publications have emerged reporting successful combination 
of the ligand-based and the structure-aided design of PK inhibitors, especially in 
cases where computational approaches were used during the initial steps of 
inhibitor development [Fischer J. R. et al., 2010; Fujiwara et al., 2010; Tal-Gan 
et al., 2010; Xu, et al., 2009]. 
 
 
2.2.3. Selectivity issues 
 
Apart from affinity, another characteristic that may be “tuned” with the aid of 
rational design of PK inhibitors is selectivity. Generally, selectivity of an in-
hibitor towards its target might be enhanced by two approaches:  
  introduction of fragments that develop interactions with non-conserved or 
mutated residues in the catalytic core of a kinase (including cases where 
inhibitor sterically interferes with or disrupts interactions between such 
residues in non-target PKs; Figure 6A–B),   
  or development of compounds that recognize the inactive state of a kinase 
(Figure 6B–D) [Grant, 2009; Morphy, 2010].  
Additionally, targeting allosteric pockets characteristic of a target kinase only or 
also very closely related PKs yields compounds with a very narrow recognition 
profile (high selectivity), although such allosteric modulators are mostly dis-
covered by chance and not designed rationally [Bogoyevitch and Fairlie, 2007]. 
The required degree of selectivity for a PK inhibitor is certainly dependent 
on its application. For instance, if the inhibitor under development will be used 
as a generic probe in assays for the screening of other inhibitors, or as an 
affinity support for the pull-down assays analyzing content of PK in various 
tissues, selectivity within the family of PKs would even be considered as dis-
advantage. Applications such as determination of certain kinomic biomarkers in 
tissues or use of inhibitor as a physiological modulator, on the other hand, 
traditionally require compounds with very high degree of selectivity not only 
within members of PK family but sometimes even within different isoforms of 
one PK [Hahmann and Schroeter, 2010].  
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Figure 6. Inhibitors with enhanced selectivity. (A) GSK690693, targeting non-
conserved residues of PKB isoforms: while red substituent at position 7 forms hydrogen 
bond with the side-chain of the conserved Glu236 and just enhances affinity, the blue 
substituent at position 4 targets the narrow back-pocket lined by Leu204 of PKB 
[Heerding et al., 2008]. (B) Methylated imatinib (Gleevec), targeting c-Kit: the blue 
methyl group displaces water from the dehydron C673-G676 (a unique wrapping defect 
in soluble proteins where backbone hydrogen bonds in are partially exposed to water 
due to an insufficient number of neighboring nonpolar side-chain groups) [Zhang X. et 
al., 2008]. (C) Lapatinib (Tykerb) targeting HER2 and EGFR: the blue fluoro-
benzyloxy group improves the selectivity for HER2 and maintains affinity for EGFR; 
additionally, the inhibitor utilizes the “C-Glu-out” state of kinases, where rotation and 
outward shift of the C-helix opens up an additional pocket near the ATP-binding site 
[Wood E. R. et al., 2004]. (DC) Nilotinib (Tasigna), targeting Abl: the inhibitor utilizes 
the “DFG-out” state of a PK, where the “flip”-out of phenylalanine of the Asp-Phe-Gly 
motif blocks access of ATP and creates a new binding pocket [Weisberg et al., 2005]. 
(E) Scheme of ATP-site and nearby pockets of PKs utilized by several selective 
inhibitors [according to Morphy, 2010]. 
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However, even in case of pharmacologically active PK inhibitors, an idea for 
development of multi-targeted drugs has recently emerged [Grant, 2009; Knight 
et al., 2010; Morphy, 2010; Zhang X. et al., 2008]. After the break-through of 
Gleevec (Imatinib) achieving multi-year increase in survival of patients in the 
treatment of chronic myeloid leukemia (CML) [Druker and Lydon, 2000], the 
further progress of PK inhibitors in clinical trials and in clinical practice has 
been uneven, which might be (at least partially) attributed to several specific 
features of the kinase-connected diseases. PK inhibitors have been most 
successful in treatment of diseases driven by a single oncogenic PK (the so-
called oncogene-addicted tumors); however, in case of diseases relying on 
several mechanisms (such as activation of surrogate kinases, inactivation of 
phosphatases, or activation of alternative redundant kinase pathways) treatment 
has been remarkably less efficient [Grant, 2009; Zhang J. et al., 2009]. More-
over, some tumors may escape inhibition of single kinase by introducing 
resistance mutations causing lowered affinity of kinase towards drugs, or 
enhanced affinity towards natural drug competitors (i.e., ATP) [Krishnamurty 
and Maly, 2010]. Therefore, a multi-targeted compound (or a mixture of single-
targeted compounds) able to inhibit both, initial PK and its mutated form, or 
able to to block several tumor-maintaining PK pathways would be of con-
siderable value.  
Indeed, first steps have already been taken in this direction, including the 
examples listed below: 
  sequential or combined therapy of CML patients with BCR-Abl inhibitors, 
of which some recognize the non-mutated form of the kinase and others may 
also inhibit different mutated forms (i.e., first imatinib, then nilotinib or 
dasatinib, and finally so-called third-generation drugs) [Fuerst, 2010; Shah 
N. P. et al., 2007]; 
  combined inhibition of VEGFR and PDGFR by the multi-targeted com-
pounds sorafenib (Nexavar) and sunitinib (Sutent) [Gridelli et al., 2007]; 
  clinical trials of dual PI3K and mTOR pathway inhibitors as well as mix-
tures of compounds targeting selectively one of these pathways [Fan and 
Weiss, 2006].  
The first marketed multi-target drug is Lapatinib, with enhanced affinity 
towards both EGFR and HER2, the kinases overexpressed in a variety of human 
tumors [Lackey, 2006]. It should also be mentioned that several PK inhibitors 
initially designed as single-targeted drugs have subsequently demonstrated high 
affinity towards off-target PKs [Karaman et al., 2008].  
Off-target effects of PK inhibitors may generally be classified into two 
categories, non-PK selectivity issues (i.e., inhibition of promiscuous proteins 
such as cytochrome P450 superfamily or hERG potassium ion channel) and 
kinase off-targeting; both may cause severe side-effects of drugs such as cardio-
toxicity, dermatological toxicity, myelosuppression, neutropenia, etc [Chico et 
al., 2009; Grant, 2009]. Additional factors that could trigger or diminish the 
risks for off-target inhibition include drug dosage (and dosing regimen, if seve-
ral drugs are applied), cell membrane permeability and intracellular accu-41 
mulation, formation of active metabolites, etc [Grant, 2009]. Hence, accurate 
measurements of the selectivity profile of PK inhibitors preferably in the habitat 
of their potential application would unambiguously facilitate drug development, 
as well as disease diagnostics and monitoring, and other fields where PK 
inhibitors may be utilized [Grant, 2009; Morphy, 2010; Zhang J. et al., 2009].  
Up to date, there are several panels of PKs on the market that allow in vitro 
biochemical selectivity profiling of an inhibitor [Grant, 2009]. However, due to 
the high costs of these services, the compounds of interest are usually tested at a 
single concentration (100 nM to 10 M), and then dose-response curves of 
inhibitors are measured just with few members of the kinome [Grant, 2009; 
Zhang J. et al., 2009]. Despite the indisputable value of biochemical kinase 
panels at the initial steps of inhibitor development, these trials may be 
compromised by the fact that the inhibitor is tested towards only a small 
fraction of kinome. Moreover, these assays are often performed at non-
physiological conditions (i.e., with low ATP concentrations, truncated and/or 
mutated forms of PKs, or artificial substrates), thus the results of such 
selectivity profiling should be cautiously interpreted [Grant, 2009; Morphy, 
2010].  
Another approach for the determination of selectivity of PK inhibitor is 
chemical proteomics (please refer to Section 2.3.1. Irreversible mono-ligand 
inhibitors), where the compound of interest is immobilized on solid beads and 
used as affinity support [Rix and Superti-Furga, 2009]. This method enables 
affinity-based profiling of the immobilized compound towards a natural system 
represented by the cell or tissue lysate; still, there might be complications 
arising from the inadequate PK activity caused by the loss of natural cellular 
environment, as well as from partial loss of inhibitor affinity resulting from 
immobilization.  
Finally, intracellular selectivity of PK-targeted compounds may be assessed 
with the aid of cell lines engineered to respond to an  increase or decrease of 
activity of a certain kinase. Mostly, these model cell lines have been developed 
from the murine Ba/F3 cell line, which under normal conditions requires the 
cytokine interleukin 3 to proliferate; however, transformation by an oncogenic 
kinase results in interleukin 3-independent proliferation [Warmuth et al., 2007]. 
The rate of proliferation and survival thereby reflects the degree of activity of 
the given oncogenic kinase, and should be reduced after the application of a 
selective inhibitor targeted to the oncogene. Whereas these assays enable testing 
of an inhibitor in the intracellular milieu most close to that of the organisms, 
misleading information may be obtained in cases where the kinase expression 
profile in the model cell line differs from that in the diseased human tumor cells 
[Morphy, 2010]. To sum up, the achievement of optimal affinity, selectivity and 
other required properties of an inhibitor as well as the assessment of these 
properties in natural-like systems still remain a challenge, and the field of PK 
inhibitor research and development is far from depletion.  
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2.3. Main classes of PK inhibitors  
 
PK inhibitors may be grouped into several types according to the following 
criteria: 
  according to origin: natural, synthetic, or semi-synthetic inhibitors (i.e., 
derivatives of natural inhibitors/substrates); 
  according to the nature of bond formed in the PK-inhibitor complex: 
reversible or irreversible inhibitors;  
  according to the kinetic mechanism of binding: competitive, uncompetitive 
or semicompetitive (including non-competitive) versus ATP and/or versus 
protein/peptide substrate, or allosteric inhibitors; 
  according to the number of PK sites occupied by the compound: mono- or 
multi-ligand inhibitors. 
Furthermore, the recent advances in the development of ATP-competitive 
tyrosine kinase inhibitors and their progression into drugs have necessitated 
introduction of one additional way of classification of compounds into Type-I 
and Type-II inhibitors [Johnson L. N., 2009; Noble et al., 2004; Zhang J. et al., 
2009]. Type-I inhibitors bind to the active conformations of PKs (i.e., those able 
to bind ATP and protein/peptide substrate); the pharmacologically important 
examples of Type-I inhibitors include gefitinib (Iressa) and erlotinib (Tarceva) 
targeting EGFR, and dasatinib (Sprycel) targeting members of Src family. All 
of these compounds bind to the ATP-cleft of the kinase, and may additionally 
occupy the adjacent pockets, i.e., the hydrophobic pocket at the back of ATP-
binding cleft. The latter is enlarged in some kinases (by virtue of incorporation 
of smaller amino acid residue positioned at the opening of the pocket, the so-
called “gate-keeper” residue), and thus provides possibilities for introduction of 
selectivity determinants [Noble et al., 2004].  
  Type-II inhibitors, by contrast, bind to and stabilize those inactive confor-
mations of PKs (i.e., “DFG-out” and “C-Glu-out”) where additional hydro-
phobic pockets are revealed in the region of the catalytic loop due to “opening” 
movement of adjacent helices or moieties of the kinase (Figure 6E) [Lee G. M. 
and Craik, 2009; Rabiller et al., 2010]. The inactive conformations have been 
considered relatively non-conserved in different PKs and thus especially attrac-
tive for drug targeting; the examples Type-II inhibitors include well-known 
pharmacological drugs imatinib (Gleevec) and nilotinib (Tasigna) targeting 
BCR-Abl, lapatinib (Tykerb) targeting HER2, and sorafenib (Nexavar) tar-
geting multiple receptor tyrosine kinases. However, it has recently been de-
monstrated that an inactive conformation may not always be unique for the 
certain PK, hence in some cases Type-II compounds might still possess lower 
selectivity towards their targets than Type-I compounds [Lewis, et al. 2008; 
Morphy, 2010]. Moreover, inactive conformations do not require preservation 
of kinase 3D structure needed for ATP binding, and are therefore more 
susceptible to resistant mutations. 
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2.3.1. Irreversible mono-ligand inhibitors 
 
Irreversible inhibitors form a covalent bond (or several covalent bonds) upon 
binding to the kinase, and hence cannot be displaced by other inhibitors or 
substrates. According to the chemical properties, irreversible inhibitors can be 
divided into two groups: the compounds carrying reactive chemical groups 
(usually electrophiles) that instantly form a covalent bond with the PK upon 
binding, and compounds possessing so-called photo-affinity groups (usually 
aromatic azides or benzophenones) that serve as reversible inhibitors in the dark 
but become reactive upon UV-irradiation. The first irreversible inhibitors 
designed for kinases were ATP and cAMP analogues labeled with radioactive 
isotopes and incorporating either a photo-affinity azide-group or a chemically 
reactive p-fluorosulfonylbenzoyl moiety [Chuan et al., 1989; Kerlavage and 
Taylor, 1980; Zoller et al., 1981] (Figure 7A). These compounds were used for 
determination of residues in the kinase sites responsible for binding ATP or 
cAMP, respectively; after covalent modification, the kinases were subjected to 
proteolytic cleavage, and the radioactively labeled residues were isolated.  
Later on, a similar approach named activity-based protein profiling (ABPP) 
was introduced, based on irreversible inhibitors termed activity-based probes 
(ABPs). An ABP consists of three fragments: a moiety endowed with affinity 
towards protein kinase(s) of interest, a chemical group responsible for gene-
ration of a covalent bond, and a reporter-tag for the detection of covalently 
modified PK (i.e., a radioactive isotope, fluorescent dye, or biotin moiety) [Rix 
and Superti-Furga, 2009; Speers and Cravatt, 2004]. ABPs selective towards 
certain PKs have been used to “catch” the target protein(s) from the biological 
samples (i.e., cell or tissue lysates), or to generate an affinity matrix where 
natural ligands interacting with enzyme (but not binding to the same site as 
ABP) may bind [Gayani et al., 2008; Kalesh et al., 2010]. Additional 
application possibilities are available for the generic ABPs, i.e., those lacking 
selectivity within a certain group of PKs or most of the kinome). The latter may 
be used for identification of kinomic pattern of biological samples (so-called 
chemical proteomics), or for assessment of affinity and selectivity of non-
covalent inhibitors added to the PK-containing sample prior to introduction of 
ABP [Ratcliffe et al., 2007; Speers and Cravatt, 2004]. Apart from kinases, 
ABPs have been generated for over 20 enzyme classes, including major families 
of proteases, phosphatases, glycosidases and glutathione S-transferases, and a 
range of oxidoreductases [Saghatelian and Cravatt, 2005].  
Another variant of irreversible inhibitors is represented by cross-linking 
compounds, which incorporate an affinity-fragment responsible for binding of 
compound to protein and two reactive groups responsible for covalent linking. 
One of the reactive groups generates a covalent bond with the PK (usually at the 
ATP-site), and the other reactive group forms a covalent bond with the protein 
or peptide binding to the substrate-binding site of the same PK [Liu K. et al., 
2008; Parang et al., 2002b]. A cross-linking compound should therefore 
protrude into the substrate-site to modify covalently one of the protein/peptide 44 
residues but not deep enough to interfere with its binding. Dialdehyde moieties 
have been frequently used as electrophilic moieties able to react irreversibly 
with nucleophilic groups of amino acid side-chains incorporated in the structure 
of kinase and substrate (Figure 7B). While in PKs, the reactive nucleophilic 
group is incorporated in the side-chain of the highly conserved Lys residue 
(corresponding to Lys72 in PKAc), the range of substrates suitable for trapping 
into cross-linked PK-substrate complexes is limited with Cys-containing 
pseudosubstrate-peptides [Kalesh et al., 2010; Liu K. et al., 2008; Maly et al., 
2004; Statsuk et al., 2008]. Thus, dialdehyde-containing cross-linking com-
pounds cannot be used for identification of novel kinase substrates in biological 
samples, but rather for selective detection of kinase itself, whereas selectivity 
may be achieved by use of a selective pseudosubstrate and/or a selective cross-
linking compound. As an alternative, cross-linking compounds have been 
developed incorporating two azide groups that are both converted to reactive 
nitrene or diazaquinodimethane intermediates upon UV-irradiation (Figure 7C) 
[Parang et al., 2002b; Polshakov, et al. 2005]. These intermediates are able to 
react with O-H and C-H bonds of proteins, and hence do not necessarily require 
presence of strong nucleophiles in the neighborhood of their binding site in 
order to form covalent bonds [Matheson et al., 1977]. 
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Figure 7. Examples of irreversible inhibitors. (A) FSBA [Ratcliffe et al., 2007]. (B) 
Dialdehyde 7 [Kalesh et al., 2010]. (C) Bifunctional azide-based crosslinker 5 [Parang 
et al., 2002b]. 
 
 
The problematic issue of all aforementioned classes of irreversible inhibitors is 
loss of affinity and/or selectivity of the PK-binding fragment upon conjugation 
with reactive groups responsible for forming the covalent bonds. However, 
several irreversible inhibitors have been developed possessing sufficient affinity 
and selectivity for application as drugs (i.e., for the treatment of non-small cell 
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lung cancer and other types of solid tumors). Most of the irreversible inhibitors 
undergoing clinical trials are targeted to ATP-sites of EGFR or HER2 and 
represent derivatives of quinazoline, anilinoquinoline, pyridopyrimidine, or 
pyrimidine incorporating unsaturated Michael acceptor groups that form 
covalent bond with Cys residues of tyrosine kinases (i.e., Cys773 in EGFR, 
Cys805 in HER2) [Fry, 1999; Heymach et al., 2006; Smaill et al., 1999; Zhang 
J. et al., 2009; Zhou W. et al., 2009]. Recently, similar compounds targeting 
Bruton's tyrosine kinase and VEGFR-2 have been reported (Figure 8A). In the 
latter case, derivatives of quinazoline were used containing two reactive groups 
positioned in such way that one (Michael acceptor) generates a covalent bond 
with EGFR or HER2 and the other (benzoquinone moiety) with VEGFR-2 
[García-Echeverría et al., 2000; Wissner et al., 2007; Zhang J. et al., 2009]. 
Another selectivity-gaining binding mode was utilized by the natural compound 
lactoquinomycin, which formed covalent bonds with the residues Cys296 and 
Cys310 of the activation loop of PKB [García-Echeverría and Sellers, 2008; 
Toral-Barza  et al., 2007]. Lactoquinomycin showed significant selectivity 
towards PKB in a panel of 45 PKs and inhibited PKB-catalyzed phospho-
rylation in cells; however, the nonspecific redox-related cytotoxicity of this 
compound strongly limited its pharmacological applications. Last but not least, 
pyrrolopyrimidine derivatives containing either a chloromethylketone (CMK) or 
a fluoromethylketone (FMK) electrophile could also be successfully applied for 
irreversible inhibition of RSK isoforms 1, 2 and 4, and showed remarkable 
target selectivity not only in biochemical in vitro systems, but also in mam-
malian cells [Figure 8B; Cohen M. S. et al., 2005]. The latter observation might 
be attributed to the incorporation of a second selectivity determinant into the 
structure of compounds, represented by  a para-tolyl substituent targeted to the 
hydrophobic pocket at the back of the ATP-site that is lined by a compact gate-
keeper residue (Thr) in case of RSK isoforms 1, 2 and 4. 
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Figure 8. Examples of selective irreversible inhibitors. (A) Compound 17 [Wissner et 
al., 2007]. (B) CMK and FMK; selectivity determinant marked with red oval [Cohen M. 
S. et al., 2005]. 
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To sum up, it should be mentioned that all irreversible inhibitors exhibit both 
time- and concentration-dependent manner of PK inactivation [Fry, 1999]. 
Moreover, in most cases the results of measurements of affinity and inhibition 
potency of irreversible inhibitors are dependent on the rate of formation of 
covalent bond with a kinase, and in case of chemically reactive compounds may 
even reflect affinity of both reversibly and irreversibly binding forms. The most 
problematic issue for the development of irreversible inhibitors remains exact 
identification of the positions in the inhibitor structure where reactive groups 
should be positioned to generate covalent binding to the protein residues. For 
irreversible inhibitors applied in crude biological systems, a problem of exces-
sive activity may also evolve, i.e., irreversible binding to the compounds 
containing nucleophilic centers and present in cell in high concentration (i.e., 
glutathione) [Wissner et al., 2007; Zhang X. et al., 2008]. In case of pharma-
cological applications, the issue of selectivity might become especially 
important, as a covalent attachment to unanticipated targets should by all means 
be avoided to reduce the toxicity of irreversible inhibitors. The advantages of 
irreversible compounds, however, sometimes outweigh the potential risks, as 
covalent inhibitors ensure prolonged inhibition of enzyme and do not need to 
achieve high plasma concentrations in order to gain inhibitory potency [Fry, 
1999; Morphy, 2010]. Moreover, ATP-site directed irreversible inhibitors do 
not suffer as much from the high intracellular concentrations of ATP as their 
reversible counterparts: once the covalent bond is formed between an inhibitor 
and a PK, the former cannot be displaced from the compex. Hence, covalently 
binding compounds are also of especial value for inhibition of proteins that 
acquire high affinity towards ATP as a result of mutation [Fry, 1999; Krishna-
murty and Maly, 2010]. 
 
 
2.3.2. Reversible mono-ligand inhibitors. Special case:  
ATP-competitive inhibitors 
 
The majority of PK inhibitors being currently in clinical trials and probably also 
the majority of small-molecule PK inhibitors under development are repre-
sented by ATP-site targeted reversible compounds that compete with ATP for 
binding. This fact may seem surprising, considering the selectivity issues of 
targeting ATP-site possessed by all 518 PKs and over 1500 other proteins, and 
the need to compete with high intracellular concentrations of ATP (over 1 mM) 
[Fischer P. M., 2004]. However, wide popularity of ATP-competitive inhibitors 
(ACI) originates from the druggability approach previously discussed (please 
refer to Section 1.3. PKs in disease), as the ATP-site being deeply buried inside 
the PK molecule and allowing generation of multiple strong interactions 
between a ligand and a protein fits perfectly under definition of the druggable 
pocket.  
  Most of the ACIs are structurally similar to ATP itself, at least to a certain 
degree; typically, potent ACIs contain an aromatic system (or several aromatic 47 
systems) incorporating nitrogen atom(s) that serves as H-bond donors or 
acceptors, and do not contain hydrolysable phosphates. The multiplicity of 
nitrogen-containing aromatic scaffolds used for the design of ACIs is illustrated 
below (Figure 9). 
 
 
 
 
Figure 9. Aromatic scaffolds widely applied in ACIs. 
 
 
Probably the best-known representatives of isoquinoline scaffold are so-called 
Hidaka-series compounds (H-inhibitors) first reported in 1984 and initially 
derived from calmoduline antagonist W-7 after replacement of naphthalene 
moiety with isoquinoline [Hidaka et al., 1984]. The first generation of H-
inhibitors consisted of relatively non-selective compounds, although later 
modifications resulted in an increase of selectivity towards certain targets, i.e. 
H-89 (Figure 10A) has been widely used as a PKAc-selective compound with a 
Ki value of 50 nM (although recent reports have demonstrated that H-89 is also 
a potent inhibitor of ROCK-II, MSK1, and S6K1) [Murray A. J., 2008; Ono-
Saito et al., 1999]. The efforts to generate a PKB-selective inhibitor based on 
isoquinoline scaffold have yielded compounds (Figure 10B–C) with a high 
affinity towards PKB and the ability to inhibit PKB-catalyzed phosphorylation 
of GSK3 in cells; however, these compounds still exposed more potent 
inhibition of PKAc [Collins et al., 2006; Li Q. et al., 2006]. The most promising 
results were obtained with 1,4-diazepine conjugates of 5-isoquinoline-sulfonic 
acid, which revealed high affinity towards ROCK; one of these compounds is 
fasudil (HA-1077, Figure 10D), the first inhibitor approved for clinical use in 
Japan in 1995 for the treatment of cerebral vasospasm [Tamura et al., 2005]. 
Fasudil inhibited ROCK-II with a Ki value of 330 nM, expressing a ca 10-fold 
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selectivity over PKG and a 30-fold selectivity over PKAc. A di-methylated 
form of fasudil, H-1152 (Figure 10E) revealed even better affinity towards 
ROCK-II (Ki = 1.6 nM) and improved selectivity versus PKAc and PKC, and 
has been recently used as a template for further derivatization aimed at impro-
vement of inhibitory properties towards ROCK. Recently, a novel isoquinoline-
derived ROCK-II inhibitor has been reported (Figure 10F), possessing a Ki 
value of 25 nM towards ROCK-II and exhibiting inhibition of ROCK-catalyzed 
MYPT1 phosphorylation in cells [Iwakubo et al., 2007a]. 
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Figure 10. Examples of isoquinoline-containing ACIs. (A) H-89 [Ono-Saito et al., 
1999]. (B) Compound 13a [Li Q. et al., 2006]. (C) Compound 9 [Collins et al., 2006]. 
(D) HA-1077 [Tamura et al., 2005]. (E) H-1152 [Tamura et al., 2005]. (F) Compound 
30-R [Iwakubo et al., 2007a]. 
 
 
Another widely accepted class of ROCK inhibitors is based on pyridine and 
pyrrolo-pyridine scaffolds. One of the most prominent representatives is Y-
27632 (Figure 11A), which has been widely applied as a ROCK-II inhibitor in 
smooth muscle assays; Y-27632 has a Ki value of 140 nM towards ROCK-I and 
a nearly 200-fold selectivity versus PKAc [Uehata et al., 1997]. The replace-
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ment of pyridine fragment of Y-27632 with pyrrolo-pyridine and elimination of 
chirality by introduction of phenyl moiety instead of cyclohexane resulted in an 
additional increase in affinity towards ROCK-II (Ki = 3.6 nM), and the com-
pound Y-39983 (Figure 11B) is undergoing clinical trials as an anti-glaucoma 
agent [Tokushige et al., 2007]. Pyrrolo-pyridine moiety has also been used in 
conjugation with difluoro-phenyl and diamino-pyrimidine fragments (Figure 
11C), the resulting compound exhibiting high affinity towards ROCK and a 
good pharmacokinetical profile, and causing an effective reduction of blood 
pressure in anesthetized rats [Schirok et al., 2008].  
  Interestingly, compounds based on pyrrolo-pyrimidine and structurally 
comparatively similar to Y-27632 and Y-39983 have been successfully applied 
as PKB and PKB inhibitors (Figure 11D–E), possessing a high affinity in 
vitro and anti-tumor effect in vivo [Caldwell et al., 2008; Freeman-Cook et al., 
2010]. The pyrimidine core in conjugation with 5-amidothiophene also yielded 
a potent inhibitor of PKB isoforms  and  (Figure 11F; IC50 values of 6 nM 
and 3 nM, respectively), although this compound was an even more potent 
inhibitor of PKAc (IC50 values of 0.1 nM) [Lin X. et al., 2006]. Other scaffolds 
frequently adopted for the design of ACIs towards pharmacologically important 
PKs such as PKB and ROCK are represented by indazoles and pyrazoles [Chen 
et al., 2008; Feng et al., 2007; Goodman et al., 2007; Iwakubo et al., 2007b; Lin 
H. et al., 2010; Saxty et al., 2007; Sehon et al., 2008, Zhu et al., 2007]. 
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Figure 11. Examples of ACIs based on pyridine and pyrrolo-pyridine. (A) Y-27632 
[Uehata et al., 1997]. (B) Y-39983 [Tokushige et al., 2007]. (C) Compound 32 [Schirok 
et al., 2008]. (D) Compound 25 [Caldwell et al., 2008]. (E) Compound 42 [Freeman-
Cook et al., 2010]. (F) Compound 2aa [Lin X. et al., 2006]. 
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One of the most promising pan-PKB inhibitors
3 being currently in clinical trials 
is the azabenzimidazole-aminofurazan conjugate GSK690693 (Figure 12A), 
which despite a wide affinity-profile within the AGC-group of PKs has been 
successfully tested in mice bearing human ovarian, prostate, and breast carci-
noma xenografts [Rhodes et al., 2008]. Structurally similar conjugates (Figure 
12B–C) have shown high affinity towards ROCK-I, and effectively reduced 
blood pressure in rats [Doe et al., 2007; Stavenger et al., 2007]. However, even 
a higher affinity was possessed by a conjugate of benzimidazole and chroman 
(Figure 12D), which strikingly demonstrated an over 400-fold selectivity versus 
PKAc and even higher selectivity indices versus other representatives of the  
AGC-group [Sessions et al., 2008].     
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Figure 12. Examples of ACIs based on azabenzimidazole and indazole. (A) 
GSK690693 [Rhodes et al., 2008]. (B) GSK269962A [Doe et al., 2007]. (C) SB-
772077-B [Doe et al., 2007]. (D) SR4030 [Sessions et al., 2008]. (E) PP1 [Liu Y. et al., 
1999]. 
 
 
  
                                                            
3   Pan-inhibitor indicates a compound with high affinity towards all isoforms of the 
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Importantly, several natural compounds may serve as generic (promiscuous) 
ACIs of PKs, the best-known examples include the following compounds [Gani 
and Engh, 2010; Pande et al., 2008; Shu, 1998]: 
  balanol (isolated from the fungus Verticillium balanoides; structurally 
identical to azepinostatin isolated from Fusarium merismoides), (Figure 
13A); 
  flavopiridol (derivative of rohitukine, an alkaloid isolated from Dysoxylum 
binectariferum), (Figure 13B); 
  staurosporine with its derivatives (initially isolated from microbial alkaloids 
of Streptomyces staurosporeus and other actinomycetes) (Figure 13C).  
Balanol is a highly potent inhibitor of Ser/Thr kinases with especially high 
affinity towards most PKC isoforms, but lacking affinity towards casein kinase 
II or Tyr kinases; however, over 500 derivatives of balanol have been 
synthesized, of which several demonstrated an improved selectivity towards 
PKC versus other kinases (i.e., PKAc) (Pande et al., 2008; Shu, 1998). Flavo-
piridol inhibits most cyclin-dependent kinases and down-regulates the cyclins 
D1 and D3, thus inducing cell cycle arrest; by virtue of its anti-tumor effects in 
patients with renal, prostate and colon cancer, flavopiridol is currently 
undergoing Phase II trials [Senderowicz, 1999]. Staurosporine possesses 
probably the most wide affinity profile of all PK inhibitors, inhibiting 87% of 
PKs with a KD value below 3 M [Karaman et al., 2008]. It has also been one of 
the compounds being extensively used as a template in the ligand-based design, 
and the efforts in the field have yielded several staurosporine derivatives with 
improved selectivity, e.g., bisindolyl maleimides targeted to PKC isoforms 
[Grodsky et al., 2006; Komander et al., 2004; Shu, 1998]. Several of the latter 
compounds are currently at different stages of clinical trials, i.e., midostaurin 
PKC412 (inhibitor of PKC, VEGFR-2, c-KIT, and PDGFR) or UCN-01 (inhi-
bitor of PKC, CDK2 and PDK1) [Fuse et al., 2005; Komander et al., 2003; 
Millward et al., 2006]. Another well-known group of inhibitors sharing struc-
ture similarity with staurosporine are the so-called K-252-series compounds 
named after the natural non-selective inhibitor K252a, which inhibits Ser/Thr 
kinases as well as receptor Tyr kinases [Ruggeri et al., 1999]. Its derivatives 
KT-5720 and KT-5823 (Figure 13D–E) have been widely used as PKAc and 
PKG-selective compounds, respectively [Kase et al., 1987; Smolenski et al., 
1998]; however, several recent studies failed to report the in vivo effects of 
these compounds [Bain et al., 2003; Burkhardt et al., 2000; Murray A. J., 2008]. 
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Figure 13. Examples of natural ACIs and their derivatives. (A) Balanol [Pande et al., 
2008]. (B) Flavopiridol [Senderowicz, 1999]. (C) Staurosporine [Gani and Engh, 2010]. 
(D) KT-5720 [Gani and Engh, 2010]. (E) KT-5823 [Kase et al., 1987]. 
 
 
ACIs have been also used in chemical genetics approaches, where non-natural 
ligand/enzyme pairs are generated by point-mutation of the enzyme (i.e., 
resulting in enlargement of certain pockets in the enzyme) and synthesis of 
sterically bulky ligand not able to bind the non-modified enzyme [Elphick et al., 
2007]. The idea behind the chemical genetics is to monitor the pathways of the 
point-mutated enzyme substituting the natural wild-type enzyme in its natural 
habitat; in case of PKs, the most frequently applied non-natural ligand is 
represented by the N6-substituted radioactively labeled ATP derivatives which 
function as 32P-phosphoryl donors [Bishop et al., 2001]. However, the latter 
compounds often yield extremely low signals, as their affinity towards the 
modified enzyme is not considerably better than that of ATP (but ATP is 
present in the cell in much higher concentration); additionally, they suffer from 
hydrolysis of phospho-diester bonds, and from poor cell membrane-penetrative 
properties. Therefore, ACIs have emerged as powerful alternative “devices”; for 
instance, derivatives of pyrazolo-pyrimidine inhibitor PP1 (Figure 12E) have 
been widely applied for the investigation of cellular responses to selective 
blocking of the PK of interest (i.e., GRK2, v-Erb, CAMK-II, etc.) achieved by 
chemical genetics [Liu Y. et al., 1999; Wang H. et al., 2003]. 
 
 
N
H
NH
O
O H
O
OH
O H
O
O
COOH
OH O
OH O
O H
N
OH
Cl
N N
O
N
H
O
O
N H
N N
N
H
O
O
OH O
O
N N
N O
O
O O
O53 
2.3.3. Reversible mono-ligand inhibitors.  
Special case: Protein/peptide substrate-competitive inhibitors 
 
Inhibitors competing with protein substrates of PKs for binding represent 
another large group of PK inhibitors, which is under the scope of intense 
research. Protein substrate-competitive inhibitors (PCIs) have been considered 
very promising from the aspect of selectivity towards their PK targets, as PCIs 
bind to the site of PK responsible for recognition of specific substrates, and are 
thus potentially able to pinpoint the pattern of interactions characteristic of the 
target PK [Bogoyevitch et al., 2005; Parang and Sun, 2004]. However, as the 
protein substrate-binding site of PKs is not well defined and opened to solvent, 
binding of compounds to this site is associated with large entropic costs that 
must be compensated by an extremely high enthalpy of binding, necessitating 
generation of multiple interactions between a PK and a PCI. The latter require-
ment, on the other hand, means that PCI itself can generally not be a small-
molecular weight compound; large molecular weight and poor proteolytic 
stability of PCIs consisting of natural amino acids have substantially raised 
doubts about efficacy of PCIs as a class of inhibitors. 
Still, PCIs are endowed with several remarkable properties that may 
outweigh disadvantages. First of all, compounds binding to the substrate site of 
PKs may express positive cooperativity with ligands binding to the ATP-site, as 
demonstrated by NMR studies with PKAc where affinity of substrate peptide 
Kemptide (Leu-Arg-Arg-Ala-Ser-Leu-Gly) was enhanced 3.4-fold in case of 
ATP-first mechanism of binding (as compared to Kemptide-first mechanism) 
[Masterson et al., 2008]. Therefore, affinity of PCIs in the presence of high 
intracellular concentration of ATP is enhanced, not reduced as in case of ACIs. 
The exact mechanism of such positive cooperativity may vary between PKs, 
i.e., PKAc relies on one residue (Tyr204) for the dispersion of perturbations 
from substrate-binding region to the distal sites of the PK molecule [Lew et al., 
1997a; Masterson et al., 2008]. Secondly, it has been established that similar to 
protein-protein interfaces, the critical contribution to the binding energy of 
peptidic compounds results from interactions of only a small number of peptide 
residues with the protein molecule, creating so-called hot-spots of binding 
[London et al., 2010]. Hence, identification of potential hot-spot regions in a 
PK and targeting those hot-spots with a PCI should enable reduction of 
molecular weight of the latter while preserving its affinity.  
Generally, the strategies for PCI discovery either use information from the 
analysis of sequences of natural PCIs, substrates or pseudosubstrates (i.e., 
autoinhibitory sequences) of PKs, or utilize libraries of peptides to determine 
the amino acid residues preferred by a PK in each position of the PCI sequence. 
The first strategy is probably best illustrated by PCIs of PKAc derived from the 
natural heat-stable protein kinase inhibitor (PKI). There are three isoforms of 
PKI expressed in human organism (PKI, PKI, and PKI), which have slightly 
different abundance in tissues (PKI is the most abundant) and affinity towards 54 
PKAc (Ki values
4 of 0.2 nM, 7.1 nM, and 0.4 nM, respectively) [Dalton and 
Dewey, 2006]. All isoforms contain a highly ordered pseudosubstrate domain 
and a leucine-rich nuclear export signal, whereas the rest of the PKI molecules 
is disordered, which probably contributes to the thermostability of this protein. 
The biochemical analysis of PKI revealed that the shortest fragment with 
affinity comparable to that of full-length PKI is the 20-mer peptide PKI(5–24) 
(Ki = 2.3 nM; Table 3A), whereas the minimal fragment of PKI retaining 
relatively high affinity towards PKAc is 9-mer PKI(14–22) with the amino 
acid sequence Gly-Arg-Thr-Gly-Arg-Arg-Asn-Ala
5-Ile (Ki = 36 nM) [Bogoye-
vitch et al., 2005]. Interestingly, the latter sequence is nearly identical to the 
“optimal sequence” of PKAc substrates as identified from subsequent screening 
of compound libraries, Arg/Xaa-Arg/Xaa-Xaa-Arg-Arg-Xaa-Ser-Hyd (where 
Xaa is any and Hyd is hydrophobic amino acid) [Pearce et al., 2010]. Moreover, 
the same sequence is contained in PKArI and PKArII subunits with only 
difference in position P±0, which is Ala in PKArI but Ser in PKArII; 
consequently, PKArI also serves as PCI of PKAc, with KD value of 0.8 nM in 
the presence of ATP and in the absence of cAMP [Diskar et al., 2007; Herberg 
and Taylor, 1993]. PKArII, on the other hand, may be either an inhibitor or a 
substrate of PKAc, with the dissociation constant values of 0.7 nM and 40 nM 
for non-phosphorylated and phosphorylated forms of PKArII, respectively (in 
the absence of cAMP) [Diskar et al., 2007]. 
 
                                                            
4   The  Ki values provided in text for PKI and PKI fragments are valid in the presence 
of ATP; in the absence of ATP, the affinity of PKI is substantially lower (for instance, 
the KD value for PKI towards PKAc is 230 nM [Herberg and Taylor, 1993]). 
5   The uderlined Ala-reside corresponds to the phosphorylatable Ser/Thr residue in 
PKAc substrates. 55 
Table 3. Structures of PCIs  
 
Code  Name Structure
A  PKI(5–24) 
[Smith C. M. et al., 1999]
Thr-Thr-Tyr-Ala-Asp-Phe-Ile-Ala-Ser-Gly-Arg-
Thr-Gly-Arg-Arg-Asn-Ala
a-Ile-His-Asp 
B  Compound 36a 
[Kayser et al., 2007] 
 
C  – 
[Ward and O’Brian, 
1993]
Myr-Arg-Lys-Arg-Thr-Leu-Arg-Arg-Leu 
D  – 
[House and Kemp, 1987]
Arg-Phe-Ala-Arg-Lys-Gly-Ala-Leu-Arg-Gln-Lys-
Asn-Val-His-Glu-Val-Lys-Asn
E  myr-PKC 
[Eichholtz et al., 1993]
Myr-Phe-Ala-Arg-Lys-Gly-Ala-Leu-Arg-Gln 
F  myr-PKC 
[Dominguez et al., 1992]
Myr-Arg-Arg-Gly-Ala-Arg-Arg-Trp-Arg-Lys 
G  WW21 
[Dostmann et al., 1999]
Thr-Gln-Ala-Lys-Arg-Lys-Lys-Ala-Leu-Ala-Met-
Ala-NH2
H  W45 
[Dostmann et al., 2000]
Leu-Arg-Lys5-His
I  DT-2 
[Dostmann et al., 2000]
Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-
Pro-Pro-Leu-Arg-Lys5-His
J  AKTide-2T 
[Luo Y. et al., 2004] 
Ala-Arg-Lys-Arg-Glu-Arg-Thr-Tyr-Ser-Phe-Gly-
His-His-Ala
K  Peptide 2 
[Luo Y. et al., 2004] 
Val-Glu-Leu-Asp-Pro-Glu-Phe-Glu-Pro-Arg-Ala-
Arg-Glu-Arg-Thr-Tyr-Ala-Phe-Gly-His 
L  IDA peptide 
[Fukami et al., 1999] 
Leu-Ala-Arg-Val-Ala-Asp-Pro-Asp-His-Asp-His-
Thr-Gly-Phe-Leu-Thr
b-Glu-Tyr-Val-Ala-thr-Arg-
Trp-Tyr-Arg-Cys
M  KRX-123.302 
[Goldenberg-Furmanov et 
al., 2004] 
Myr-Gly-Leu-Val-Thr-(3,5-dITyr)-(D-Lys)-Lys-
Ile-(-abLys)-NH2 
 
N  P15 
[Perea et al., 2004] 
cyclic* Cys-Trp-Met-Ser-Pro-Arg-His-Leu-Gly-
Thr-Cys
N
O
O NH N H2
NH
N HO
NH
NH
O
NH
O56 
Code  Name Structure
O  Compound 18 
[Priestman and 
Lawrence, 2010] 
 
a Underlined are the residues corresponding to P0 position of the substrate; 
b in italics is 
given the Tyr residue which serve as phosphorylation sites in a PK; * cyclic peptide 
generated via formation of S-S bond between the side-chains of Cys residues; Myr, 
myristoyl residue; 3,5-dITyr, 3,5-diiodo-tyrosine; -abLys, -aminobenzoyl-lysine. Red 
lines indicate positions where bonds are broken upon irradiation. 
 
 
For PKB, several PCIs were designed based on the PKB substrate protein 
GSK3, i.e., the 6-mer mimicking the structure of the GSK3 sequence Gly-
Arg-Pro-Arg-Thr-Thr-Ser-Phe (Table 3B); the N-terminal derivatization of this 
compound with cholesterol yielded the compound PTR6164, which effectively 
inhibited the growth of prostate cancer cells in xenograft models [Collins, 2009; 
Kayser et al., 2007]. In case of PKC, one of the first examples was the N-
myristoylated 8-mer derived from the major site of PKC-catalyzed phospho-
rylation on EGFR (Table 3C); interestingly, the latter served as an inhibitor of 
PKC despite containing a phosphorylatable Thr residue [Ward and O’Brian, 
1993]. Other PKC-targeted PCIs based on the pseudosubstrate motif from the 
N-terminal regulatory domain of PKC were represented by the 18-mer peptide 
corresponding to residues 19–36 of PKC and PKC (Ki value of 150 nM 
towards PKC; Table 3D) [House and Kemp, 1987], and the myristoylated 9-
mer myr-PKC (Table 3E) [Eichholtz et al., 1993]. The same approach was 
also used to generate a highly selective PCI targeted to the PKC isoform 
(Table 3F), taking advantage of the fact that the pseudosubstrate motif of PKC 
differs from those of PKC, PKC, and PKC isoforms [Dominguez et al., 
1992]. PCIs derived from the sequences of substrates and pseudosubstrates have 
also been designed for other Ser/Thr-kinases (i.e., MLCK, MAP kinases) as 
well as Tyr-kinases (i.e., Src) [Bogoyevitch et al., 2005; Parang and Sun, 2004]. 
The best progress in the library-aided strategy of PCI discovery was 
demonstrated by the PKG-targeted compounds. Kinetic screening of exhaustive 
8-mer, 12-mer and 14-mer substrate libraries (where an optimal amino acid 
residue out of 20 natural amino acids was found for every position in the 
peptide) identified sequences with high selectivity towards PKGI  versus 
closely related PKAc [Dostmann et al., 1999; Tegge et al., 1995]. The 
subsequent replacement of Ser with Ala in one of these substrates yielded a 12-
NH
O
N H
Arg-Asn-Ala-Ile-NH2 Gly-Arg-Thr-Gly
N H N
H
O
O
O
NO2
O57 
mer PCI with a Ki value of 7.5 M and 100-fold selectivity versus PKAc (Table 
3G). In analogical approach, kinetic screening of 8-mer PCI libraries identified 
the inhibitor W45 with a Ki value of 0.8 M towards PKGI and a 700-fold 
selectivity versus PKAc (Table 3H) [Dostmann et al., 2000]. Conjugation of 
W45 with the membrane translocation signal of HIV-1 Tat-protein yielded 
inhibitor DT-2 (Table 3I), demonstrating an astonishing Ki value of 0.012 M 
towards PKGI and remarkable vasodilatory effects in isolated rat arteries 
[Dostmann et al., 2000; Dostmann et al., 2002; Taylor M. S. et al., 2004]. DT-2 
possessed a competitive mechanism of inhibition versus the substrate peptide; 
interestingly, the recent mass-spectroscopic studies of DT-2 complex with 
homodimeric PKGI revealed that one DT-2 molecule binds simultaneously to 
both monomers of PKGI [Pinkse et al., 2009]. 
  The library-aided strategy has also yielded high-affinity PCIs towards PKB, 
such as 14-mer AKTide-2T with a Ki value of 12 M towards PKB (Table 
3J); interestingly, AKTide-2T acted as an inhibitor despite incorporation of Tyr 
and Ser residues [Cheng J. Q. et al., 2005; Luo Y. et al., 2004]. The subsequent 
modification of AKTide-2T and conjugation with the PKB substrate FOXO3 
resulted in a 20-mer PCI with a Ki value of 110 nM towards PKB and high 
selectivity towards PKB versus closely related PKs (PKA, p70 S6K, PKC 
and  ,  etc) [Table 3K; Luo Y. et al., 2004]. This compound successfully 
inhibited PKB-catalyzed GSK3 phosphorylation in HeLa cell culture, but was 
not stable long enough to induce apoptosis. Finally yet importantly, peptide 
libraries have also been successfully used for generation of PCIs towards PKC 
[Lee J. H. et al., 2004], and PKs from a substantially different group of kinome 
such as c-Src [Lam et al., 1995].  
An interesting approach for substrate-competitive inhibition of PKs has been 
proposed in 1999, with the rationale to protect PK substrates from phospho-
rylation by development of an inhibitor that binds these substrates (i.e., a 
compound that actually competes with the PK for the substrates) [Fukami et al., 
1999]. Such a PCI should structurally correspond to a short segment of PK, or 
mimic a PK region situated near the catalytic site of a PK and composed of the 
amino acids unique for the PK of interest (or at least for the PK family of 
interest). For instance, the MAPK fragment situated between the highly con-
served sequence Asp-Phe-Gly and triad Ala-Pro-Glu has been utilized for the 
design of inhibitors of the MAPK pathway (i.e., Table 3L), demonstrating 
activity in both, in vitro and in oocytes [Fukami et al., 1999]. Another example 
is represented by the substrate-binding loop of the Src family member Lyn, 
which was used as a template for the generation of 8-mer peptides with high 
sequence similarity; one of the resulting peptides, KRX-123.302 (Table 3M) 
inhibited the Lyn-catalyzed phosphorylation of physiological substrate Syk with 
an IC50 value of 300 nM [Bogoyevitch et al., 2005; Goldenberg-Furmanov et 
al., 2004]. The same principles were applied for the discovery of PCIs towards 
another Tyr-kinase c-Kit, and towards Ser/Thr-kinases PKB, PDK1 [Niv et al., 
2004]. An analogical compound P15 competing with CK2 for the substrates 58 
was derived from the screening of the cyclic peptide phage display library 
towards a substrate of CK2 (Table 3N); upon conjugation with Tat-peptide, P15 
revealed proapoptotic antitumor effects in mice bearing solid tumors [Perea et 
al., 2004]. 
PCIs have been recently applied as so-called caged compounds, i.e., com-
pounds that acquire or loose inhibitory properties upon structural modification 
resulting from illumination of the sample [Lee H.-M. et al., 2009]. Caged com-
pounds are especially useful in cellular assays where a “switch” of PK activity 
is monitored, as those may induce such switch without altering the endogenous 
protein expression levels. Typically, a PCI is labeled with a photolabile group 
(i.e., ortho-nitrobenzyl, hydroxyphenacyl, coumarin, or cinnamate moiety) that 
prevents binding of the PCI to its target; however, the inhibitor is present in the 
cellular environment, and when the photolabile group is cleaved by photolysis, 
the PCI is released that may inhibit its target PK [Priestman and Lawrence, 
2010]. An elegant variant of caged PCI has been reported for PKAc (Table 3O), 
where a sequence derived from PKI was modified at the side-chain of Arg in-
volved in forming of hot-spot interactions when binding to PKAc (cor-
version of the same PCI was released, possessing a Ki value of 0.42 M and 
successfully blocking the morphological changes induced by a cell-permeable 
PKAc activator [Priestman and Lawrence, 2010].   
In all of the aforementioned PCIs, the primary concern for usage inside the 
cell is the lack of ability of several peptides to cross the plasma membrane. 
Several techniques have been used for improvement of the membrane-
penetrative properties of PCIs, including introduction of hydrophobic fragments 
(i.e., myristoyl, palmitoyl, or cholesterol moieties, or conjugation with the 
peptide sequences endowed with cell membrane-penetrative properties [Collins, 
2009; Dostmann et al., 2000; Eichholtz et al., 1993; Harris et al., 1999; Perea et 
al., 2004; Prudent and Cochet, 2004]. The latter sequences termed CPPs (cell-
penetrating peptides) represent a variety of structures, differing in amino acid 
sequence and consequently, electrostatic charge; CPPs have been used to 
deliver a large variety of cargos into cells, such as peptides or proteins, and 
oligo-nucleotides [Fischer R. et al., 2002; Watkins et al., 2009]. The most 
widely applied CPPs (Table 4) are represented by fragments of transcription 
factors, i.e., the antennapedia peptide derived from Drosophila melanogaster 
Antennapedia homeodomain protein (Antp), and the previously mentioned Tat-
peptide derived from the HIV-1 Tat protein; other well-known CPPs are oligo-
Arg peptides [Duchardt et al., 2007; Fischer R. et al., 2002; Watkins et al., 
2009].  
 
   
responsing to P-2 position of PKI); the caged compound had a Ki  value  of        
20  M towards PKAc. However, upon irradiation at 300...400 nm, the uncaged 59 
Table 4. Structures of CPPs (according to [Duchardt et al., 2007; Fischer R. et al., 
2002]) 
 
Name  Sequence 
Antp  Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys 
MTS  Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-leu-Leu-Ala-Pro 
oligo-Arg  Arg6...Arg18 
Tat-peptide  Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg 
MTS, Kaposi fibroblast growth factor (FGF)-derived membrane-translocating sequence. 
 
 
Given the highly charged cationic nature of several CPPs (espicially Tat and 
oligo-Arg), it is surprising that those are able to cross the lipophilic plasma 
membrane; despite the fact that the exact mechanism of membrane translocation 
of CPPs has been an object of thorough research, no consensus currently exists 
considering this issue. Endocytosis has been suggested as the major variant, 
further supported by several studies demonstrating the independence of cellular 
uptake of CPPs on temperature, receptors, or energy of ATP hydrolysis 
[Duchardt et al., 2007; Watkins et al., 2009]. However, other experiments have 
shown different mechanism of uptake at higher concentrations of CPPs, 
occurring at spatially restricted sites of the plasma membrane and leading to a 
rapid cytoplasmic distribution of CPPs without formation of endocytotic 
vesicles [Duchardt et al., 2007; Watkins et al., 2009]. All in all, it has been 
suggested that several mechanisms might be responsible for membrane 
translocation of CPPs, whereas the latter process may also be influenced by the 
cargo attached to the CPP. Considering the latter issue, the use of CPPs should 
be carefully guided, as cargo may influence the properties of CPP and vice 
versa [Fischer R. et al., 2002]. For instance, the Tat-peptide has been shown to 
affect the affinity and selectivity of PCIs targeted to PKG, whereas recent 
studies indicated that the Tat-peptide itself acts as a potent PCI of PKC and 
PKA (IC50 values of 22 nM and 1200 nM, respectively), and may also inhibit 
other representatives of AGC-group [Ekokoski et al., 2010]. 
Another major concern from the aspect of intracellular applications of PCIs 
is the poor proteolytic stability of peptides composed of L-amino acids.  The 
two major strategies to overcome this issue are represented by use of backbone-
modified PCIs, or generation of peptidomimetics. The first strategy takes 
advantage of the fact that backbone-modified peptides may not be recognized 
by proteases, and therefore are more stable in complex biological systems; the 
main way of backbone modification is generation of enantio-, retro- or retro-
inverso variants of the PCI (Figure 14) [Fischer P. M., 2003]. An enantio-
peptide is composed of D-amino acids, whereas the sequence of AAs is exactly 
the same as in initial peptide; a retro-peptide, on the other hand, is composed of 
L-amino acids, but the sequence of amino acids in N -> C direction of the retro-
peptide corresponds to the same sequence of amino acids in C -> N direction of 
the initial peptide. A retro-inverso peptide involves both changes of the initial 
peptide structure, being composed of D-amino acids with the reversed order of 60 
amino acids in N -> C direction; such peptide may be regarded as a derivative 
of initial peptide where the relative topology of amino acid side-chains is 
maintained, but the backbone termini and the direction of peptide bonds is 
reversed [Fischer P. M., 2003]. All of these modifications may also be used just 
in some regions of the PCI, if the aim is to prevent the modification of the 
backbone of the whole molecule. Although an introduction of such profound 
changes into the structure of a PCI may raise doubts considering the affinity of 
the modified inhibitor, the backbone-modification strategy has proved its 
efficiency in several PCIs [Bonny et al., 2001; Ricouart et al., 1989; Phipps and 
Terreux, 2007; Wood J. S. et al., 1996]. Probably the best illustration is 
represented by enantio- and retro-inverso variants of PKGI-targeted DT-2 that 
had 15-fold and 2-fold lower Ki values, respectively, than DT-2 itself, and also 
possessed improved selectivity as well as enhanced cell membrane-penetrative 
properties [Nickl et al., 2010]. 
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Figure 14. Backbone-modified variants of Leu-Arg-Arg-Ala-Ser peptide (the initial 
peptide is coloured green). (A) Enantio-variant (magenta). (B) Retro-variant (cyan). (C) 
Retro-inverso variant (yellow). 
 
 
Peptidomimetics can be designed by the following ways (Figure 15A) [Grauer 
and König, 2009; Li S. and WenFang 2009]: 
  modification of amino acid side-chains (i.e., -disubstitution for introduction 
of conformational restrictions);  
  backbone modifications (i.e., exchange/derivatization of N-H, C-H or C(=O) 
groups of backbone, extension of the peptide chains, or replacement of 
amide bonds);  
  global restrictions (i.e., head-to-tail or side chain-to-side chain cyclization).  
Some of the backbone modifications could result in loss of chirality associated 
with replacement of C atoms. For instance, in azapeptides (Figure 15C); 
synthesized from substituted hydrazines or hydrazides) the nitrogen atom is 
substituted for the C, and in peptoids Figure 15D; synthesized from bro-
moacetic acid and primary amines) the carbon atom corresponding to C is not 
chiral (resembling Gly moiety) and the “side-chain” is attached to backbone 
nitrogen atom [Grauer and König, 2009]. Whereas elimination of chirality 61 
provides several synthetic opportunities (i.e., originating from the fact that 
deprotonation of C would not cause enantiomerization), it may result in a con-
siderable loss of affinity of PCI. However, peptidomimetics have been success-
fully applied as inhibitors of PKB; although being less potent than original 
peptidic inhibitors, these compounds demonstrate the potential of the whole 
peptidomimetic strategy [Collins, 2009; Tal-Gan et al., 2010]. 
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Figure 15. Examples of peptidomimeics and small molecular weight-PCIs. (A) Variants 
of peptidomimetics (adapted from [Grauer and König, 2009]). (B) ON012380 [Gumi-
reddy  et al., 2005]. (C) Azapeptide variant of Leu-Arg-Arg-Ala-Ser peptide. (D) 
Peptoid variant of Leu-Arg-Arg-Ala-Ser peptide. 
 
 
Finally, several small molecular weight-inhibitors have been recently disco-
vered from screening of compound libraries, representing a variety of non-
peptidic structures and expressing substrate-competitive inhibition patterns; the 
examples of PKs targeted by these compounds involve ERK, polo-like kinase-1, 
BCR-Abl, and IGFR1 [Bogoyevitch and Fairlie, 2007; Levitzki and Mishani, 
2006]. One of the most potent small molecular weight-PCIs was the BCR-Abl 
inhibitor ON012380 (Figure 15B), possessing low nanomolar inhibition 
characteristics (IC50 = 9 nM), and inducing cell death at a 10 nM concentration 
of the inhibitor in cell lines expressing wild-type BCR-Abl or imatinib-resistant 
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Thr315Ile mutant BCR-Abl [Gumireddy et al., 2005]. Moreover, ON012380 
was effective in mice injected with cells expressing the T315I mutant, and 
showed no toxicity or other acute side-effects. 
To sum up, the PCI strategies for inhibition of PKs have proved their effi-
ciency both in vitro and in vivo, and are gradually evolving as physiologically 
active reagents in parallel to ACIs. 
 
 
2.3.4. Reversible mono-ligand inhibitors. Special case:  
Allosteric inhibitors and inhibitors of activation 
 
Apart from the design of ACIs and PCIs, another technique for the development 
of PK inhibitors is targeting remote sites and pockets not directly involved in 
catalytic functioning of kinases, i.e., allosteric sites. Allosteric inhibitors (ALIs) 
do not directly compete with ATP
6 or protein/peptide substrates but rather in-
duce conformational changes in PK that indirectly lead to impedance of the 
phosphorylation reaction; thus, ALIs usually exhibit a non-competitive inhi-
bition pattern versus both ATP and protein/peptide substrates [Bogoyevitch and 
Fairlie, 2007; Lewis et al., 2008].  
The binding sites of few ALIs have been determined after obtainment of the 
crystal structure of PK-ALI complexes. For instance, co-crystals of MEK1 and 
MEK2 with ATP and the allosteric inhibitor PD318088 (Figure 16A) revealed 
existence of a unique binding pocket adjacent to the ATP-site in kinases; this 
pocket probably also binds PD318088 analogue PD184352, which has 
demonstrated antiproliferative effects in vivo and is currently undergoing 
clinical trials [Ohren et al., 2004]. Other methods for the identification of ALI 
binding sites involve the following approaches: 
  deuterium-exchange mass-spectrometry (i.e., applied for CMPD1 binding to 
p38 MAPK) (Figure 16B), [Davidson et al., 2004]);  
  proteolytic degradation and site-directed mutagenesis, i.e., applied for 
polyoxometalates targeting CK2 [Prudent and Cochet, 2009], and for GNF-1 
and GNF-2 targeting BCR-Abl (Figure 16C [Adrian et al., 2006]);  
  structure-activity relationships and molecular docking studies, i.e., applied 
for thiadiazolidinone-derived ALIs binding to GSK3 (Figure 16D, [Marti-
nez et al., 2002; Martinez et al., 2005]) and for coumarine derivative G8935 
inhibiting MEK1 (Figure 16E, [Han et al., 2005]). 
                                                            
6  Type II-inhibitors are also frequently considered as allosteric, but in the context of 
given thesis the range of allosteric inhibitors is limited with compounds not binding to 
the catalytic cleft of PK. 63 
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Figure 16. Examples of ALIs. (A) PD318088 [Ohren et al., 2004]. (B) CMPD1 
[Davidson et al., 2004]. (C) GNF-1 [Adrian et al., 2006]. (D) Compound 11 [Martinez 
et al., 2002]. (E) G8935 [Han et al., 2005]. 
 
 
By virtue of targeting unique pockets of PKs considerably less conserved than 
the catalytic cleft, ALIs are supposed to possess a higher selectivity than any 
other class of PK inhibitors. However, the development of ALIs is compro-
mised by the fact that little is known about allosteric pockets of PKs as well as 
about structures of compounds that may fit these pockets. Historically, ALIs 
have been discovered as a result of screening of compound libraries, whereas 
the allosteric nature of inhibition of these compounds has been proven only 
during  subsequent studies [Bogoyevitch and Fairlie, 2007; Lewis et al., 2008].  
Another class of compounds binding outside the catalytic cleft is represented 
by inhibitors of PK activation, which target pockets of catalytic or regulatory 
domains/subunits responsible for recognition of co-factors and secondary 
messengers. A well-known family of activation inhibitors is constituted by 
analogues of cyclic nucleotides, which interact with cyclic nucleotide-binding 
regions of PKAr and regulatory domains of PKG and thus stabilize interactions 
between the regulatory subunit/domains and the corresponding catalytic 
subunits. The examples of cyclic nucleotide analogues inhibiting activity of PKs 
(Figure 17A–B) involve Rp-cAMPS, Rp-8-Br-cAMPS, Rp-8-pCPT-cGMPS, 
Rp-8-Br-cGMPS and Rp-8-Br-PET-cGMPS; all of those share two structural 
features, presence of a sulfur atom bound to phosphorus and an R-configuration 
of the corresponding phosphorus atom [Anand et al., 2010; Butt et al., 1995; 
Poppe et al., 2008; Smolenski et al., 1998; Wei et al., 1998]. Within these 
compounds, the best affinity as well as selectivity towards its target is possessed 
by Rp-8-Br-PET-cGMPS with a Ki value of 35 nM towards PKGI and an over 
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500-fold selectivity versus PKArI [Hofmann et al., 2009]. In general, cGMP 
analogues demonstrate better selectivity towards PKG versus PKAr than cAMP 
analogues towards PKAr versus PKG, revealing the same trend as in case of 
cGMP and cAMP themselves. This fact has been attributed to the presence of 
single Thr177 residue in PKGI (Ala211 in PKAr), which specifically interacts 
with the 2-amino position of cGMP guanine base [Shabb and Corbin, 1992]. 
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Figure 17. Examples of inhibitors of PK activation. (A) Rp-8-pCPT-cGMPS [Wei et 
al., 1998]. (B) Rp-8-Br-PET-cGMPS [Butt et al., 1995]. (C) DPIEL (PX-316) [Collins, 
2009]. (D) AKT-I-1,2 [Lindsley et al., 2005]. (E) API-2 (TCN) [Cheng J. Q. et al., 
2005]. (F) Compound 13 [Priestman and Lawrence, 2010]; red line indicates the posi-
tion where bond is broken upon irradiation. 
 
 
The PH-domain of PKB has also served as an attractive pocket for inhibitors 
preventing PKB activation by interfering with binding of PtdInsP3, which 
recruits PKB to the plasma membrane. Currently, PH-targeting PKB inhibitors 
constitute a large group of compounds (Figure 17C–E) involving PtdInsP3 
analogues (i.e., DPI, DPIEL, DCIEL, etc.), piperidinyl benzimidazolone deriva-
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tives (i.e., AKT-I-1, AKT-I-2, and AKT-I-1,2), di- and tricyclic nucleosides 
(i.e., API-1, API-2, TCN-P), benzene tetrakisphosphate, and alkylphospholipid 
perifosine (D-21266) [Bogoyevitch and Fairlie, 2007; Cheng J. Q. et al., 2005; 
Collins, 2009; Kim D. et al., 2010; Yang L. et al., 2004]. Practically all of these 
compounds have demonstrated not only in vitro inhibition of PKB, but also 
showed antitumor effects in mice xenograft models; additionally, most com-
pounds have been tested with PKB mutants lacking the PH-domain or myris-
toylated PKB (not requiring PtdInsP3 for association with membrane) and 
exhibited either absent or considerably reduced affinity. Out of this set, the best 
properties from the aspect of inhibition potency and selectivity are possessed by 
AKT-I-1, AKT-I-2, and AKT-I-1,2, which are not only selective versus other 
kinases, but also distinguish between the isoforms of PKB. AKT-I-1 inhibits 
potently only PKB (IC50 = 760 nM), AKT-I-2 only PKB (IC50 = 325 nM), 
and AKT-I-1,2 both PKBand PKB (IC50 values of 58 nM and 210 nM, 
respectively) but not PKB [Lindsley et al., 2005; Zhao et al., 2005].  
  Other examples of PK inhibitors preventing activation include cyclic 
peptides that disrupt the interactions between the CK2 catalytic and regulatory 
subunit, cyclic peptides and cyclin A-derived peptides that block binding of 
cyclin A to Cdk2, and compounds containing phosphorylated Tyr moieties or 
their analogues recognized by SH2 domains of various PKs [Bogoyevitch et al., 
2005; Parang and Sun, 2004; Prudent and Cochet, 2009]. The SH2-targeting 
compounds have also served as caged sensors of Lck (Kd values of 127 M and 
2.6 M for caged and uncaged forms, respectively), and as photo-deactivatable 
probes of Src with photolabile moiety positioned between the inhibitor frag-
ments targeting SH1 and SH2 sites of PK (Figure 17F) [Li H. et al., 2008; 
Priestman and Lawrence, 2010]. The latter compounds (Ki value of 26 nM for 
the most potent representative) were cleaved into two fragments by photolysis, 
resulting in a 50-fold decrease of affinity; this rationale illustrated well the idea 
of affinity enhancement by linking two fragments targeting different sites of 
PKs, which had given stimulus for the development of biligand inhibitors.  
 
 
2.3.5. Reversible biligand inhibitors.  
Special case: Bisubstrate inhibitors  
 
Biligand inhibitors are compounds that contain two interlinked fragments, where-
as each fragment binds to one site of a target PK. The group of biligand inhibitors 
comprises compounds that target only sites distant from the catalytic core of PKs 
(i.e., SH1 and SH2, or SH2 and SH3), the compounds which bind with one 
fragment targeting the distant site and another fragment targeting one of the sites 
in the catalytic core (i.e., either ATP-site of protein/peptide substrate-site), and 
bisubstrate inhibitors [Parang and Cole, 2002a; Shen et al., 2005]. 
  Bisubstrate inhibitors (BSIs) constitute a sub-group of biligand inhibitors 
that incorporate two interlinked fragments targeting the binding site for ATP 
and the binding site for protein/peptide substrate, respectively. By virtue of 66 
association with two sites of which one (ATP-site) enables development of 
multiple strong interactions and another (protein substrate-site) is responsible 
for selective recognition of ligands, BSIs should hypothetically be endowed 
with both, high affinity and high selectivity towards their PK-targets [Schneider 
et al., 2005]. The realization of those hypothetic advantages presupposes exact 
pinpointing of crucial interactions without entropic penalty, which in turn 
necessitates the precise design of BSIs. Historically, the basic principles of BSI 
design have been connected to two methodologies widely used for drug 
development, the fragment-based drug design and the transition-state analogue 
inhibitor approach [Borsi et al., 2010; Wolfenden, 1972].  
  The leading concept of the fragment-based approach implies that a high-
affinity inhibitor can be constructed by tethering with a suitable linker two or 
more fragments (ligands) that bind to separate yet adjacent sites [Borsi et al., 
2010; Gill, 2004]. The fragment-based inhibitor discovery thus relies on the 
initial identification of moieties that bind to different sites of the target PK, and 
subsequent covalent linkage of these moieties. The choice of fragments in the 
initial step is generally performed by screening of large fragment libraries by 
NMR, by computational approaches, or by summarizing data from crystallo-
graphic studies; typically, the molecular weight of a fragment is below 150 Da 
[Akritopoulou-Zanze and Hajduk, 2009; Hajduk et al., 2005; Vieth et al., 2009]. 
The examples of two main approaches used for the conjugation of fragments are 
as follows [Akritopoulou-Zanze and Hajduk, 2009; Morphy, 2010]: 
  “front-to-back”-mechanism when a hinge-binding fragment if first estab-
lished and the rest of the compound is “grown” by the attachment of 
fragments targeting more distal sites;  
  the opposing “back-to-front”-mechanism where expectedly selective frag-
ment targeting a distal site is first identified and subsequently connected to 
less selective but more potent moieties.  
Provided that the fragments and the linker(s) are properly arranged, the net 
binding free energy change of the formed conjugate (GB) should be equal to 
the sum of changes of the binding free energies of the fragments (G1 and G2) 
plus an additional linking gain (GL) according to Equation 12. The latter term 
is primarily explained by the relative entropic gain resulting from the interaction 
of a single molecule rather than multiple fragments with the protein molecule, 
which may contribute to the net increase in conjugate affinity (as compared to 
affinities of the initial fragments) up to three orders of magnitude [Borsi et al., 
2010]. Moreover, GL may reflect other effects, such as:  
  unfavorable enthalpic contributions that arise from distortions of the frag-
ment binding geometry;  
  unfavorable entropic contributions originating from increased confor-
mational flexibility in case of longer linkers (if the connected fragments bind 
to spatially distal sites);  
  unfavorable or favorable interactions between the linker and the target;  
  positive synergistic effects upon binding of one fragments of the conjugate.  67 
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Equation 12. The relationship between the change of the net binding free energy of the 
conjugate and the changes of the binding free energies of the fragments composing the 
conjugate. 
 
 
The concept of the transition-state analogue inhibitor approach, on the other 
hand, lies in the notion that if enzymes per se are supposed to facilitate reaching 
the transition state for the reaction, they should possess especially high affinity 
towards the altered substrate in the transition state, exceeding that towards the 
initial form of the substrate [Wolfenden, 1972]. Consequently, PK inhibitors 
that are composed of two substrate-mimicking fragments should utilize the 
features of the PK-catalyzed reaction between the initial substrates. The first 
kinase inhibitors designed according to the transition-state analogue approach 
were reported in 1973, and since then this paradigm has been widely applied for 
the development of PK inhibitors [Lienhard and Secemski, 1973].  
  The first PK inhibitors utilizing ATP fragment were represented by the 
PKAc-targeted BSI composed of ATP linked to the PKAc substrate Kemptide 
via the oxygen atom of the Ser side-chain incorporated in Kemptide [Medzih-
radszky et al., 1994], and EGFR inhibitors composed of sulfobenzoyl-adenosine 
moieties linked covalently to small peptides via side-chain of the Tyr residue 
incorporated in peptide structures [Rosse et al., 1997]. Unfortunately, all of 
these conjugates showed low affinity towards their target PKs, which in sub-
sequent works was attributed to the utilization of a wrong model of the 
transition state for the phosphorylation reaction. On the basis of experimental 
studies with Tyr-kinases, it was proposed that PKs generally utilize the 
dissociative mechanism of phosphoryl transfer, hence the distance between the 
entering slightly nucleophilic oxygen and the attacked phosphorus should be 
over 4.9 Å [Kim K. and Cole, 1998]. The IRK-targeting inhibitor modified 
according to the latter model by introduction of the linker (Figure 18A) had 
considerably higher affinity (Ki value of 370 nM) than the composing frag-
ments, ATP and substrate peptide (Km values of 71 M and 280 M, respecti-
vely) [Parang et al., 2001]. Later on, analogical constructs of ATP conjugated 
with substrate peptides or their analogues via short linker were designed as BSIs 
of PKAc (Ki value of 3.8 M [Hines and Cole, 2004]), Csk (IC50 value of 600 
nM [Shen and Cole, 2003]), CAMK-II (IC50 value of 22 nM [Ahn et al., 2007]) 
or CDK2 (Ki value of 0.83 nM [Cheng K.-Y. et al., 2006]). The latter com-
pound (Figure 18B) represented a multiligand rather than a biligand class of 
inhibitors, as the fragment of the applied substrate peptide contained not only 
sequence binding to the protein/peptide substrate-site, but also the recognition 
motif Arg-Xaa-Leu which binds to the distal site located on CDK-2 activator 
cyclin A [Cheng K.-Y. et al., 2006].  
 68 
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Figure 18. Examples of BSIs incorporating the ATP moiety. (A) Compound 2 [Parang 
et al., 2001]. (B) CDC6 bispeptide [Cheng K.-Y. et al., 2006]. (C) Compound 1b 
[Green and Pflum, 2007]; red arrow indicates the beginning of chain transferred to the 
hydroxyl group of phosphorylatable residue of a substrate. (D) BHAcATP [Patricelli et 
al., 2007]; blue arrow indicates the beginning of chain transferred to the Lys residue of 
a PK. 
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Interestingly, recent studies have demonstrated that a conjugate where biotin 
was covalently attached to the -phosphorus of ATP via a hydrophobic flexible 
linker incorporating a nucleophilic NH group (Figure 18C) served as reagents 
for biotinylation of PK substrates, as PKs from different groups of kinome (i.e., 
PKAc, CK2 and Abl) catalyzed transfer of biotin-modified phosphoryl groups 
from the conjugate to the substrate peptides [Green and Pflum, 2007]. By 
contrast, an analogical conjugate of biotin and ATP where the linker was shorter 
and incorporated an electrophilic carbonyl group (Figure 18D) could be applied 
for biotinylation of PKs themselves [Patricelli et al., 2007]. The latter conjugate 
enabled biotinylation of an amazing amount of ATP-utilizing proteins, whereas 
394 PKs from different proteomes were labeled [Patricelli et al., 2007]. The 
mechanism of the biotinylation reaction involved attack of the highly conserved 
lysine residues in the catalytic cleft of kinases (corresponding to Lys 72 and 
Lys168 of PKAc) on the electrophilic center of the conjugate, causing covalent 
attachment of the linker-biotin moiety to the kinase via amide bond [Patricelli et 
al., 2007]. 
The next step in the development of BSIs was the elimination of phosphoryl 
groups of ATP. The best-studied compounds of this type are probably 
exemplified by adenosine analogue-oligoargine conjugates (ARCs); ARCs have 
evolved as a variety of structures, according to which these conjugates have 
been grouped into several “generations” [Lavogina et al., 2010a]. Generations 
ARC-II and ARC-III constitute the object of investigation of the current thesis, 
and will be discussed in detail in the following sections; generation ARC-I is 
composed of conjugates consisting of adenosine-4’-dehydroxymethyl-4’-carbo-
xylic acid moiety (Adc) and oligo-(L-arginine) joined by hydrophobic flexible 
linkers [Loog et al., 1999]. The most potent representative of ARC-I generation 
possessed an IC50 value of 700 nM towards PKAc (Figure 19A). It was also 
shown that ARC-I compounds could be derivatized with fluorescent dyes 
(Bodipy FL, TAMRA), PEG and biotin without remarkable loss of affinity of 
the conjugates, and applied as affinity supports for isolation and extraction of 
PKAc and other basophilic PKs from biological systems [Loog et al., 2000; Uri 
et al., 2002; Viht et al., 2003]. Moreover, by virtue of incorporation of oligo-
arginine, ARC-Is penetrated successfully plasma cell membrane and inhibited 
ROCK in living cells [Räägel et al., 2009]. 
Logically, ATP moiety is not the only fragment to be incorporated into the 
composition of bisubstrate inhibitors of PKs. First of all, application of other 
nucleoside-triphosphate moieties and their analogues (i.e., deoxy-variants) is 
possible, as it has been demonstrated that several PKs may utilize other 
phosphoryl donors than ATP, and large-scale utilization of ATP in the cellular 
signaling should primarily be attributed to the high concentration of the latter 
[Shugar, 1996]. Secondly, nucleoside-triphosphates and their close analogues 
do not possess high affinity towards PKs, whereas according to Equation 12, the 
higher  affinity of the fragments is, the better is the binding of the conjugate. 
Thus, it would be more considerable to use potent ATP-competitive inhibitors 
than the ATP-site targeting fragments of BSIs.  70 
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Figure 19. Examples of BSIs incorporating adenosine anologues. (A) Compound VII 
[Loog et al., 1999]. (B) Compound 17 [Ricouart et al., 1991]. (C) PTR-6132 [Livnah et 
al., 2003]; Orn = ornithine. (D) Compound 1a [Shomin et al., 2009]; * cyclic peptide 
generated via formation of S-S bond between the side-chains of Cys residues; the cyclic 
peptide fragment attached to the rest of the conjugate via the N-terminus of the Cys 
residue. 
 
 
Indeed, the latter rationale has yielded several potent PK inhibitors, the first 
examples represented by conjugates of H-series inhibitors with oligo-arginine 
peptides; the most potent of these compounds (Figure 19B) possessed a Ki value 
of 100 nM towards PKC and 4 nM towards PKAc [Ricouart et al., 1991]. Iso-
quinoline moieties have also been applied in conjugates with PKB-selective 
peptides to generate potent BSIs targeted to PKB; one of the most potent 
compounds (Figure 19C) exhibited a high affinity towards PKB (IC50 value of 
20 nM) as well as PKAc, and efficiently inhibited cell growth of cancer cells 
[Livnah  et al., 2003; Livnah et al., 2004]. The ATP-competitive inhibitor 
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staurosporine as well as its derivatives have also been used for the design of 
BSIs targeting CDK, PKC, or PKAc, whereas the most promising results from 
the aspect of both, affinity and selectivity, were achieved for PKAc-targeted 
BSIs [Schneider et al., 2005; Shomin et al., 2009]. The latter compounds 
involved a conjugate of the staurosporine derivative K252a with miniature 
protein derived from the recognition epitope of PKI, and a conjugate of another 
staurosporine derivative with cyclic peptide discovered from the phage-
displayed library (Figure 19D); both conjugates possessed low nanomolar 
inhibition potencies towards PKAc (IC50 values of 3.6 nM and 2.6 nM, respecti-
vely) [Schneider et al., 2005]. Moreover, both conjugates were profiled versus a 
panel of PKs and revealed enhanced selectivity towards PKAc; the latter 
phenomenon was especially pronounced in the case of K252a conjugate, which 
demonstrated an over 180-fold selectivity towards PKAc versus other tested 
PKs [Schneider et al., 2005]. All in all, large increase in the selectivity of con-
jugates as compared to the corresponding non-selective staurosporine deriva-
tives used as ATP-mimicking fragments confirms the hypothesis that BSIs may 
indeed join the advantages of highly potent ACIs and selective PCIs, and 
therefore represent one of the most attractive strategies for the development of 
PK inhibitors. 
 
   72 
METHODS 
 
This part will briefly introduce the principles, advantages and limitations of the 
main methods used for the accomplishment of the given thesis. Starting from 
the insight into compound synthesis via utilization of solid phase synthesis 
approach, the review will proceed to the biochemical in vitro assays for the 
measurement of inhibitory and affinity properties of PK inhibitors, focusing on 
the techniques with fluorescence detection. Finally, a highlight of protein 
crystallography will be provided, exemplified by a more detailed analysis of 
(co-)crystal structures of PKAc. 
 
 
1. Solid phase peptide synthesis  
 
The principle of solid phase peptide synthesis (SPPS) was introduced in 1963 
by R. B. Merrifield [Merrifield, 1963], and the synthesis of compounds on solid 
phase has subsequently become an extremely popular technique not only for 
obtaining peptides, but also peptide analogues (i.e., peptoids, azapeptides) 
oligonucleotides, etc [Desai et al., 1994; Obrecht and Villalgordo, 1998]. The 
basic idea behind the SPPS protocol lies in the fact that a growing chain com-
posed of monomers is covalently attached via one terminus to the porous in-
soluble solid support (so-called resin), so that each next monomer is incorpo-
rated only to the “free” terminus of the chain [Benoiton, 2005; Chan and White, 
2000].  
In order to understand the ultimate advantages of SPPS, one first needs to 
consider the structural crotchet of amino acids, namely incorporation of a 
nucleophilic amino group and an electrophilic carboxyl group within one amino 
acid molecule. Such combination of two mutually reactive fragments within one 
molecule necessitates the use of the so-called protective groups, i.e., the entities 
that are conjugated with potentially reactive centers in the molecule in order to 
render the latter non-reactive until the protective group is removed [Green and 
Wuts, 1999]. In case of the “classical” solution synthesis methods, the obtain-
ment of each peptide bond therefore presupposes protection of two groups: 
  the protection of the amino acid at the N-terminus of forming the peptide 
bond (by groups withdrawing electron density),  
  and the protection of the amino acid at the C-terminus of forming the peptide 
bond, to avoid the formation of by-products (by groups increasing electron 
density).  
In SPPS, however, one of the termini (usually the C-terminus) of the growing 
chain is permanently protected by the insoluble resin bead until the whole chain 
is synthesized and then removed (cleaved) from the resin (Figure 20). Thus, the 
isolation of the intermediate product after every step of SPPS is usually 
performed barely by filtration, whereas the remaining reagents and by-products 
of the synthesis are flushed away. The latter fact in turn enables utilization of 73 
high concentration of the reagents, which according to the mass law increases 
the rate of the reaction. On the other hand, the use of large amount of reagents 
and solvent increases the cost of SPPS; however, this downside is compensated 
by the high yield (usually, over 99% yield of each coupling step) and quickness 
[Benoiton, 2005; Chan and White, 2000]. 
 
 
Figure 20. Scheme of SPPS. p1, N-terminal protecting group; x, activated C-terminus; 
RC, reaction center or growing chain; z, part of the initial reaction center of the resin 
(i.e., amine group).  
 
 
The question of the utmost importance for SPPS is the choice of the resin, 
formed by the polymeric beads usually composed of cross-linked polystyrene, 
polyacrylamide, or polyethylene glycol [Benoiton, 2005; Chan and White, 
2000; Sigma-Aldrich
 Resin Explorer]. Additionally, the beads bear the so-
called reaction centers, where the growth of the peptide chain is initiated; 
dependent on the structure of the reaction center of the resin and on the 
cleavage conditions, part of the reaction center may remain attached to the 
resin, or become conjugated with the C-terminus of the growing chain after the 
cleavage. The amount of the reaction centers on and in the bead as related to the 
mass of the bead is expressed as loading, whereas the optimal loading number is 
dependent  on  the  certain  synthesis.  If  the  loading  number  is  high  (2…                
3 mmol/g), the density of the growing chains per bead will also be high, which 
may restrict the diffusion of reagents into and between the beads, and cause 
incomplete coupling of sterically hindered growing chains. On the other hand, 
the low loading number (below 0.1 mmol/g) will result in a low amount of the 
final product, as the loading also shows the maximal amount of the final 
product released after the cleavage per mass of the resin initially taken for the 
synthesis. The additional important criteria for the resin choice are as followed: 74 
the resin must be physically stable, possess chemical inertness towards all 
reagents except those used for the attachment of the first monomer residue and 
for the final cleavage, and demonstrate good swelling in the solvent used for the 
synthesis. The most popular solvents are aprotic, and dependent on the synthesis 
may be either more or less polar (i.e.,  N,N-dimethylformamide or dichlo-
roethane, respectively), to secure good solubility of all applied reagents [Be-
noiton, 2005; Chan and White, 2000]. 
Each monomer added to the growing chain is generally initially protected at 
the terminus that should not participate in the coupling reaction. Thus, after the 
coupling, the growing chain is blocked on one terminus (usually, C-terminus) 
with the resin and on the other terminus (usually, N-terminus) with the pro-
tecting group, whereas the latter is removed prior to coupling of the new mono-
mer. Additionally, as the side-chains of amino acids frequently bear other 
functional groups, side-chain protecting groups are also required. Importantly, 
the group protecting N-terminus should be removable in conditions different to 
those where side-chain protecting groups are removed or where the cleavage of 
the final product from the resin is performed; this orthogonality requirement is 
usually fulfilled by application of either the Boc- or the Fmoc-strategy (Figure 
21) [Benoiton, 2005; Chan and White, 2000]. In the former, the Boc-group is 
used as the N-terminal protecting group that is be removed by treatment with 
trifluoroacetic acid, whereas the cleavage of the product is performed by HF; in 
the latter, Fmoc-group is used as the N-terminal protecting group removable by 
a weak base, usually piperidine, whereas the cleavage of the product is per-
formed by treatment with trifluoroacetic acid [Greene and Wuts, 1999]. Thus, 
the Fmoc-strategy utilizes milder conditions, but is also more susceptible to 
side-reactions due to involvement of a base (i.e., racemization of chiral amino 
acids caused by deprotonation of C during the Fmoc-deprotection steps) 
[Benoiton, 2005].  
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Figure 21. Structures of the most popular N-terminal protecting groups in SPPS. (A) 
Fmoc. (B) Boc. 
 
 
The addition of a new monomer to the growing chain is comprised with the aid 
of the so-called activators. As the reaction between the carboxyl group and the 
amine group resulting in formation of the amide bond is associated with a very 
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high activation energy barrier, it is necessary to convert the carboxyl group to 
more reactive species (i.e.,  O-acylisourea or triazol ester) prior to coupling 
[Benoiton, 2005; Chan and White, 2000]. This task is accomplished by addition 
of one or several activating reagents to the coupling mixture (Figure 22), which 
are afterwards removed during the washing step. In order to avoid the side-
reactions originating from the excess reactivity of the activators, the amount of 
activators should be in general smaller than that of the monomer added to the 
growing chain. 
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Figure 22. Structures of activators. (A) BOP. (B) DIC. (C) HBTU. (D) HOBt. 
 
 
Probably the most pronounced downside of SPPS is the poor opportunity to 
monitor the course of reactions, as the resin bead interferes with the detection 
and quantification of the intermediate products attached to the resin. Despite the 
fact that several spectroscopic methods (i.e., IR) have been suggested as 
possible variants for the establishment of the on-resin products, the most wide-
spread techniques are still qualitative or semi-quantitative tests determining the 
presence or absence of certain chemical groups on the resin or in the solution 
collected from the resin (such as Kaiser-test or Fmoc-deprotection test) [Chan 
and White, 2000; Yan, 1998]. These tests utilize compounds that upon reaction 
with the isolated resin bead or the solution collected from the resin generate 
products with specific spectral properties (i.e., a certain UV-VIS absorbance 
maximum), which are subsequently detected by a suitable technique. An alter-
native method is the isolation of a small portion of resin from the reaction 
vessel, cleavage of intermediate products, and subsequent qualitative or quanti-
tative analysis (i.e., by mass-spectroscopy); however, the latter variant is not 
suitable for the continuous usage, as it would remarkably decrease the net yield 
of the synthesis.  
It should also be mentioned that the maximal size of the peptide “under 
construction” is limited in SPPS, in order to maintain the high yield of each 
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coupling step; the maximal number of monomers is dependent on the resin 
loading and on the structure of monomers, but is generally below 70 amino 
acids [Chan and White, 2000]. Still, longer chains may be obtained by separate 
synthesis of shorter fragments followed by the subsequent ligation. Moreover, 
several advancements in the field of SPPS (especially automation) have contri-
buted to the development of other techniques enabling synthesis of large com-
pound collections (libraries), either by parallel synthesis or by combinatorial 
approaches [Lam et al., 1997; Maillard et al., 2009; Obrecht and Villalgordo, 
1998; Shin et al., 2005]. Furthermore, combination of SPPS with solution 
synthesis (i.e., where some fragments are synthesized in solution and sub-
sequently conjugated with the growing chain on resin) provide additional 
possibilities for the synthesis of structurally variable compounds, such as 
conjugates of peptides or peptide analogues with (oligo)nucleotides, etc [Bonke 
et al., 2008; Wu Y. and Xu, 2000]. 
 
 
2. Biochemical in vitro assays for  
the assessment of PK inhibitors 
 
2.1. Inhibition assays versus binding assays 
 
The biochemical in vitro assays for the assessment of PK inhibitors can be 
divided into two main groups according to the characteristics measured, inhi-
bition assays and binding assays. The former group of assays takes advantage of 
the phosphorylation reaction catalyzed by the PK of interest, whereas the 
reference (non-inhibited) reaction is performed in the absence of an inhibitor 
and the trial reaction in the presence of the inhibitor. Generally, inhibition 
assays are performed in a form of kinetic studies, where the PK-catalyzed 
reaction (either in the absence or in the presence of the inhibitor) is artificially 
stopped at a certain point of time, i.e., by dilution into concentrated acid; the 
phosphorylated product is subsequently isolated and quantified. Inhibition 
assays therefore measure the ability of the inhibitor to block the catalytic pro-
perties of PK and thus reduce the amount of the phosphorylated product formed 
(until the reaction was stopped). Additionally, from the non-inhibited reaction 
the activity of the PK in the given experiment may be established [Hastie et al., 
2006; Segel, 1993]. By variation of the concentration of the phosphoryl donor 
or phosphoryl acceptor in the presence of the same concentration of the kinase 
and inhibitor, it is also possible to determine the inhibition mechanism of the 
compound under investigation versus ATP or versus protein/peptide substrate, 
respectively [Segel, 1993]. 
As inhibition assays allow a direct determination of the ability of the 
inhibitor to protect the protein/peptide substrate from the phosphorylation (the 
ultimate goal of development of PK inhibitors), this group of biochemical in 
vitro assays have become a “classical” method for the characterization of PK 
inhibitors [Hastie et al., 2006; Ma H. et al., 2008]. However, their time-77 
consuming and multi-step nature, as well as the requirement for application of 
phosphoryl donor and phosphoryl acceptor, has triggered the search for and 
development of alternative assays more compatible with the HTS format, i.e., 
binding assays [Degorce et al., 2009].  
In contrast to the inhibition assays, the binding assays do not utilize the PK-
catalyzed reaction and thus do not require a phosphoryl donor or a phosphoryl 
acceptor; instead, the amount of a ligand (i.e., an inhibitor) bound to the PK is 
detected  via change of physical or physico-chemical characteristics of the 
system. Generally, the binding assays are performed at equilibrium conditions, 
and can be performed in direct binding format or displacement (competition) 
binding format [Segel, 1993]. While the former format allows determination of 
the degree to which the inhibitor is able to bind to the PK of interest (i.e., the 
affinity of the inhibitor), the latter format measures the ability of the inhibitor to 
compete for binding to a PK with a ligand with previously determined affinity. 
Apart from assessment of the affinity characteristics, binding assays also enable 
determination of the PK site where the compound binds if the displacement of 
compound under investigation is performed by a ligand targeted to a certain 
binding site of a PK. While binding assays are generally less time-consuming 
and better amenable to automation than the inhibition assays, the major dis-
advantage of binding assays has been low affinity of ligands used in the dis-
placement format experiments [Huang X., 2003], which in turn necessitates 
high consumption of the PK and limits the range of affinities of displacing 
compounds that can be reliably established. However, the recent advances in the 
field of PK-targeting compounds as well as detection techniques have re-
markably dissipated the latter issues [Brown M. J., 2008; Degorce et al., 2009; 
Lebakken et al., 2007; Li Y. J. et al., 2008]. 
The detection techniques are shared by both inhibition and binding assays, 
whereas the most common detection methods are radiometric and spectro-
photometric [Li Y. J. et al., 2008; Technikova-Dobrova et al., 1991; Uri et al., 
2010]. The latter category includes fluorescence techniques, which have 
increasingly grown in number and popularity due to their low quantification 
limit and applicability for the in vitro assays in living cells and tissues. 
 
 
2.2. Radiometric methods 
 
Since the 1970s when first introduced for PKAc [Handa and Johri, 1977; 
Adelstein  et al., 1978], the majority of radiometric PK assays have been 
performed in a form of kinetic assays where the PK-catalyzed phosphorylation 
reaction is carried out in the presence of -radioactive 
32P-ATP or 
33P-ATP 
mixed with non-radioactive ATP. As a result of the phosphorylation reaction, a 
fraction of the phosphoryl moieties introduced into substrate protein/peptide is 
also endowed with -radioactivity; the phosphorylated substrate molecules are 
isolated from the reaction mixture and the amount of incorporated radioactive 78 
phosphoryl is quantified by scintillation counting [Hastie et al., 2006; Ma H. et 
al., 2008].  
The isolation step is most crucial for the whole strategy, as the method 
presupposes elimination of the non-reacted radioactive ATP from the mixture. 
Usually, the isolation of phosphorylated protein/peptide substrate is performed 
via dilution of the reaction mixture into concentrated phosphoric acid, and 
subsequent filtration through phosphocellulose paper. The latter is negatively 
charged and binds the protein/peptide substrates that are in turn positively 
charged due to protonation of basic amino acid side-chains after treatment with 
phosphoric acid (in order to bind to phosphocellulose paper, the substrates 
should possess a minimal charge of +2). The small peptide substrates that do 
not contain basic amino acid residues are modified prior to application in the 
given assay by addition of 2…3 Lys residues to the N-terminus or to the C-
terminus of the substrate (i.e., into positions where Lys would not interfere with 
binding of peptide substrate to the PK) [Hastie et al., 2006]. The negatively 
charged ATP binds to the phosphocellulose filter only to the minor extent.  
Recently, a new format of 
32P-ATP -based radiometric kinetic assay was 
introduced under the name scintillation proximity assay [PerkinElmer Scintil-
lation Proximity Assay (SPA)]. This format utilizes microscopic beads that are 
added to the reaction mixture; these beads contain scintillant, which emits light 
upon stimulation with -radiation if the -emitter is bound to the surface of the 
bead. As the beads bind only protein or peptide substrate (the exact mechanism 
of recognition has not been reported by PerkinElmer) but not ATP, the need for 
isolation and washing steps is eliminated.  
Apart from reliability and low quantification limit, the important advantage 
of the radiometric kinetic assays is their generic nature, i.e., the possibility to 
utilize practically any PK and its protein/peptide substrate, whereas the size of 
the substrate is not limited [Hastie et al., 2006]. However, the personal and 
environmental risks associated with the use of radioactive materials as well as 
the short half-life of 
32P-ATP (14 days) strongly limit the field of application of 
radiometric assays. 
 
 
2.3. Fluorescence techniques 
 
2.3.1. Fluorescence phenomenon 
 
Fluorescence is one of the variants of luminescence, a phenomenon of light 
emission occurring from excited states of a molecule [Lakowicz, 2006]. An 
electron is excited by photon absorption from the ground singlet state (S0) to 
higher singlet states (S1, or S2); subsequently, in case of fluorescence a rapid 
relaxation to the lowest vibrational energy level of S1 (so-called internal 
conversion) occurs within 10
–12 s or less (Figure 23A). Finally, the return to the 
ground state takes place, which is associated with the emission of a photon; 
again, in case of fluorescence this return process occurs rapidly, with a typical 79 
emission rate of more than 10
8 s
–1. In most cases, the electron returns to the 
higher vibrational energy level of S0, but then rapidly reaches the thermal 
equilibrium (within 10
–12 s). As the energy of the photon used for excitation is 
generally higher than the energy of the emitted photon, the wavelength of the 
excitation photon is smaller than that of the emitted photon; this wavelength 
difference is called the Stokes shift, and it varies for different fluorescent 
compounds (fluorophores). 
 
 
 
A  B 
 
Figure 23. Principles of fluorescence. (A) Jablonski diagram of fluorescence. Ab-
sorption is shown as solid blue arrow, internal conversion as dotted blue arrow, and 
fluorescence emission as solid green arrow. S0, S1 and S2 are singlet states, hA is ex-
citing photon and hB emitted photon. (B) Absorption (left) and emission (right) spect-
rum of 5-TAMRA at pH 7.0 (adapted from Invitrogen
TM Product Spectra 5-TAMRA/pH 
7.0). The Stokes shift is indicated with red arrow. 
 
 
Structurally, fluorophores represent a variety of classes of organic as well as 
inorganic compounds. On the basis of size and chemical composition, three 
main groups of fluorophores can be distinguished: 
  fluorescent proteins initially derived from living organisms (i.e., jellyfish, 
corals) [Baird et al., 1999; Cox et al., 2007; Craggs, 2009; Tsien, 2009];   
  small molecular-weight organic compounds (i.e., fluorescein, rhodamine, 
etc.) usually containing conjugated aromatic cycles [Lakowicz, 2006]; 
  nanoparticles, which may either be fluorescent on their own (i.e., semicon-
ductor quantum dots), may acquire fluorescent properties upon ligation (i.e., 
lanthanide ions), or can serve as compound enhancing or diminishing 
emission of other fluorophores (i.e., gold and silver particles) [Moore et al., 
2009; Resch-Genger et al., 2008; Seydack, 2005]. 
Each fluorophore has a characteristic spectrum of absorption, excitation and 
emission; in condensed phase, absorption and excitation spectra are nearly 
identical, and the discrete electronic transitions corresponding to the excitation 
and emission peaks are replaced by broader energy spectra (i.e., Figure 23B) 80 
[Lakowicz, 2006]. Consequently, the excitation of the fluorophore might be 
performed at a wavelength slightly different from the excitation maxima. 
Importantly, the profile of the fluorescence emission spectrum is independent of 
the excitation wavelength (logically, if excitation still occurs), due to the 
internal conversion occurring during the excited-state lifetime. However, the 
fluorescence emission intensity (or just fluorescence intensity) is proportional to 
the amplitude (intensity) of the fluorescence excitation spectrum at the given 
excitation wavelength, i.e., the closer to the maximum the excitation is per-
formed, the more intensive will be the emission within the whole range of 
emission wavelengths.  
The latter fact also means that the more intensive is the maximal absorption 
of the fluorophore is, the more intensive will be the emission. According to the 
Beer-Lambert law, the absorbance at a certain wavelength is dependent on the 
extinction coefficient () of the compound (Equation 13A); thus, a fluorophore 
with a higher  value yields a stronger signal than the fluorophore with a lower 
 value at the same concentration. However, the intensity of signal is also 
dependent on the quantum yield of the fluorophore, the ratio of the number of 
emitted photons to the number of absorbed photons; the value of quantum yield 
smaller than one results from the fact that depopulation of S1 may occur not 
only via photon emission but also via other non-radiative processes (Equation 
13B). The product of values of the extinction coefficient at a certain wavelength 
and the quantum yield is defined as brightness, i.e., the fluorescence output of 
the fluorophore; the higher is brightness value, the more preferable is the 
fluorophore for application in assays with low quantification limit.  
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Equation 13. Parameters of fluorescence. (A) A, absorbance; , molecular extinction 
coefficient; c, molar concentration of substance in solution; l, the length of the optical 
path; index  indicates the wavelegth. (B) Q, fluorescence quantum yield; kr, rate of the 
radiative decay; knr, rate of a non-radiative decay. (C) , fluorescence lifetime. (D) It, 
fluorescence intensity at time t; , scale factor; c, a time-independent component of the 
background noice. 
 
 
Another important parameter of a fluorophore is the lifetime of its fluorescence 
(Equation 13C), which reflects the average time the fluorophore spends at the 
excited state before the return to the ground state. The return may occur via 
emission of photon, or via non-radiative processes, whereas the speed of the 81 
latter strongly depends on the surrounding environment; in this case, measure-
ment of fluorescence lifetime can be used as detection method for monitoring 
the binding of a fluorophore-containing ligand to the PK [Lakowicz, 2006; 
Lebakken et al., 2007]. The typical fluorescence lifetime is 10
–8…10
–9 s, but in 
some fluorophores it may be exceptionally long (100 ns...few s) [Degorce et 
al., 2009]. Such compounds are of especial value in applications where back-
ground fluorescence may be an issue, as the measurement of the emission after 
time delay should not influence the signal of a long lifetime-fluorophore, 
whereas the background noise is reduced (Equation 13D).  
  Finally, the criteria posed for the fluorophores also include high solubility, 
high stability, and low photobleaching; the latter parameter ensures that the 
fluorophore can be repeatedly excited and detected, which is a fundamental 
requirement for the low quantification limit of fluorescence detection [Lako-
wicz, 2006]. 
 
 
2.3.2. Measurement of fluorescence intensity (FI) 
 
The measurement of FI requires the least complicated equipment, and may be 
performed with a simple fluorescence spectrometer. There are several types of 
assays that utilize FI detection, whereas the value of FI can increase or decrease 
as a result of certain molecular event, or remain the same: 
  assays where a gain of FI takes place as a result of a change in the fluoro-
phore structure (i.e., gain of fluorescence associated with spatial conver-
gence of fluorophore-composing fragments as a result of conformational 
change of PK substrate upon phosphorylation) [Souslova and Chudakov, 
2007; Tsien and Baird, 2006]; 
  assays where a change of FI takes place as a result of a change in the 
fluorophore conformation (i.e., change of FI associated with translation of 
conformational change to the fluorophore from the PK substrate upon 
phosphorylation or from the PK inhibitor upon binding) [Kawai et al., 2004]; 
  assays where a change of FI takes place as a result of a change in the 
fluorophore environment (i.e., change of pH or polarity associated with 
phosphorylation of the PK substrate [Sharma et al., 2008; Wang Q. and 
Lawrence, 2005] or with binding of a PK inhibitor, or change of the  spatial 
distance from the other chromophores or quenchers [Allen and Zhang, 2006; 
Rininsland et al., 2004; Simard et al., 2010], please refer to Section 2.3.3. 
Measurement of fluorescence intensity (FI). Special case: Förster-type 
resonance energy transfer (FRET)); 
  assays where a change of FI takes place as a result of induction of or 
interference with the cleavage of fluorophore (i.e., upon phosphorylation of 
PK substrate) [Promega ProFluor® PKA Assay]; 
  separation-based assays where substrates and products of the PKAc-
catalyzed reaction of the PK substrate, or PK-bound and non-bound forms of 
an inhibitor are isolated on the basis of other physical or chemical properties, 82 
whereas the fluorophore retains its FI during isolation [Viht et al., 2005] or 
is introduced after isolation [Charter et al., 2006]. 
A representative of the latter category is the inhibition kinetic assay (so-called 
TLC-assay) that is based on a PK-catalyzed phosphorylation reaction utilizing 
ATP and a fluorescently labeled protein kinase substrate (i.e., 5-TAMRA-
Kemptide) [Viht et al., 2005]. After the reaction, the non-phosphorylated 
substrate  and phosphorylated product are separated with the aid of thin layer 
chromatography (TLC). The fluorescence intensity of both fluorescent com-
pounds is measured on the TLC plate by fluorescence imaging, and the extent 
of phosphorylation is calculated. The ratiometric nature of the assay enables 
diminishing of artifacts such as well-to-well variation of the fluorescent 
compound concentration or pipetting errors. 
  TLC-assay is applicable for both, assessment of the PK activity (in this case, 
the reaction is performed in the absence of a PK inhibitor) as well as the 
determination of the inhibition properties of PK inhibitors (if the reaction is 
performed in the presence of a PK inhibitor). In the latter case, increase in 
concentration of ATP or labeled peptide substrate also allows determination of 
the inhibition mechanism of a PK inhibitor [Enkvist et al., 2006]. Dependent on 
the labeled peptide substrate used for the phosphorylation reaction, the TLC-
assay may be applied for different PKs; so far, it has been utilized for studies 
with PKAc and PKB inhibitors [Enkvist et al., 2006; Enkvist et al., 2009]. 
 
 
2.3.3. Measurement of fluorescence intensity (FI). Special case:  
Förster-type resonance energy transfer (FRET)  
 
FRET is a form of non-radiative relaxation of the fluorophore, where the energy 
is transferred to a suitably oriented dipole moment of another spatially close 
non-excited fluorophore, if the emission spectrum of the first (donor) fluoro-
phore overlaps with the excitation (absorption) spectrum of the second (accep-
tor) fluorophore [Gadella 2009; Lakowicz, 2006]. The efficiency of FRET is 
strongly dependent on the distance between the donor and acceptor (Equation 
14A); the distance at which the probability of the FRET between fluorophores 
is equal to 50% is called the Förster distance (R0; Equation 14B).  
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Equation 14. Parameters of FRET. (A) E, FRET efficiency; R0, Förster distance; R, 
distance between the FRET donor and acceptor. (B) 
2, dipole orientation factor; QD, 
fluorescence quantum yield of the FRET donor; J, spectral overlap between the donor 
emission spectrum and acceptor excitation spectrum; n, refractive index of the medium. 83 
Typically, FRET occurs at distance of 20…90 Å between the donor and 
acceptor, which is hence comparable with the size of biological macromolecules 
[Lakowicz, 2006]. Detection of FRET enables the monitoring of several 
dynamic intra- and intermolecular processes; in case of PKs, the FRET pheno-
menon is most frequently utilized for monitoring the following events [Kalab 
and Soderholm, 2010; Wang H. et al., 2009]: 
  conformational changes of PKs (i.e., upon binding of ligands), monitored by 
detection of FRET between the fluorophores attached to two different 
positions of the PK [Zaccolo et al., 2002; Honda et al., 2005]; 
  conformational changes of protein/peptide substrates of PKs (i.e., upon 
phosphorylation), monitored by detection of FRET between the fluorophores 
attached to two different positions of the substrate [Allen and Zhang, 2006]; 
  binding of ligand(s) to the PK, monitored by detection of FRET between two 
fluorescently labeled ligands (i.e., a protein substrate and an antibody [Kwan et 
al., 2009]) or between a labeled ligand and a labeled PK [Vaasa et al., 2010]; 
  phosphorylation of a  PK protein/peptide substrate, monitored by detection 
of FRET between the fluorescently labeled substrate and a phosphoryl-
specific fluorescently labeled antibody [Carlson et al., 2009]. 
FRET might be detected in several ways, including the increase in acceptor 
fluorophore emission intensity (Equation 15A), decrease of donor fluorophore 
emission intensity (Equation 15B), or the change of the donor fluorophore 
lifetime (Equation 15C); the latter variant is possible by virtue of the fact that 
FRET increases the non-radiative relaxation rate of the donor and thus shortens 
the donor lifetime in the presence of the acceptor. A specific variant of FRET is 
represented by the fluorescence quenching, where the acceptor is not a 
fluorophore, i.e., after excitation by energy transfer from the donor it does not 
emit a photon but undergoes non-radiative relaxation [Gadella 2009; Lakowicz, 
2006; Sharma et al., 2008]. Fluorescence quenching may accompany the 
“classical” FRET phenomenon (where the acceptor emits the photon), thus 
measurement of donor emission intensity or donor lifetime may provide more 
accurate data than measurement of acceptor emission intensity. 
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Equation 15. Measurement of FRET. (A) E, FRET efficiency; A, molecular extinction 
coefficient of the acceptor; D, molecular extinction coefficient of the donor; IAD, 
intensity of the acceptor emission in the presence of the donor; IA, intensity of the 
acceptor emission in the absence of the donor. The ratio of  values should be taken into 
account as the acceptor may be directly excited at the same wavelength as the donor. 
(B) IDA, intensity of the donor emission in the presence of the acceptor; ID, intensity of 
the donor emission in the absence of the acceptor. (C) DA, fluorescence lifetime of the 
donor in the presence of the acceptor; D, fluorescence lifetime of the donor in the 
absence of the acceptor. 84 
FRET offers several advantages as compared to the other fluorescence techni-
ques, such as the possibility to perform measurements in a complex biological 
matrix (i.e., cell lysate) and in several cases the ability to increase the selectivity 
of detection (i.e., if one of the fluorescently labeled components is not selective 
towards the biological target on its own) [Gadella 2009; Lakowicz, 2006]. 
However, the quantitative measurement of FRET is frequently compromised by 
the excess donor (i.e., due to the so-called bleed-through of the donor emission 
to the wavelength where the acceptor emission is measured), excess acceptor 
(i.e., due to the off-peak excitation at the wavelength where the donor excitation 
is performed), and other factors [Wlodarczyk et al., 2008]. 
 
 
2.3.4. Measurement of fluorescence anisotropy (FA) 
 
Fluorescence anisotropy measurements are based on the phenomenon of selec-
tive excitation of fluorophores by linearly polarized light [Jameson and Ross, 
2010; Lakowicz, 2006]. In linearly polarized light, the electric field vector 
assumes only one unique oscillation axis, which is perpendicular to the light 
propagation direction. When the linearly polarized light impinges on a 
fluorophore, only those fluorophore molecules are excited which are appropria-
tely oriented relative to the oscillation axis of the electric vector, i.e., molecules 
that upon excitation are able to generate the induced dipole moment (so-called 
transition dipole) which is parallel to the oscillation axis of the electric vector. 
The radiation emitted by the fluorophore is also polarized, whereas dependent 
on the structure of fluorophore, the transition dipole corresponding to the 
emission of light may be either parallel or perpendicular to the excitation dipole. 
The actual oscillation axis of the electric vector of emitted light is determined 
by two polarizers oriented in  parallel and in perpendicular directions relative to 
the initial oscillation axis. Fluorescence polarization (FP) is then defined as 
Equation 16A; an analogical term with identical information content as in the 
case of fluorescence polarization, is the fluorescence anisotropy (FA; Equation 
16B); however, in case of the FA function the denominator represents the total 
intensity of emission. 
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Equation 16. Measurement of FP and FA. (A), (B)   and   are respectively the 
fluorescence intensities of the vertically and horizontally polarized components of 
emission, if the sample was excited with vertically polarized light. (C) FA0, limiting 
(intrinsic) anisotropy (in the absence of rotation of the fluorophore); R, universal gas 
constant; T, absolute temperature; , fluorescence lifetime; , viscosity of the medium; 
Vfl, the effective molar volume of the fluorophore-containing unit. (D) M, molecular 
weight of the fluorophore-containing unit; v, partial specific volume; h, degree of 
hydration. 
 
 
If the emitted light is completely polarized in the axis parallel to the polarization 
axis of the exciting light (i.e., the polarization is totally maintained), the value 
of FA is +1; if the emitted light is totally polarized in the perpendicular axis, 
then the value of FA is -0.5. However, these theoretical limits are generally not 
realized: firstly, even in a highly viscous or frozen medium some of the dipoles 
excited will not be exactly parallel to the direction of the exciting light; se-
condly, in solutions the excited fluorophores may rotate during the lifetime of 
the excited state [Jameson and Ross, 2010; Lakowicz, 2006]. The latter pheno-
menon is dependent on the effective molar volume of the fluorophore-
containing unit (Vfl); therefore, a relationship between the observed FA and Vfl 
can be derived (so-called Perrin equation, Equation 16C). As Vfl is in most cases 
linearly dependent on the molecular weight of the fluorophore-containing unit 
(Equation 16D), the complexation of the small-molecular weight fluorescent 
ligand with the large protein results in an increase of FA of the ligand, which is 
frequently  used for development of assays based on FA detection. 
One of such assays applicable for the assessment of the properties of PKs 
and PK inhibitors is the homogeneous FA-assay that utilizes ARC-derived 
fluorescent probes (ARC-Photo, molecular weight below 3 kDa) [Vaasa et al., 
2009]. The idea behind the FA-assay lies in the principle of the additivity of 
anisotropy (Equation 17A), meaning that in the mixture of free and bound 
ARC-Photo, both components contribute to the measured FA signal with 
different magnitudes (Equation 17B). The maximal and the minimal FA is 
correspondingly equal to the FAbound and FAfree; if the contribution of FAbound is 
X1, the contribution of FAfree is (1 – X1), whereas X1 hence reflects the ratio of 
bound ARC-Photo concentration to the total concentration of ARC-Photo 
[Vaasa et al., 2009].  86 
〈  〉 =     ∙     
 
  〈  〉 =    ∙          +( 1−   )∙         
A  B 
 
Equation 17. FA-assay based on ARC-Photo. (A) <FA>, observed anisotropy; FAi and 
fi, the anisotropy and the fractional contribution of the i
th specie. (B) FAbound, anisotropy 
value of the PK-bound ARC-Photo; X1, the fractional contribution of FAbound; FAfree, 
anisotropy of the free ARC-Photo. 
 
 
The FA-assay can be performed either as a direct binding format, or as a 
displacement (competition) binding format [Vaasa et al., 2009]. In the first case, 
the binding of ARC-Photo to a PK is monitored by titration of a constant 
concentration of ARC-Photo with PK. In these conditions, X1 is dependent on 
the total concentrations of ARC-Photo and PK, and on the affinity of ARC-
Photo towards PK; additionally, the possible change of the fluorophore quantum 
yield caused by binding of fluorophore to the PK should be considered. 
Importantly, apart from the determination of the affinity of ARC-Photo, the 
binding format of the FA-assay also enables the assessment of the concentration 
of the active enzyme in the sample [Vaasa et al., 2009].  
  In the second case, displacement of ARC-Photo from its complex with PK is 
performed by compounds targeting the ATP-site and/or protein substrate-site of 
PK; here, X1 is additionally dependent on the concentration of the competing 
compound and its affinity towards PK [Vaasa et al., 2009]. The higher the 
affinity is possessed by ARC-Photo, the wider is the range of affinities of 
competing compounds that can be reliably determined by the assay [Huang X., 
2003]. It should also be noted that generic ARC-Photo probes are strongly 
preferred for the displacement (competition) binding format of  an FA-assay, as 
the promiscuous nature of the probe allows the application of the assay for wide 
variety of PKs [Uri et al., 2010]. 
 
 
3. Protein crystallography 
 
3.1. General features 
 
The physical phenomenon behind X-ray crystallography is the diffraction of X-
rays from the crystal lattice, whereas the transformation of the detected 
diffraction picture yields the three-dimensional structure of the electron density 
for the atoms composing the given crystal (so-called crystal structure). The 
range of wavelengths of the X-radiation used for the crystallography is 0.4 to 25 
Å, which is on the same scale as the chemical bond lengths between the atoms 
composing the crystal [Giacovazzo et al., 2005]. According to the nature of a 
chemical bond within the object, several branches of crystallography may be 87 
defined, utilizing metallic, ionic, covalent, molecular or macromolecular crys-
tals, the latter group also involving protein crystals. Protein crystals are 
composed of the discrete molecular entities hold together by intermolecular 
long-distance interactions (i.e., weak dispersion or polar forces), whereas the 
variable intramolecular short-distance interactions are responsible for the 
conservation of the primary and higher structures of the protein. A characteristic 
feature of protein crystals is their large content of solvent (up to 70% of crystal 
volume [Matthews, 1968]), which enables preservation of the solubilized 
conformation of protein in the crystal; on the other hand, high water content 
may decrease  the crystal symmetry, which in turn lowers the quality of 
diffraction. 
The main steps for the obtainment of a crystal structure are represented by 
crystallization of the object of interest, measurement of diffraction from the 
crystal, and interpretation of diffraction data. The necessary condition for 
protein crystallization is a large amount (tens of milligrams) of pure material, 
which is one of the downsides of crystallography [Davis et al., 2008; Wlodawer 
et al., 2008]. Moreover, while the crystallization of water-soluble proteins is 
generally a matter of choosing right conditions, the crystallization of membrane 
proteins and proteins with large unordered regions still represents a challenge. 
The latter issue is pursued by different techniques, such as use of truncated 
forms of proteins, reduction of surface entropy, and enhancement of hydro-
phobicity of the protein surface to facilitate formation of intermolecular 
contacts [Argiriadi et al., 2009; Joachimiak, 2009].  
The crystallization process starts from the supersaturated protein solution 
and can be divided into two steps, nucleation and crystal growth. The super-
saturating conditions can be obtained by addition/diffusion of precipitating 
solutions (salts, organic solvents and polyethylene glycols), and variation of pH, 
temperature, or concentrations of substances in the mother solution [Breiten-
lechner et al., 2005; Giacovazzo et al., 2005]. Additional possibilities involve 
the addition of cofactors or metal ions, which should form conformationally 
fixed complexes with the protein of interest and possibly induce crystallization. 
Another approach is microseeding, where pieces of other protein crystals are 
added to the crystallization solution to form nucleation centers; this technique 
has proved especially useful in case if crystals of the same protein have already 
been obtained [Oswald et al., 2008]. An important factor is also the incubation 
time, as the equilibrium between dissolved and crystallized protein may not be 
reached quickly; moreover, the amorphous precipitate can sometimes form 
ordered crystal structures after prolonged incubation. Finally, if the goal is to 
crystallize a complex of protein (i.e., to generate a co-crystal), the necessary 
secondary messengers, substrates, inhibitors, etc. are added to the crystallization 
mixture. The addition can be performed either prior to formation of crystal, or 
via back-soaking after the initial crystal lattice of apoprotein is formed; in the 
latter case, the high water content of the crystal enables quick diffusion of the 
reagents added to the crystallization solution [Breitenlechner et al., 2005]. 
Importantly, in all of the techniques mentioned above it is of utmost importance 88 
to grow crystals in conditions maximally resembling the physiological environ-
ment, in order to restrict chemical and conformational changes in the protein 
and prevent obtainment of a crystal structure not applicable for studying 
naturally occurring processes [Davis et al., 2008]. 
Prior to the measurement of diffraction, a procedure of cryoprocessing is 
frequently carried out, especially if synchrotron radiation is used as source of X-
rays due to the elevated risk of damaging the crystal via generation of labile 
radicals. Performance of measurements at low temperatures decreases the 
mobility of free radicals, and also increases the maximum resolution of the 
diffraction pattern due to reduction of general thermal disorder [Giacovazzo et 
al., 2005; Rogers, 1994]. The main task of cryogenic techniques is to cool the 
crystal without enabling the formation of crystalline ice, which could develop 
cracks in the crystal and damage the diffraction picture. The most applicable 
technique is flash-cooling, where the sample temperature is rapidly lowered 
(usually, by transferring the crystal into liquid nitrogen) so that the ice 
nucleation does not occur before the viscosity of the solution is high enough to 
prevent ice lattice formation [Rogers, 1994]. In order to avoid damaging of 
crystal, several precautions are applied before cooling the crystal, i.e., 
immersion into hydrocarbon oil to remove the most of external liquid or 
addition of cryoprotective reagents (i.e., glycerol, PEG, or methyl-pentanediol). 
The measurement of diffraction might be performed via various techniques, 
which differ in the method of obtainment of the maximal number of diffraction 
maxima with one crystal set [Giacovazzo et al., 2005]. Most of the techniques 
use monochromatic radiation, oscillating crystal mount and either a stationary 
or a moving detector; however, there are exceptions such as the Laue method, 
which uses polychromatic radiation. The advances in charge-coupled device 
technology have also enabled quick and precise detection of X-ray diffraction 
data with stationary crystal mount.  
The detected diffractogram records the intensity of diffraction maxima 
(reflections), whereas the position of each atom in the crystal lattice influences 
the intensities of all the reflections and vice versa; this wealth of diffraction data 
is analyzed via Fourier transformation of the structure factors, yielding the 
three-dimensional electron density map for the given crystal [Giacovazzo et al., 
2005]. However, the equation for the Fourier transformation includes both the 
amplitudes and phases of the waves, whereas the X-ray detectors measure just 
the intensities (which are proportional to the square of the structure factor 
amplitudes), but not the phases (Equation 18A). This limitation is known as the 
phase problem, and recovering of phases may be performed via several 
methods,  i.e., multiwavelength anomalous diffraction, multiple isomorphous 
replacement, molecular replacement, or direct ab initio methods [Giacovazzo et 
al., 2005; Hauptman, 1991]. 
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Equation 18. Fourier transformation of the difractogram and calculation of a quality 
parameter (R-factor). (A) (x,y,z), electron density in real space; V, volume of the unit 
cell; |F(h,k,l)|, structure factor amplitude (whereas h, k, and l are the coordinates in the 
reciprocal space); (h,k,l), phase of the reflection. (B) |Fobs|, the observed reflection 
amplitudes; |Fcalc|, reflection amplitudes calculated from the model. 
 
 
The primary electron density map calculated by Fourier transformation from the 
set of experimental structure factor amplitudes and the modeled phases is 
named (Fobs, calc) map, and represents an approximation of the true structure, 
with its quality dependent on the accuracy of the phase modeling [Wlodawer et 
al., 2008]. Another type of electron density map is calculated using the diffe-
rences between observed amplitudes and amplitudes calculated with phases, 
(Fobs – Fcalc, calc); this difference electron density map can be used to determine 
parts of the structure that can be used again to simulate a new set of phases 
[Wlodawer  et al., 2008]. The latter process involves repetitive rounds of 
automated optimization (according to the least-squares or maximum-likelihood 
algorithms) as well as manual corrections, until the previously defined quality 
parameters of the new density map reach their satisfactory values. Sub-
sequently, the obtained electron map is interpreted in terms of positioning the 
atoms constituting protein, solvent and possible other components of crystalli-
zation mixture into the obtained density, and then subjected to the so-called 
refinement. The refinement procedure is performed both automatically and 
manually by variation of model parameters to achieve the best agreement 
between the observed reflection amplitudes (Fobs) and those calculated from the 
model (Fcalc) [Wlodawer et al., 2008]. After the refinement procedure, the final 
three-dimensional crystal structure is obtained, whereas the most important 
parameters of quality of the crystal structure are the following [Wlodawer et al., 
2008]: 
  resolution, which reflects the minimum spacing of crystal lattice planes that 
may still provide measurable diffraction; the medium resolution value is in 
the range 2.0…2.7 Å;  
  R-factor (Equation 18B), which includes both, the experimental errors and 
the information considering the deviation of model from reality; the medium 
R value is below 20%; 90 
  Rfree-factor, which is calculated analogically to the R-factor, but only for ca 
1000 of randomly selected reflections that might have influenced the model 
definition but were not applied for model refinement; the value of Rfree-factor 
should not differ from the R-factor more than 7%; 
  Rmerge, which reflects the deviation of the individual measurements of 
equivalent reflections; the medium Rmerge value is below 5%; 
  B-factors, also referred to as ‘temperature factors’ or Debye-Waller factors, 
which shows the  degree of “mobility” of each atom (i.e., the attenuation of 
X-ray scattering caused by thermal motion of the given atom); the values 
may range from 2 Å
2 (for atoms with fixed positions) to 100 Å
2 (for poorly 
fixed atoms). 
Other important parameters involve completeness of the data, signal-to-noise 
ratio, root-mean-square deviations from geometrical standards, etc [Wlodawer 
et al., 2008]. 
  The main downside of protein crystallography lies in the fact that a crystal 
structure may provide only a static picture about the crystallized protein, i.e., 
only one conformation (although a certain amount of information considering 
flexibility of different fragments of the protein may also be provided by the B-
factors). Moreover, the crystal structures of protein complexes cannot predict 
the thermodynamical parameters such as binding energies, thus the application 
of information obtained from crystallographic studies for the design of protein-
targeting compounds should be taken with some degree of reservation [Davis et 
al., 2008]. 
 
 
3.2. Models of diffraction 
 
The theory behind the phenomenon of diffraction of X-rays from the crystal 
ultimately relies on the high symmetry of the crystal lattice, which may be con-
sidered as a system formed by repetitive translation of identical three-
dimensional smallest building blocks (unit cells) in space. By virtue of high 
molecular weight and folding into high-order structures, protein crystals 
generally possess a lower degree of symmetry than ionic or metallic crystals 
(i.e., no axis or plane of symmetry may pass through the protein molecule). 
Hence, the basic principles of diffraction are more easily explained using the 
Bravais lattice as an example, i.e., as an infinite set of points generated by a set 
of discrete translation operations described by the position vector R
7 (Equation 
19A) [Kittel, 1986]. 
  One of the first models of diffraction of X-rays by crystal was proposed by 
W. L. Bragg and W. H. Bragg in 1913; this model considered the crystal as a set 
                                                            
7 In the text and legends for equations of the given section, vectors are denoted as bold 
underlined characters. 91 
of discrete parallel atomic planes (Miller planes
8) separated by a constant 
parameter d [Bragg, 1913] (Figure 24A). The incident X-ray emerging onto the 
lattice plane is elastically reflected, i.e., the angle of incidence is equal to the 
angle of scattering (), whereas the wavelength of the photon is preserved. In 
this case, the waves scattered from the successive crystallographic planes are in 
constructive interference (i.e., are in the same phase) if the difference of the 
path length of waves (Equation 19B) is equal to an integer multiple of the 
wavelength (Equation 19C).  
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Equation 19. Real space and Bragg’s law. (A) R, position vector of the Bravais lattice; 
n, integer; a, unit vector of the Bravais lattice (the length of the unit vector is called 
lattice parameter). (B) , the difference of the path length of waves; dhkl, distance 
between the planes; , angle of incidence. (C) m, integer; , wavelength of the incident 
X-radiation. 
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Figure 24. Models of laws of diffraction. (A) Bragg’s law. (B) Laue’s law. 
 
 
An alternative model of diffraction from a crystal proposed by M. T. F. von 
Laue differs from the Bragg model in the aspect that no certain pattern is used 
to define the atomic planes within the crystal, and the scattering of X-rays is not 
considered as reflection [Figure 24B; Kittel, 1986]. Every particle positioned at 
the point R of the Bravais lattice may scatter the incident X-ray in different 
directions, but the diffraction maxima are observed only for those directions and 
wavelengths that yield constructive interference upon scattering from all points 
of lattice. If two parallel incident X-rays with the wave vector k (Equation 20A) 
                                                            
8 Miller plane intercepts the three points         /ℎ,        / ,and         / ,where         ,         ,          are the 
three lattice vectors and h, k, l are Miller indices proportional to the inverses of the 
intercepts of the plane in the basis of the lattice vectors. 
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propagating in direction n are elastically scattered by lattice points positioned at 
distance  d from each other, the rays scattered in direction n’ will yield 
constructive interference if the Equation 20B is fulfilled. If both sides of 
Equation 20B are multiplied by factor 2/ and scattering by all points of 
Bravais lattice is considered (given the fact that the points of Bravais lattice are 
positioned at distance R from each other), Equation 20C is obtained.  
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Equation 20. Reciprocal space and Laue’s law. (A) |k|, length of wave vector; , 
wavelength. (B) d, vector separating the two lattice points scattering X-radiation; n, 
vector coinciding with the direction of the incident X-rays; n’, vector coinciding with 
the direction of the scattered X-rays; m, integer. (C) R, vector separating the lattice 
points scattering X-radiation; k, wave vector of the incident wave; k’, wave vector of 
the scattered wave; m, integer. 
 
 
Basically, both, Bragg's law and Laue’s law express the conservation of 
momentum transfer. Considering the reciprocal lattice
9 where the set of Miller 
planes of the Bravais lattice is described by a vector K normal to this set 
(Equation 21A), the Equation 20C means that the change of wave vector should 
be equal to a vector K of reciprocal lattice. On the other hand, from the Figure 
25 it can be seen that the length of vector K may be defined as Equation 21B, 
thus the Equation 20C is equivalent to Equation 19C.  
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Equation 21. Reciprocal space. (A) K, position vector of the reciprocal lattice; h, k, l, 
Miller indices; b, unit vector of the reciprocal lattice. (B) k, wave vector of the incident 
wave; , angle of incidence.  
 
                                                            
9  The reciprocal lattice of a Bravais lattice is the set of all vectors K such that for all 
lattice point position vectors R, equation      ∙       =2      is valid. 93 
 
Figure 25. Model describing the diffraction conditions according to Bragg’s and Laue’s 
laws. The Bragg’s plane is colored blue. 
 
 
Overall, the wave vector of the scattered wave satisfies the conditions of Laue’s and 
Bragg’s laws only if the end of this vector lies in the Bragg’s plane, i.e., the plane 
which is perpendicular to the fragment of axis joining origin O with the point K of 
the reciprocal lattice, and divides fragment OK in two halves (Figure 25). As the 
length of fragment OK is defined by the crystal lattice, and the wavelengths of the 
incident and scattered waves are equal (due to elastic scattering), it is evident that 
either  or  may be varied to yield diffraction of X-rays from the given crystal, as 
described in the previous Section 3.1. General features. 
 
 
3.3. Crystal structures of PKAc 
 
3.3.1. General features 
 
The first crystal structure of PKs was reported in 1991, and represented a 
ternary complex of PKAc with AMP-PNP and a fragment of PKI, PKI(5–24) 
[Knighton  et al., 1991]. This crystal structure (PDB code 1ATP) revealed 
several structural motifs that in subsequent studies proved to be common for the 
whole kinome, and important for the activation of PK, recognition of substrates, 
and catalysis of phosphoryl transfer. By virtue of good crystallizability, PKAc 
has been subsequently crystallized as apoenzyme, co-crystallized with a variety 
of physiological and synthetic regulators, and used as a model scaffold for other 
PKs (i.e., after introduction of point-mutations into PKAc structure that were 
expected to simulate the modeled kinase) [Bonn et al., 2006; Davies et al., 
2007; Taylor S. S. et al., 2004]. 
  PKAc is a globular enzyme with a bilobal structure of the catalytic core, a 
feature conserved within the whole family of PKs (Figure 26A); the small N-
terminal lobe (residues 40…127) is mainly composed of β-strands, whereas the 
large C-terminal lobe (residues 128...300) mainly comprises α-helices. The N-
terminal tail and the C-terminal tail span the surface of both lobes and serve as 
regulatory elements. The catalytic cleft is situated between the lobes, with the 
ATP-binding site buried deep inside the molecule, and the protein/peptide-
substrate binding site positioned at the surface of the large lobe, being more 
opened to the solvent. The main motifs of secondary structure and connecting 
loops important from the point of PK functioning are presented in Table 5. 
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Table 5. Motifs and residues important for functioning of PKAc  
 
Motif  Number in 
PKAc
Important residues
N-terminal tail, 
including Helix A 
1…39  
11…31
 
Trp30
-strand 1, 
partially overlapped with Gly-rich loop
43…51 
50…55  
Lys47, Thr48 
Gly50, Gly52, Ser53, Phe54, Gly55 
-strand 2  56…62 Arg56
-strand 3  67…75 Lys72
Helix B  76…81  
Loop between Helix B and Helix C 82…84 Gln84
Helix C  85…97 His87, Glu91, Lys92, Arg93, Gln96 
Loop between Helix C and -strand 4 98…105 Phe100, Pro101, Phe102 
-strand 4  106…111  
-strand 5  115…120 Met120
Loop between -strand 5 and Helix D  121…127 Glu121, Val123, Glu127 
Helix D  128…135  
Helix E  140…159  
-strand 6   162…163 Arg165
Catalytic loop 166…171 Asp166, Lys168, Leu169, Glu170, 
Asn171
-strand 7  172…174  
-strand 8  180…182  
Mg
2+-positioning loop  184…187 Asp184, Phe185, Gly186, Phe187 
-strand 9  189…190 Lys189, Arg190
Activation loop 191…197 Thr195, Trp196, Thr197 
Peptide-positioning loop  198…208 Leu198, Gly200, Thr201, Pro202, 
Glu203, Tyr204, Leu205, Glu208 
Helix F  218…233 Asp220, Trp221, Trp222, Glu230 
Loop between Helix F and Helix G 234…242 Tyr235
Helix G  243…252  
Helix H  263…272  
Loop between Helix H and Helix I 273…288 Arg280
Helix I  289…292  
C-terminal tail, 
including Helix J 
301…350 
302…306
Tyr330 
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Figure 26. 1ATP. (A) PKAc shown as cartoon (with catalytically important loops 
colored red), ATP as black lines, Mg
2+-ions as spheres, PKI(5–24) as blue ribbon. (B) 
Helix A. Phe26 and Trp30 fill the hydrophobic pocket lined by residues at the end of 
helix C (in the small lobe) and Arg190 from the -strand 9 (in the large lobe, not 
shown). Backbone carbonyls of residues Lys29 and Ser34 at the end of Helix A make 
polar contacts to the Gln96 from the C-helix. (C) ATP-site (ATP shown as sticks, Gly-
rich loop as cartoon). Met120 preceding the cleft serves as a gatekeeper residue
10, 
closing the “entrance” to the pocket situated behind the cleft (near the N6 atom of 
                                                            
10 Importantly, the mutation of the gate-keeper residue is the common mechanism 
providing resistance of the disease-modifying PKs (i.e., BCR-Abl, EGFR) towards 
therapeutic PK inhibitors [Krishnamurty and Maly, 2010; Zhang J. et al., 2009]. Also, 
the mutation of the gate-keeper residue is frequently used in the chemical genetics 
approaches (please refer to Section 2.3.2. Reversible mono-ligand inhibitors. Special 
case: ATP-competitive inhibitors). 96 
adenine moiety of ATP) and formed by residues 104…106 and 118..119. Glu121 and 
Val123 of the cleft form the hydrogen bonds considered as the interactions providing 
strong gain in binding energy of ligands binding to the ATP-site: in case of ATP, 
Glu121 accepts the hydrogen bond donated by N6 of adenine moiety, and Val123 
donates hydrogen bond to N1 of purine ring. Additionally, Glu127 makes hydrogen 
bond with hydroxyl in 2' position of ribose moiety of ATP and is responsible for the 
recognition of Arg residue in the P-3 position of the substrate. 
 
 
3.3.2. Ternary complex of PKAc with  
AMP-PNP and PKI(5…24) 
 
The N-terminal tail of PKAc is comprised of thirty-nine residues and a 
myristoyl moiety attached to the N-terminal Gly. In the non-myristoylated 
protein (i.e., recombinant PKAc expressed in E.coli) the first ten residues of the 
tail are disordered, but in the myristoylated PKAc those residues form a loop 
that serves as a node joining several parts of the molecule [Johnson D. A. et al., 
2001]. This loop folds onto the hydrophobic pocket formed by residues 
100…102 of the loop between Helix C and -strand 4, the end of the conserved 
C-lobe, and the beginning of C-terminal tail. The following residues 11…31 of 
the N-terminal tail form an amphipatic Helix A, which docks via its 
hydrophobic surface (Leu19, Ala22, Phe26, Trp30) to the residues of the large 
lobe (Ile 94, Ala 97, Val 98, Tyr156, Leu160, Leu162), and constitutes a 
“backbone” that fixes the mobility of the lobes in respect to each other (Figure 
26B).  
The small lobe is composed of five -strands (1…5) constituting an anti-
parallel -sheet, and a conserved Helix C positioned between -strands 3 and 4. 
In general, the parts of the small lobe distant from Helix A are uncoupled from 
the large lobe, with the exception of a hydrogen bond between His87 from 
Helix C and Thr197 from the activation loop which is formed only if the kinase 
is in closed conformation (please refer to Section 3.3.3. Conformational 
versatility of PKs). However, the ATP molecule bound to the cleft formed by 
the loop between -strand 5 and Helix D (residues 121…127) serves as a 
“bridge” possessing multiple contacts to both lobes of PKAc (Figure 26C). 
From the top, the phosphate moieties of ATP are capped by the Gly-rich loop of 
the small lobe; at the top of this loop, a crucial contact is formed between the 
backbone amide of Ser53 and one of the oxygen atoms of the -phosphate. The 
highly conserved Gly50, Gly52 and Gly55 residues of Gly-rich also act in 
orchestra to position the -phosphate suitably for phosphoryl transfer [Cheng Y. 
et al., 2005]. Other conserved residues in the small lobe are Lys72 and Glu91 
that are within hydrogen bond distance from each other; while Lys72 anchors 
- and -phosphates of ATP and thus stabilizes the transition state, Glu91 is 
mainly important for the correct positioning of Lys72 [Cheng Y. et al., 2005].  
  97 
The large lobe contributes to the catalytic cleft with -strands 6…9 and the 
loops positioned between the strands, catalytic loop (Figure 27), Mg
2+-
positioning loop (Figure 28A), and peptide-positioning loop (Figure 29A). Not 
surprisingly, these loops are highly conserved within the family of PKs, which 
points to their significance for functioning of PK [Johnson D. A. et al., 2001]. 
 
 
 
 
 
Figure 27. Catalytic loop (loop shown as magenta cartoon and lines, ATP as sticks, 
Mg
2+ ions as spheres, Arg from P-2 position of PKI as black lines). Arg165 preceding 
the loop makes two hydrogen bonds with phosphorylated Thr197, providing a link 
between catalytic loop and activation loop. Asp166 from the catalytic loop serves as 
catalytic base to accept the proton delivered by the protein/peptide substrate. Lys168 
interacts with the -phosphate of ATP and thus keeps ATP and the substrate in the 
reactive near-attack conformation. Glu170 is responsible for the recognition of Arg 
residue in the P-2 position of the substrate, and also forms a hydrogen bond with 
hydroxyl in 3' position of ribose moiety of ATP. Asn171 binds to the lower Mg
2+-ion, 
which is in turn bound to the - and -phosphates of ATP (both Mg
2+-ions aid the 
catalysis, but the lower Mg
2+ causes poor dissociation of the ADP from the PK after 
reaction [Cheng Y. et al., 2005]). Asn171 also stabilizes the whole loop via formation 
of a hydrogen bond with the backbone carbonyl of Asp166. 
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Figure 28. Loops of PKAc. (A) Mg
2+-positioning loop (loop shown as pink cartoon and 
lines, ATP as sticks, Mg
2+ ions as spheres, other interacting residues as green lines). 
Asp184 binds to the upper Mg
2+-ion bridging the - and -phosphates of ATP, orients 
the -phosphate of ATP towards the substrate, and serves as a link between the small 
and the large lobe by forming catalytic triad with Lys72 and Glu91. Phe185 and Phe187 
are responsible for exclusion of water from the site of phosphoryl transfer. (B) 
Activation loop (loop shown as orange cartoon with pThr-197 shown also as lines, other 
interacting residues as green lines and cartoons). Phosphorylated Thr197 forms multiple 
contacts with different parts of enzyme, ensuring adaptation of the catalytically active 
form of PKA; apart from formation of hydrogen bonds with His87 and Arg165, 
phosphorylated Thr197 also interacts with Lys189, which translates the conformational 
change to the Helix A (via interaction of Arg190 with Trp30). 99 
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Figure 29. Peptide-positioning loop and interactions within the hydrophobic core. (A) 
Loop shown as brown cartoon and lines, PKI(5–24) as black ribbon (residues in 
positions P-6, P-3, P-2 and P+1 also as lines), interacting residues of PKAc as green 
lines. Pro202 and Leu205 form a hydrophobic pocket for accommodation of the 
hydrophobic residue in the P+1 position of the substrate. Thr201 makes hydrogen bonds 
with catalytic base Asp166 and with Lys168. Glu203 is responsible for the recognition 
of Arg residue in the P-6 position of the substrate. Tyr204 is critical for anchoring of the 
P+1 loop to the catalytic core, with the main contribution provided by hydrophobic 
interaction of Tyr204 with Leu167 of the catalytic loop and involvement of Tyr204 in 
the hydrophobic core formed by Helix E and Helix F [Yang J. et al., 2004]. Glu208 
forms the anchor for the P+1 loop by generating hydrogen bond with Arg280 from the 
loop between Helix H and Helix I. (B) Mg
2+-positioning loop, catalytic loop and Helix 
F are colored pink, the rest of PKAc is green. Below the Mg
2+-positioning loop and on 
the top of catalytic loop, a hydrophobic network is formed by Tyr164, Val182, Phe185, 
Phe187 and Trp221, whereas below the catalytic loop and on top of Helix F, another set 
of hydrophobic interactions is clustered around Leu167 and involves additionally 
Phe154, Leu172, Ala223 and Leu227. Trp222 below Helix F develops hydrophobic 
interactions with the Phe238 from the loop between the F and G helix, and links Helix F 
with peptide-positioning loop via with interaction with Arg280 that serves as a bridge. 
 
 
The latter part of the large lobe is relatively hydrophobic, especially Helix F, 
which defines the hydrophobic core of PKAc. This core consists of two parts, 
one clustered around Tyr164 and another around Leu167 (Figure 29B); these 
two layers of interactions orchestrate the ordering of the large lobe of PKAc by 
signaling from the Mg
2+-positioning loop to the catalytic loop, and from the 
catalytic loop to the Helix F [Akamine et al., 2003; Kornev et al., 2006; Kornev 
and Taylor, 2010]. However, there are also two conserved charged residues in 100 
Helix F, Asp220 and Glu230; while Asp220 forms hydrogen bonds with the 
amide hydrogen atoms of Tyr164 and Arg165 and thus contributes to the 
positioning of the catalytic loop, Glu230 is in parallel to Glu170 responsible for 
the recognition of Arg residue in the P-2 position of the substrate. Additionally, 
the interaction of Glu230 with Arg133 creates the upper part of the PKAc site 
for the recognition of the amphipatic helix of PKI in the position P-8…P-16 of 
the substrate, whereas the essential lower part of this site is formed by Phe239 
of the loop between the Helix F and Helix G [Johnson D. A. et al., 2001]. 
  The C-terminal tail wraps around the surface of both lobes [Yang J. et al., 
2009], whereas the first fourteen residues are anchored to the large lobe and 
constitute a part of the hydrophobic pocket where the N-terminal myristoyl 
group binds. The intermediate part of the tail is relatively flexible; while 
residues 315…327 form a “gate” over the ATP-binding site, the residues 
328…334 incorporating several acidic amino acids contribute to the recognition 
of protein/peptide substrate (i.e., Tyr330 in parallel to Glu127 is responsible for 
the recognition of the Arg residue in the P-3 position of the substrate). The last 
four residues of the C-terminal tail are anchored to the small lobe, whereas 
Phe347 and Phe350 form the hydrophobic pocket which is also lined by resi-
dues of Helix C (Ile85, Leu89) and -strand 5 (Leu116, Met118). Importantly, 
residues 347…350 of the C-terminal tail as well as the preceding residues 
327…330 have also been shown to contribute to the recognition of PKAc by 
PDK1, the PK that performs phosphorylation of PKAc on Thr197 in vivo; 
additionally, the recognition of PKAc by PDK1 is facilitated by the phospho-
rylated state of Ser338 [Romano et al., 2009]. 
 
 
3.3.3. Conformational versatility of PKs 
 
Despite the fact that a protein crystal structure may provide only a static picture 
of the protein, the obtainment of several crystal structures from different 
complexes of one protein enables the construction of a model of conformational 
changes of the protein associated with its functioning. The crystal structure of 
the apoenzyme of PKAc (PDB 1J3H), in parallel with crystal structures of 
PKAc binary complexes with adenosine (PDB 1BKX) or PKI (PDB 2GFC), 
and quaternary complex with ADP, AlF3 and the phosphorylatable analogue of 
PKI(5...24) (PDB 1L3R) reveal the dynamic changes in PKAc associated with 
the binding of ligands and performance of catalysis [Akamine et al., 2003; 
Bonn et al., 2006; Madhusudan et al., 2002; Narayana et al., 1997; Taylor S. S. 
et al., 2004].  
The crystal structure of the active PKAc apoenzyme (with phosphorylated 
Thr197) revealed that according to the B-factors, the small lobe is relatively 
dynamic in the absence of ligands, while the large lobe is remarkably stable and 
most of the catalytically residues from the large lobe are ready for the catalysis 
already in the apoenzyme [Akamine et al., 2003]. PKAc adopts open confor-
mation, i.e., the part of the small lobe distant from the spanning Helix A is 101 
moved away from the large lobe (i.e., as compared to the previously discussed 
1ATP structure). Numerically, the degree of openness of conformation is 
assessed according to the distances Tyr330…Glu127, Ser53… Asp166, and 
His87…phosphorylated Thr197 [Johnson D. A. et al., 2001]; in apoenzyme, the 
corresponding distances are >20 Å, 12.8 Å and 10.4 Å (Figure 30A).  
The residues of the small lobe responsible for the fixation of phosphate 
moieties of ATP are mostly disordered in the apoenzyme, i.e., the side-chain of 
Lys72 is not visible, and the residues 52…55 of the Gly-rich loop possess very 
high B-factors [Akamine et al., 2003]. On the contrary, the residues responsible 
for binding of adenine moiety of ATP are generally in the same positions as in 
the binary complex with adenosine, with exception of Val57, Met120, Leu173, 
and Phe327. Whereas the side-chains of Val57 and Leu173 are not visible in the 
apoenzyme crystal, Met120 (which otherwise serves as the gate-keeper residue) 
points away from the catalytic cleft, and the portion of the C-terminal tail 
including Phe327 is disordered. The latter fact demonstrates that the “gate” 
formed by the residues 315…327 and regulating access to the ATP-site is 
ordered only upon binding of the ligand to the ATP-site [Taylor S. S. et al., 
2004].  
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Figure 30. Conformational versatility of PKAc and interaction networks. (A) Super-
imposition of crystal structures 1ATP (ternary complex PKAc-AMPPNP-PKI(5–24); 
green), 1YDT (ternary complex PKAc-H89-PKI(5–24); magenta), and 1J3H (PKAc 
apoenzyme; cyan). (B) Hydrophobic network in PKAc. PKAc shown as green cartoon, 
hydrophobic residues constituting most important “spines” as magenta spheres; the 
main vertical spine surrounded with red oval is formed by Leu95 from Helix C, Leu106 
from  -strand 4, Phe185 from Mg
2+-positioning loop, and Tyr164 from the region 
preceding catalytic loop [according to Kornev and Taylor, 2010]. 102 
The stable core of the apoenzyme is formed by Helix C, Helix D, Helix E, and 
-strand 6; importantly, the catalytically crucial residues Asp166 and Lys168 
belonging to this region are pre-positioned for catalysis [Akamine et al., 2003]. 
Apart from those, several residues are pre-formed for binding of the protein/ 
peptide substrate, i.e., Glu170, Glu203, Glu230, and residues creating the P+1 
pocket. However, residues Arg133 and Phe239 are not properly oriented, and 
the side-chain of Glu127 is not visible in the apoenzyme. The latter fact 
indicates that ordering of this residue occurs upon binding of ATP (i.e., 
interaction with hydroxyl in 2' position of ribose moiety of ATP positions the 
side-chain of Glu127 suitably for the recognition of Arg residue in the P-3 
position of the substrate) [Taylor S. S. et al., 2004].  
  The observation considering the stability of the large lobe is also true for 
other crystal structures of active PKAc, as no major conformational changes are 
induced in the large lobe upon binding of ligands [Bonn et al., 2006; Narayana 
et al., 1997; Taylor S. S. et al., 2004]. Instead, there are two major networks 
responsible for the communication of conformational changes in the active site 
to the remote regions of PKAc: the network started by ordering of Glu127, as 
discussed above, and the hydrophobic network (plase also refer to Section 3.3.2. 
Ternary complex of PKAc with AMP-PNP and PKI(5…24)) [Akamine et al., 
2003; Kornev et al., 2006; Kornev and Taylor, 2010]. The latter consists of two 
hydrophobic spines, one spine formed by the hydrophobic amino acid moieties 
from the ATP-binding hinge, Helix D and C-terminus of Helix F, and another 
spine incorporating residues from -strand 4, Helix C, the region preceding 
catalytic loop and Mg
2+-positioning loop (Figure 30B). 
  The small lobe, still, can rotate and slide away in respect to the large lobe in 
different crystal structures, which allows the Gly-rich loop of PKAc to adopt a 
variety of intermediate conformations between the fully opened (corresponding 
to the apoenzyme) and fully closed (corresponding to the complex resembling 
the transition state). In case of fully closed conformation (i.e., transition state 
model), the distances Tyr330…Glu127, Ser53…Asp166, and His87…phospho-
rylated Thr197 are 4.4 Å, 7.6 Å and 2.7 Å, respectively. In general, the crystal 
structure modeling of the phosphoryl transition state (where AlF3 is used instead 
of the transferable phosphoryl group) is remarkably similar to the previously 
discussed ternary complex of PKAc with AMP-PNP and PKI(5…24) [Madhu-
sudan et al., 2002]. Importantly, the AlF3 molecule is positioned between ADP 
and the phosphorylatable analogue of PKI(5...24) according to the dissociative 
mechanism of the direct in-line transfer, confirming the dissociative character of 
the phosphoryl transfer by PKs [Parang et al., 2001]. 
  Unfortunately, no crystal structure of the inactive state of PKAc (with non-
phosphorylated Thr197) has so far been resolved. However, the comparison of 
crystal structures of various PKs in their activated versus inactivated states 
(Figure 31) allowed formulation of a model reflecting profound conformational 
changes in PKs associated with phosphorylation of the Thr residue from the 103 
activation loop (corresponding to Thr197 of PKAc
11) [Johnson, 2009; Kornev et 
al., 2006]. Generally, there are several features of crystal structures of PKs 
characteristic of an inactive state (whereas for different PKs, different features 
are valid) [Huse and Kuriyan, 2002; Nolen et al., 2004]: 
  opening of the small lobe in respect to the large lobe; 
  inordered activation loop, or the activation loop bound to the catalytic loop 
and thus serving as autoinhibitory domain; 
  “swung-out” conformation of Helix C, where Glu
91 is exposed to the solvent 
and its interaction with catalytically important Lys
72 is disrupted; 
  “DFG-out” state of the Asp-Phe-Gly motif of the Mg
2+-positioning loop, 
where Asp
184 points out of the catalytic cleft (and no longer binds to the 
upper Mg
2+-ion) and Phe
185 points into the catalytic cleft. 
The “swing-in” movement of Helix C upon phosphorylation of Thr
197 from the 
activation loop results from the gain of interaction between phosphoryl of Thr
197 
and Lys
189 or Thr
197 and Arg
190 (Figure 31A–D). In the “swung-out” Helix C, 
Glu
91 pointing to the solvent usually forms a charge-assisted hydrogen bond to 
Arg
190; however, the phosphoryl of Thr
197 successfully outcompetes this 
interaction by forming the charge-assisted hydrogen bond with Arg
190 itself or 
the preceding residue (Lys
189) [Levinson et al., 2006]. The reorganization of the 
“DFG-out” state of the Asp-Phe-Gly motif, on the other hand, involves several 
steps, but is also initiated by the interaction between Thr
197 and Lys
189, and 
another interaction between Thr
197 and Arg
165  (Figure 31E). Dephosphorylation 
of Thr
197 causes repellence of Arg
165 and Lys
189, and thus destroys the ensemble 
of residues holding Asp
184 in the “DFG-in” state [Kornev et al., 2006]. 
  
                                                            
11  Further on in this section, the residues of PKs corresponding to the residues of PKAc 
are denoted with three-letter code of the amino acid with superscript number of the 
residue in PKAc; i.e., the Thr residue corresponding to Thr197 in PKAc is denoted as 
Thr
197. 104 
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Figure 31. Comparison of active and inactive conformations of PKs. (A) 1ATP, 
representing the active conformation of a kinase (PKAc). Helix C, activation loop and 
Mg
2+-positioning loop shown as cartoon, residues responsible for active conformation 105 
of Helix C and Asp-Phe-Gly triad shown as lines. (B) 3LCK, representing the active 
conformation of a kinase (LCK). (C) 2G1T, representing an inactive C-Glu-out 
conformation of a kinase (Bcr-Abl). (D) 3GVU, representing an inactive DFG-out 
conformation of a kinase (Bcr-Abl); activation loop disordered. (E) 1ATP, organization 
of Asp-Phe-Gly motif by phosphorylated Thr
197. The positioning of Arg
165 resulting 
from interaction with Thr
197 triggers turning of the amide bond between DFG+1 and 
DFG+2 residues towards Arg
165, and formation of two additional hydrogen bonds (I and 
II). Subsequently, the amide bond between Phe
185 and Gly
186 turns and generates a 
hydrogen bond (III) with the amide hydrogen of DFG+2 residue. Additionally, this 
positioning of the amide bond between Phe
185 and Gly
186 favors formation of hydrogen 
bond (IV) between the amide hydrogen of Gly
186 and the side-chain of Asp
184, which 
finally fixes the catalytically correct position of the latter. 
 
 
3.3.4. PKAr subunits and holoenzyme 
 
PKAr subunits serve as physiological regulators of PKAc activity, and are also 
responsible for the intracellular localization of the enzyme via interaction with 
AKAPs. PKAr consists of the N-terminal docking/dimerization domain (D/D) 
and the C-terminal cAMP-binding domains A and B; these domains are joined 
by a linker that contains the so-called inhibitor sequence, i.e., the fragment that 
can bind to the protein/peptide substrate-site of PKAc [Kinderman, et al. 2006; 
Sarma  et al., 2010]. According to its name, the main function of the D/D 
domain of PKAr is the formation of a dimer of PKAr subunits, whereas the 
joined D/D regions of two PKAr subunits constitute a motif for binding to 
AKAP, and the latter part of the PKAr dimer interacts with PKAc or with 
cAMP. Unfortunately, no crystal structure is available about the full-length 
PKAr; however, there are crystal structures of PKArI and PKArII D/D 
domains with or without AKAPs, and of N-terminally truncated PKArI, 
PKArII or PKArII with PKAc or with cAMP [Brown S. H. J. et al., 2009; 
Kim C. et al., 2007; Kinderman, et al. 2006; Sarma et al., 2010; Wu J. et al., 
2007]. 
  The dimerized PKArI D/D domains as well as the dimerized PKArII D/D 
domains have been co-crystallized with the dual-specificity AKAP, D-AKAP2 
(PDB 3IM4 and PDB 2HWN, respectively) [Kinderman, et al. 2006; Sarma et 
al., 2010]. Both crystal structures showed that the D/D dimer is in both cases 
formed by the XX-shaped antiparallel bundle of four helices, 1 (residues 
25...38 of PKArI, 8…24 of PKArII) and 2 (residues 44...60 of PKArI, 
27…42 of PKArII) from each monomer. Additionally, in 3IM4 two helices 0 
(residues 13...21) contribute to this surface, as the Cys16 from helix 0 of each 
monomer forms disulfide bridge with Cys37 from helix 1 of another monomer 
(Figure 32). The amphipatic helix of D-AKAP2 (residues 628–654 in 3IM4, 
residues 631…649 in 2HWN) binds diagonally across one face on the formed 
surface, and generates multiple contacts with helices 1 of each monomer. 
Interestingly, in 2HWN the binding of the asymmetric sequence of D-AKAP2 106 
induces an asymmetry of the PKArII dimer: only in one monomer, the N-
terminus (residues 1…8) preceding the helix 1 is ordered, and the residues Ile3 
and Ile5 interact with the D-AKAP2 helix [Kinderman, et al. 2006]. Such 
flexibility of structure probably contributes to the wider AKAP-selectivity 
profile of PKArII as compared to PKArI. 
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Figure 32. Interactions between PKArI and D-AKAP2. (A) 3IM4. D/D fragments of 
PKArI subunits are shown as cartoon (cyan for one subunit and green for another; 
residues participating in interactions with D-AKAP2 also shown as sticks), D-AKAP2 
as magenta ribbon (the residues participating in strong interactions with PKArI are 
also shown as lines and numbered). Black boxes indicate four main regions of binding 
at the interface. (B) 2HWN. D/D fragments of PKArII subunits are shown as cartoon 
(yellow for the more ordered subunit and magenta for the less ordered one; residues 
participating in interactions with D-AKAP2 also shown as sticks), D-AKAP2 as cyan 
ribbon (the residues participating in strong interactions with PKArII are also shown as 
lines and numbered). Black boxes indicate two main regions of binding at the interface. 
 
 
Despite higher KD value towards PKArI (48 nM towards PKArI, 2 nM 
towards PKArII[Kinderman, et al. 2006]), the interface between PKAr and D-
AKAP2 is larger in 3IM4 than in 2HWN: while in the former, there are four 
main regions of binding at the interface, in 2HWN there are only two regions 
(Figure 32). The formed interactions are mainly hydrophobic, although several 
polar contacts are also present. Interestingly, in co-crystal with PKArII, a shift 107 
of D-AKAP2 helix by one helix turn towards the N-terminus occurs in 
comparison to the co-crystal with PKArI. Importantly, the pockets on the 
surface of dimerized PKAr subunits where residues of D-AKAP2 bind show 
preference for different hydrophobic residues (i.e., as binding partners) 
dependent on the isoform of the PKAr, revealing the basis for selectivity of 
several AKAPs towards PKArII[Kinderman, et al. 2006; Sarma et al., 2010]. 
Analogically, different isoforms of PKAr display similar patterns of binding to 
the PKAc subunit and similar conformational changes upon binding of cAMP, 
although the details and the extent of these processes are dependent on the 
PKAr isoform [Brown S. H. J. et al., 2009; Kim C. et al., 2007; Wu J. et al., 
2007]. As the effects are most pronounced in case of PKArI, the co-crystal of 
the truncated mutant form of PKArI(91…379:Arg333Lys) with PKAC and 
ATP (PDB 2QCS) and the co-crystal of another truncated form of 
PKArI(113…376) with cAMP (PDB 1RGS) will be used as the illustrative 
examples [Kim C. et al., 2007]. 
The PDB 2QCS co-crystal revealed that PKAc is in closed conformation, 
whereas PKArI binds to PKAc in an extended conformation where cyclic 
nucleotide binding domains A and B are separated by the elongated helix B/C 
from domain A of PKArI. There are four major sites on the surface of PKAc 
subunit involved in interactions with PKArI [Kim C. et al., 2007]: 
  Site 1, spanning the C-terminal tail, protein/peptite substrate-site of PKAc, 
and P+1 loop (Figure 33A); 
  Site 2, created by the hydrophobic surface of Helix G and P+1 loop (Figure 
33B); 
  Site 3, formed by the activation loop (Figure 33C); 
  Site 4, involving the loop between Helix H and Helix I (Figure 33D). 
The linker of PKArI (residues 91…123, in full-length protein 45…123) binds 
to sites 1 and 2, domain A (123…258) binds to sites 2 and 3, and domain B 
(259…379) binds to sites 3 and 4 (Figure 34). Interestingly, the helix B/C from 
domain B of PKArI is not elongated as its counterpart from domain A, but 
represents a construction containing three short segments, helices B, C, and C’. 
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Figure 33. 2QCS, PKAc colored as green and PKArI as magenta; numbers are given 
only for PKAc residues. (A) Site 1 is filled by the inhibitor sequence (residues 92…98) 
from the linker region of PKArI; while Arg95 of PKArI
12 (in position P-2) binds to 
Glu170
c and Glu230
c, Arg94
r (P-3) interacts with the side-chains of Glu127
c and 
Tyr330
c, Arg93
r (P-4) forms charge-assisted hydrogen bond to Glu203
c, and Arg92
r (P-
5) makes two contacts with Asp328
c. Such hydrogen bond network is characteristic of 
PKArI isoforms, as only PKArI subunits (but not PKArII) contain Arg residues in 
positions P-4 and P-5. (B) Site 2 forms a hydrophobic interface with residues 97…101 
and 204…205 of PKArI; additionally, a hydrogen bond is generated between Tyr247
c 
and Tyr205
r, and polar interactions are developed between Lys213
c, Glu143
r, and 
Lys240
r. (C) The three “hot-spots” of binding between Site 3 and PKArI are 
represented by the hydrophobic pocket formed by Trp196
c, Met234
r and Leu238
r, the 
                                                            
12 Further on in this section, the residues of PKAc are denoted with superscript 
c, and 
the residues of PKAr with superscript 
r. 109 
polar network of interactions between Arg194
c, Arg241
r and Asp267
r, and the 
hydrophobic contact area lined by Lys192
c, Trp260
r and Leu263
r. (D) In Site 4, the 
side-chains of Asp276
c and Thr278
c make a hydrogen bond to Arg352
r; additionally, 
Thr278
c via its side-chain and its backbone carbonyl group forms two hydrogen bonds 
to Arg355
r. 
 
 
Binding of two cAMP molecules to PKArI induces a profound reorganization 
of the latter subunit, with the most drastic conformational change represented 
by bending of helix B/C from domain A, and rotation around the points in this 
helix corresponding to residues Arg226
r, Gly235
r, and Tyr244
r [Kim C. et al., 
2007]. As a result of such a bending and twisting movement, the cAMP-bound 
PKArI is folded into a globular structure (Figure 34B). In both domains A and 
B, the phosphate moiety of cAMP molecule makes multiple hydrogen bonds 
with the backbone nitrogen atoms of the short helix positioned inside the 
cAMP-binding site and termed phosphate-binding cassette (PBC, residues 
200…205 in domain A, 324…329 in domain B). Additionally, in the cAMP-
binding site of each domain a hydrogen bond is formed between the phosphate 
moiety of cAMP and the conserved arginine residue (Arg209
r in domain A, 
Arg333
r in domain B). Moreover, after cAMP-induced folding of PKArI, the 
residues Trp260
r and Tyr371
r are positioned under the five-stranded -sand-
wiches of domain A and domain B, respectively, and become the “capping 
residues” for the cAMP-binding sites [Kim C. et al., 2007]. By contrast, in 
PKAc-bound state, residue Trp260
r is involved in interactions with Site 3, and 
Tyr371
r is kept away from the rest of domain B by the intramolecular salt 
bridge formed by the preceding Arg366
r with Glu261
r. 
As Tyr371
r is better accessible for cAMP than Trp260
r, the proposed 
mechanism for the cAMP-mediated activation of PKA starts from occupation of 
cAMP-binding site in domain B and “capping” of the bound cAMP molecule by 
Tyr371
r [Kim C. et al., 2007]. The development of this hydrophobic interaction 
causes breakage of the salt bridge between Arg366
r with Glu261
r, and thus 
triggers bending of helix B/C from domain A; bending of the latter helix 
enables formation of the interface between the domains of PKArI. Finally, 
binding of another cAMP molecule to domain A necessitates “capping” of the 
bound cAMP molecule by Trp260
r, which causes dissociation of PKArI from 
PKAc.  110 
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Figure 34. Conformational versatility of PKArI. (A) 2QCS, PKAc-bound confor-
mation of PKArI. Domain A of PKArI is shown as cyan cartoon, domain B as ma-
genta cartoon, PBCs of either domain are colored green; residues important for cAMP 
binding are also shown as lines and numbered. (B) 1RGS, cAMP-bound conformation 
of PKArI.The interface between the two lobes of the globular structure of cAMP-
bound PKArIa is formed by the cAMP molecule binding to domain A, the kinked helix 
B/C from domain A, and helices A and B from domain B. The helices A and B from 
domain B are aligned parallel to each other and perpendicular in respect to the helix B/C 
from domain A. 
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This model is most likely valid for all isoforms of PKAr subunits, at least for 
PKArII and PKArII, as indicated by co-crystals of truncated forms of the 
latter with PKAc (PDB 2QVS and PDB 3IDC, respectively) [Brown S. H. J. et 
al., 2009; Wu J. et al., 2007]. However, there are other aspects in which PDB 
2QVS and PDB 3IDC differ from 2QCS, such as conformation of PKAc 
subunit. In 2QVS, PKAc is in an open conformation due to the lack of ATP in 
the co-crystal, and the C-terminal tail of PKAc is disordered [Wu J. et al., 
2007]. By contrast, in 3IDC (similarly to 2QCS), the C-terminal tail of PKAc is 
ordered and the conformation of PKAc is more closed, but the hydrogen bond 
between Ser53
c and -phosphate moiety of ATP is absent [Brown S. H. J. et al., 
2009]. Still, in all three crystal structures the N-terminus of PKAr subunits 
becomes ordered as a result of binding to PKAc, in contrast to the unordered N-
terminal linker of cAMP-bound PKAr subunits. Importantly, in case of 3IDC 
the linker residues 103…105 corresponding to the positions P-9…P-7 are not 
disordered as in 2QCS or 2QVS, but instead form an extended strand generating 
hydrophobic interactions with the loop between Helix F and Helix G of PKAc 
[Brown S. H. J. et al., 2009]. The latter loop is also utilized as a binding partner 
by the amphipatic helix of PKI, but not by other isoforms of PKAr (as those 
possess an acidic linker that probably cannot bind to the hydrophobic surface) 
[Johnson D. A. et al., 2001]; the latter fact emphasizes the multiplicity of 
mechanism for recognition of ligands binding to the protein/peptide substrate-
site of PKAc. 112 
AIMS OF THE STUDY 
 
The main aims of this study were as follows: 
  focussed design and synthesis of ARCs with improved proteolytic stability 
and enhanced affinity towards basophilic PKs; 
  co-crystallization of ARCs with PKAc  aimed at facilitation of the structure-
aided design of new inhibitors; 
  establishment of PK selectivity profiles for the most efficient ARCs, and 
determination of the fragments in the structure of ARCs responsible 
affecting their selectivity towards certain PKs; 
  application of the most efficient ARCs for the in vitro experiments in living 
tissue by utilizing ability of ARCs to block certain PK pathways. 113 
RESULTS AND DISCUSSION 
 
1. Development of ARC-II conjugates  
[Paper 1: Enkvist et al., 2006,  
Paper 3: Lavogina et al., 2010a] 
 
Despite several attractive properties such as combination of enhanced potency 
and selectivity, the bisubstrate inhibitors of protein kinases have been sub-
stantially less intensively explored than ATP-competitive compounds. One of 
the subgroups of BSIs is represented by ARCs, conjugates of an adenosine 
analogue (nucleosidic Fragment 1) and an arginine-rich peptide (peptidic 
Fragment 2), with Fragment 1 targeted to the ATP-site and Fragment 2 to the 
protein/peptide substrate-site of a PK (Figure 35). 
  
 
Figure 35. General scheme of ARC-I and ARC-II inhibitors. Below are shown 
examples of structures of Fragment 1, Fragment 2, and linker. 
 
 
According to the initial design (prior to the given thesis) Adc moiety had been 
applied as Fragment 1 and oligo-(L-arginine) as Fragment 2, linked via a 
hydrophobic flexible linker [Loog et al., 1999]. By virtue of incorporation of 
highly charged cationic oligo-arginine peptide, ARCs had initially been 
developed as group-selective inhibitors targeting basophilic protein kinases (i.e., 
PKAc, PKC, CAMK, etc). The moderate inhibitory potency of the initial ARCs 
(IC50 values in the submicromolar range) motivated the further optimization of 
the structure of these compounds aimed at increase of affinity towards PKAc. 
The latter was chosen as a model PK, as its mechanisms of activation and 
functioning are thoroughly described in the literature, and PKAc is available 
from several commercial resources in high purity and as the non-truncated 
active form.  
The changes in the structure of initial ARCs included the following 
variations: 
  amidation of the C-terminus of the conjugates; 
  conversion of the peptidic Fragment 2 to its enantio-modification, i.e., use 
of D-arginines instead of L-arginines; 114 
  modification of the linker part by reversion of direction of the amide bond 
between Fragment 1 and Fragment 2, by N-methylation of the amide bond 
between Fragment 1 and Fragment 2, and by introduction of rigid aromatic 
amino acids or additional hydrogen bond donors (i.e., NH groups); 
  conversion of the peptidic Fragment 2 to its retro-analogue, i.e., attachment 
of Fragment 1 to the C-terminus of Fragment 2, not vice versa; 
  modification of Fragment 1 by elimination of ribose moiety of Adc, or by 
replacement of Adc with H-series inhibitor H-9 moiety (analogically to the 
work by Ricouart et al., 1991).  
In all novel conjugates, two structural units were preserved as in the initial 
ARCs: the length of the linker between Fragment 1 and Fragment 2, and the 
use of oligo-arginine as Fragment 2. The structure of the first unit was 
optimized for inhibitory potency in studies with initial ARC-s  by variation of 
the length of hydrophobic flexible linkers, and it had been shown that at the 
distance corresponding to the length of 6-aminohexanoic acid moiety, the 
highest affinity towards PKAc was achieved [Loog et al., 1999]. The second 
unit, on the other hand, was kept intact because oligo-arginine had been 
demonstrated to provide conjugates with high affinity towards basophilic PKs 
as well as cell-penetrative properties [Uri et al., 2002; Viht et al., 2003]. It was 
acknowledged that application of oligo-arginine would possibly result in 
promiscuous nature of ARCs; however, at that point of ARC-development it 
was primarily important to achieve high affinity, not selectivity. The range of 
ARC-based applications was envisioned to be connected with generic affinity 
supports and fluorescent probes of PKs [Loog et al., 2000], where selective 
pinpointing of certain PKs might be performed via other mechanisms (i.e., 
elution/displacement with selective ACIs, PCIs, or BSIs). Moreover, it was 
presumed that in case if selectivity of ARCs would be set into the focus of 
attention, it could be possible to “tune” it by exchange of Fragment 1 or linker. 
Twenty-five new ARCs were synthesized by combination of solid phase-
peptide synthesis and solution synthesis approaches. The general synthetic 
scheme involved preparation of Fragment 1 in solution and Fragment 2 on 
solid phase, whereas the linker could be initially attached to either of the frag-
ments and the procedure of conjugation could be performed either on solid 
phase or in solution, dependent on the course of preceding synthesis. The 
assessment of inhibitory potency of compounds towards PKAc was performed 
with the aid of non-radioactive TLC-based assay [Viht et al., 2005], where the 
retarding effect of an inhibitor on PKAc-catalyzed phosphorylation reaction was 
monitored  via the chromatographic separation of phosphorylated and non-
phosphorylated forms of fluorescently labelled peptide substrate (5-TAMRA-
Kemptide).  
From the results of inhibition studies, the following modifications that 
significantly enhanced the inhibitory potency of ARCs were established (please 
refer to Table 1 from Paper 1): 
  Amidation of the C-terminus of the conjugates resulted in 4–6-fold increase 
in potency, i.e., IC50 value of 170 nM for ARC-341 (compound 3 from 115 
Paper 1; (Figure 36A) versus IC50 value of 700 nM for the corresponding 
non-amidated conjugate [Loog et al., 1999]. 
  Use of D-arginines instead of L-arginines in Fragment 2 resulted in a 20-
fold increase in potency, i.e., IC50 value of 8.3 nM for ARC-902 (compound 
5 from Paper 1; Figure 36B) versus IC50 value of 170 nM for the cor-
responding conjugate ARC-341 containing oligo-(L-arginine) moiety (com-
pound 3 from Paper 1). Moreover, application of D-arginines substantially 
improved the stability of novel ARCs towards proteolysis, as was detected in 
degradation experiments with fetal bovine serum and trypsin. 
  Introduction of H-9 moiety as Fragment 1 and Hex as linker resulted in 
slight increase in potency in case of conjugates containing oligo-(D-
arginine), i.e., IC50 value of 5.3 nM for ARC-903 (compound 26 from Paper 
1; Figure 36D) versus IC50 value of 8.3 nM for the corresponding conjugate 
ARC-902 containing Adc moiety (compound 5 from Paper 1). However, 
the comparison of conjugates containing oligo-(L-arginine) revealed a 65-
fold increase in potency, i.e., IC50 value of 30 nM for ARC-349 (compound 
25  from  Paper 1; Figure 36E) versus IC50 value of 2000 nM for the 
corresponding conjugate containing Adc moiety (compound 2 from Paper 
1). All in all, as compared to the Compound 17 reported in Ricouart et al., 
1991, the inhibitory properties of H-9-containing ARCs were not more 
efficient. However, in case of ARCs the all-D-arginine fragment was 
substituted for the all-L-arginine fragment of Compound 17 unstable in 
biological systems, and the overall structure of the conjugate was also 
simplified by elimination of chiral and phosphorylatable Ser residue. 
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Figure 36. Examples of ARC-II. (A) ARC-341. (B) ARC-902. (C) ARC-659-1b. (D) 
ARC-349. (E) ARC-903. 
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Additionally, it was demonstrated that the most suitable arrangement of 
structural elements of ARCs was Fragment 1 – linker – Fragment 2 (i.e., not 
the retro-modification of the conjugate Fragment 2 – linker – Fragment 1), 
and that the linker moiety yielding highest potency of novel ARCs was 6-
aminohexanoic acid moiety (Ahx), just as in case of the  initial compounds. At 
this point, the latter result was slightly unexpected, as the flexible nature of Ahx 
raised doubts considering the entropic gain characteristic of ideally optimized 
BSIs (resulting from the interaction of a single BSI-molecule rather than its 
multiple fragments with the PK).  
Overall, the most potent novel compounds towards PKAc were ARC-902 
and ARC-903; importantly, the IC50 value of 8.3 nM for ARC-902 was 130-
fold lower than the product of IC50 values of compounds used as Fragment 1 
(IC50 value of 350 M) and Fragment 2 (IC50 value ca 3000 M). However, the 
IC50 value of 5.3 nM for ARC-903 was only 2-fold lower than the product of 
IC50 values of Fragment 1 (IC50 value of 3.7 M) and Fragment 2 (IC50 value 
ca 3000 M), revealing that the optimal linkage of fragments had not been 
achieved. The latter fact in turn most probably pointed to a different mode of 
binding for H-9-containing compounds than for Adc-containing conjugates.  
The profiling of ARC-902 and ARC-903 (each at concentration of 1 M) 
versus a panel of 52 kinases revealed the promiscuous nature of these com-
pounds, whereas ARC-903 was more generic and slightly more effective than 
ARC-902. In addition to PKAc, both ARCs inhibited strongly ROCK-II, PKB, 
MSK1, and PRK2 (all representing AGC-group of kinome); as expected, 
neither compound inhibited acidophilic kinases (i.e., CK1, CK2). In general, the 
profiling confirmed the tendency of ARCs to inhibit basophilic PKs, as all 14 
kinases that were inhibited by both, ARC-902 and ARC-903 to an extent over 
85%, represented basophilic PKs from AGC-group and from CAMK group.  
It should also be mentioned that compound ARC-659-1b (Figure 36C) 
subsequently developed on the basis of ARC-902  [Enkvist  et al., 2007], 
successfully confirmed the hypothesis that despite incorporation of non-
selective oligo-(D-arginine) moiety, the selectivity of ARCs towards certain 
targets may be achieved by application of a selective ATP-mimicking entity as 
Fragment 1. In case of ARC-659-1b, the latter fragment was represented by 
the carbocyclic analogue of 3’-deoxyadenosine; the resulting conjugate 
demonstrated 3.5-fold increased affinity as compared to ARC-902 (IC50 values 
of 2.4 and 8.3 nM, respectively), and astonishingly increased the selectivity 
towards PKAc [Enkvist et al., 2007]. When ARC-659-1b was profiled at 10 nM 
concentration towards a panel of 34 PKs, the determined residual activity of 
PKAc was 7%, whereas the only other kinases retaining less than 50% of the 
residual activity were ROCK-II (41%) and MSK1 (37%).  
To sum up, the substantial improvement of inhibitory characteristics of 
oligo-(D-arginine)-containing amidated ARCs towards PKAc gave reason for 
introduction of two new terms, ARC-II and ARC-I, denoting respectively the 
set of compounds (“generation”) with structural features characteristic of the 
novel ARCs, and of the initial ARC-compounds [Lavogina et al., 2010a]. 117 
2. Confirmation of the bisubstrate character of ARC-IIs 
[Paper 1: Enkvist et al., 2006,  
Paper 3: Lavogina et al., 2010a] 
 
Notwithstanding the fact that BSIs have been developed as inhibitors of kinases 
since 1973 [Lienhard and Secemski, 1973], surprisingly little emphasis has been 
put on the confirmation of the bisubstrate nature of conjugates. While enhance-
ment of affinity of a conjugate as compared to the composing fragments may 
indicate biligand (but not necessarily bisubstrate) binding, three main methods 
exist that may prove the bisubstrate inhibition character: 
  kinetic analysis of the competitiveness of a BSI versus either substrate; 
  binding studies where a BSI is displaced from its complex with a PK by 
either ATP- or protein substrate-competitive inhibitors; 
  analysis of the BSI–PK co-crystal structures. 
Additionally, improvement of selectivity of non-selective ATP-mimicking 
moiety upon conjugation with selective protein/peptide substrate-mimicking 
moiety also provides indirect evidence that the resulting conjugate is indeed a 
BSI.  
Historically, kinetic studies of inhibition mechanism have been considered 
the most “universal” way for characterization of BSIs; as a first approximation, 
one would consider that a BSI should be competitive both versus ATP and 
versus a protein/peptide substrate. However, the studies of the mechanism of 
PKAc inhibition by ARC-902 revealed competitive inhibition versus ATP and 
non-competitive inhibition versus peptide substrate (5-TAMRA-Kemptide), 
which was identical to the data obtained for several other BSIs, especially those 
targeted to PKAc [Parang and Cole, 2002a]. This phenomenon has been an 
object of thorough discussions [Lawrence and Niu, 1998; Lawrence, 2005; 
Magalhaes et al., 2008], and it has been argued that a non-competitive inhi-
bition mechanism versus one of the (co-)substrates (usually, the protein/peptide) 
does not rule out the bisubstrate character of inhibition, but is rather indicative 
of ordered (i.e., ATP-first) mechanism of ligand binding by PK (please refer to 
Section 2.2.1. Affinity and inhibitory potency). Indeed, studies of Kemptide 
phosphorylation by PKAc indicated that the preferred kinetic pathway is an 
initial binding of ATP, which induces conformational changes facilitating 
binding of peptide substrate [Lew et al., 1997a]. Another idea proposed for the 
explanation of the non-competitive inhibition mechanism of BSIs versus 
peptide substrates is an ordered mechanism of BSI binding [Ricouart et al., 
1991], where the ATP-mimicking moiety binds first and by triggering positive 
cooperative effects and/or by increasing the local concentration of the peptide 
substrate-mimicking moiety enables further binding of the latter to the PK. 
The recent progress in the development of high-affinity probes has caused 
substantial rise of application of binding/displacement assays. Derivatives of 
ARC-902 have been used as affinity sensors for SPR [Viht et al., 2007], and as 
probes (ARC-Photo) for the assay with detection of fluorescence anisotropy/ 118 
polarisation [Vaasa et al., 2009]. In the first case, biotinylated ARC-II com-
pound  ARC-704  (Figure 37A) was immobilized on the SPR chip via 
streptavidin-biotin complex, yielding a high-affinity surface that bound effi-
ciently PKAc and ROCK-II [M. Lust, unpublished data]. The solution compe-
tition experiments with compounds targeted to the ATP-site (i.e., H-1152, H-
89) and to the  protein/peptide substrate-site (i.e., PKArII, GST-tagged PKI) 
of PKAc showed that the latter could be displaced from its complex with 
immobilized ARC-704 by both ACIs and PCIs, and thus confirmed the BSI 
nature of immobilized ARC-704 [Viht et al., 2007]. In the second case, 
labelling of an ARC-II representative with fluorescence dye 5-TAMRA yielded 
ARC-583 (Figure 37B), which exhibited KD values of 0.48 nM and 3.6 nM 
towards PKAc and ROCK-II, respectively, according to the direct titration 
experiments. Subsequenly, ARC-583 could be successfully displaced from its 
complex with PKAc by increasing concentrations of compounds targeted to 
ATP-site (i.e., H-89) and to protein/peptide substrate-site (i.e., PKArI, 
PKArII, PKI) of the kinase, confirming again the bisubstrate nature of kinase 
inhibition by ARC-II compounds [Vaasa et al., 2009]. 
The crystal structures of complexes of a PK inhibitor bound to its target 
allow unambiguous visualization of PK sites where the inhibitor binds as well 
as the interactions between the PK and the inhibitor; this information is 
crucially important for the structure-aided optimization of compounds. There-
fore, co-crystallization of PKAc with several representatives of ARC-II 
inhibitors was carried out, and two crystal structures were resolved yielding the 
results presented below. 
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Figure 37. Examples of derivatized ARC-II. (A) ARC-704; blue polygon surrounds the 
attached biotin moiety. (B) ARC-583; red rounded rectangle surrounds the fluorescent 
dye TAMRA. 
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3. Crystallographic studies of ARC-II conjugates  
[Paper 2: Lavogina et al., 2009, Paper 3: Lavogina et al., 
2010a, Paper 5: Pflug et al., 2010] 
 
3.1. PKAc – ARC-1034 complex (PDB 3BWJ)  
[Paper 2: Lavogina et al., 2009, Paper 3: Lavogina et al., 2010a] 
 
The first ARC-II representative yielding co-crystal structure with PKAc was 
ARC-1034 (Figure 38A) incorporating amidated (D-Arg)2-peptide and hence 
only partly representing the interactions between PKAc and longer ARC-II 
compounds (i.e., conjugates containing amidated (D-Arg)6-peptide). The 
electron density of the co-crystal indicated that two ARC-1034 molecules (so-
called “inner” and “outer”) were bound to one PKAc molecule, the “inner” 
ARC-1034 expectedly positioned in the catalytic cleft and the “outer” molecule 
situated on the surface of PK in the contact region with the symmetry-related 
PKAc – ARC-1034 complex. The presence of the “outer” ARC-1034 was 
classified as a crystallographic artefact, as the evidence from SPR experiments 
[Viht et al., 2007] as well as kinetic studies [Viht et al., 2005] supported only an 
1:1 stoichiometry of ARC-II binding to PKAc. 
  The electron density of the “inner” ARC-1034 was well defined for the Adc-
moiety occupying the ATP-site, and for the linker bound under the Gly-rich 
loop of PKAc. Apart from the “classical” pattern of hydrogen bond interactions 
developed by Adc-moiety with PKAc residues constituting ATP-binding hinge 
(i.e., Glu121, Val123, Thr183 binding to purine of Adc and Glu127, Glu170 
binding to hydroxyl groups of ribose moiety), a new interaction was spotted 
between the oxygen of carbonyl group of Adc and a water molecule situated 
inside the cleft (Figure 38B). This water molecule was itself connected via 
hydrogen bonds with side-chains of Thr183 and of the conserved residue Lys72; 
such network of interactions explained the previously reported higher affinity of 
Adc-containing ARC-IIs as compared to the analogical compounds containing 
adenine or adenosine fragments [Enkvist et al., 2006].  121 
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Figure 38. ARC-1034 and its co-crystal with PKAc. (A) Structure of ARC-1034 with 
arginine residues numbered. (B) ATP-site of 3BWJ. ARC-1034 is shown as sticks, 
water molecule as red sphere, PKAc as cartoon; the residues of the ATP-site of PKAc 
interacting with ARC-1034 are shown as lines and numbered. (C) Interactions 
developed between the linker of ARC-1034 and PKAc. (D) Interactions developed 
between the Fragment 2 of ARC-1034 and PKAc. 
 
 
The binding mode of the linker, on the other hand, provided a good explanation 
for the previous observations that Ahx moiety was an optimal linking chain for 
both ARC-I and ARC-II compounds [Loog et al., 1999; Enkvist et al., 2006]. 
The length and flexibility of Ahx allowed positioning of the terminal carbonyl 
of the linker exactly below the flexible top of the Gly-rich loop, enabling 
generation of extensive hydrogen bond interactions between the terminal 
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carbonyl of the linker and the residues Ser53, Phe54, and Gly55 of PKAc, as 
well as above-plane hydrophobic interaction with the aromatic ring of Phe54 
(Figure 38C). The conformation of PKAc was intermediate (half-closed), 
according to the distances Tyr330...Glu127 (4.7 Å), Ser53...Asp166 (10.5 Å), 
and His87...phosphorylated Thr197 (2.9 Å). In case of fully closed confor-
mation (i.e., transition state analogue), the corresponding distances are 4.4 Å, 
7.6 Å and 2.7 Å (PDB 1L3R), and in case of fully open conformation (i.e., 
apoenzyme) over 20 Å, 12.8 Å and 10.4 Å (PDB 1J3H). Overall, the con-
formation of the Gly-rich loop in PKAc – ARC-1034 complex was similar to 
that reported for the binary complex PKAc – adenosine (PDB 1BKX) and for 
the ternary complex PKAc – H-89 – PKI(5-24) (PDB 1YDT) (Figure 39). 
However, in the former crystal the Gly-rich loop had not been fixed, and in the 
latter a hydrophobic above-plane interaction had been developed between the 
bromine group of H-89 and the aromatic ring of Phe54.  
 
 
Figure 39. Overlay of Gly-rich loops of co-crystals PKAc – ARC-1034 (3BWJ, blue), 
PKAc – adenosine (1BKX, cyan), and PKAc – H-89 – PKI(5-24) (1YDT, pink). Gly-
rich loops of PKAc molecules are shown as ribbon and ligands as sticks; black dots 
indicate hydrogen bonds between ARC-1034 and PKAc from 3BWJ, Phe54 of PKAc 
from 1YDT is shown as lines and numbered. 
 
 
Prior to co-crystallization, it was expected that the D-Arg residues of ARC-
1034 develop interactions with Glu127 and Glu170 of PKAc, the residues 
responsible for recognition of PKAc protein/peptide substrates. It was also 
presumed that in case of longer ARC-II conjugates containing the amidated (D-
Arg)6-peptide, their D-Arg residues #3...#6 develop contacts with downstream 
amino acids of PKAc such as Glu203 and Glu230, both also involved in PKAc 
substrate recognition. Surprisingly, the electronic density of the amidated (D-
Arg)2-peptide incorporated in ARC-1034 was not continuous and well-defined 123 
only for the D-Arg residue closer to the linker moiety (Arg#1), whereas the D-
Arg residue closer to the C-terminus of the conjugate (Arg#2) was exposed to 
the solvent. Moreover, Arg#1 did not protrude to Glu127 or Glu170 of PKAc 
but instead pointed “down” (Figure 38D), developing hydrogen bonds with 
side-chain groups of Asp166 and Thr201, and an in-plane interaction of the 
guanidinium-group with Phe187; additionally, the carbonyl of Arg#1 was an 
acceptor for the hydrogen bond donated by the side-chain of Ser53.  
Overall, the absence of interactions between Fragment 2 of ARC-1034 and 
Glu residues of PKAc involved in binding of substrates demonstrated that 
ARC-1034 did in fact not represent bisubstrate ARC-II compounds, but rather 
served as a simplified model for mapping interactions of Fragment 1 and linker 
moiety with PKAc.  
 
 
3.2. PKAc – ARC-670 complex (PDB 3AGM)  
[Paper 3: Lavogina et al., 2010a, Paper 5: Pflug et al., 2010] 
 
Subsequently, a crystal structure of complex between PKAc and a representa-
tive of longer ARC-II compounds, ARC-670 was solved; ARC-670 contains a 
6-derivatized purine analogue as Fragment 1 linked via 1,8-octanedioic acid 
moiety to amidated (D-Arg)6-peptide in Fragment 2 (Figure 40A).  
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Figure 40. ARC-670 and its co-crystal with PKAc. (A) Structure of ARC-670 with 
arginine residues numbered. (B) ATP-site of 3AGM. ARC-670 is shown as sticks, 
PKAc as cartoon; the residues of ATP-site of PKAc interacting with ARC-670 are 
shown as lines and numbered.  
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The electronic density was well defined for the most of the ARC-670 molecule; 
according to expectations, its Fragment 1 occupied the ATP-site of the protein 
kinase, although the positioning of the purine moiety was different compared to 
the purine moiety of Adc contained in ARC-1034. In case of the latter crystal 
structure, three hydrogen bonds were developed with PKAc residues: the 
backbone amide carbonyl oxygen of Glu121 served as an acceptor for the N6 of 
Adc purine, the backbone amide nitrogen of Val123 was a donor for the N1, 
and the side-chain hydroxyl group of Thr183 was a donor for the N7. In case of 
ARC-670 co-crystal, on the other hand, only two crucial hydrogen bonds were 
developed: Glu121 of PKAc served as an acceptor for the N9 of purine, and 
Val123 was a donor for the N3; the piperazine ring in the 6-position of purine 
developed no interactions with PKAc (Figure 40B). This binding mode of 
Fragment 1 influenced the positioning of the linker moiety, directing the 
oxygen of carbonyl group closer to the Fragment 1 out of the catalytic cleft; 
still, the carbonyl group closer to Fragment 2 adopted the position highly 
similar to that of the corresponding carbonyl of the Ahx linker in the PKAc – 
ARC-1034 complex. Due to the movement of the Gly-rich loop closer to -
stand 3 and helix B of PKAc (away from the C-tail) in the ARC-670 co-crystal, 
the carbonyl of ARC-670 was not positioned exactly below the Gly-rich loop 
and could develop interactions with only two residues of PKAc, Ser53 and 
Phe54 (Figure 41A). The part of the Gly-rich loop closer to the C-tail of PKAc 
was more opened than in the ARC-1034 co-crystal resulting in distances 
Tyr330...Glu127 (6.9 Å) and Ser53...Asp166 (11.3 Å), whereas the part of the 
Gly-rich loop facing -stand 3 and helix B was slightly more closed as reflected 
by the distance His87...phosphorylated Thr197 (2.6 Å) (Figure 41B).  
Such movement of Gly-rich loop was needed to accommodate the Fragment 
2 of ARC-670, representing probably the most interesting feature of the given 
co-crystal (Figure 41C). Expectedly, the side-chain of Arg#1 of ARC-670 
developed the same interactions with Asp166 and Phe187 of PKAc as the 
Arg#1 of ARC-1034, although the hydrogen bond between ARC-670 and 
Thr201 was much weaker. The carbonyl of Arg#1 of ARC-670, however, 
pointed towards the catalytic cleft (not towards the solvent as in ARC-1034 co-
crystal), and the side-chain of Arg#2 of ARC-670 was therefore exposed to the 
solvent and not well covered with electron density. Arg#3, on the other hand, 
protruded deep into the catalytic cleft and was involved in interactions with 
Glu127 and Asp184 of PKAc; Arg#4, in its turn, pointed out of the catalytic 
cleft, but developed interactions with Glu203. Surprisingly, Arg#5 was solvent-
exposed and poorly defined by the electron density, despite the fact that it 
protruded towards the Glu-rich C-tail of PKAc; by contrast, Arg#6 pointed 
deeply into the protein/peptide substrate-binding pocket of PKAc and developed 
hydrogen bonds with Glu230. Finally, an additional in-plane hydrophobic 
interaction was developed between the C-terminal amide of ARC-670 and the 
aromatic side-chain of Phe129 of PKAc.  
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Figure 41. Comparison of 3AGM and 3BWJ. (A) Interactions developed between the 
linker of ARC-670 and PKAc from 3AGM (green) overlaid with co-crystal PKAc – 
ARC-1034 (3BWJ, blue). Ligands are shown as sticks, PKAc as cartoon; the residues 
of ATP-site of PKAc interacting with ARC-670 are shown as lines and numbered. (B) 
Overlay of 3AGM (green) and 3BWJ (blue); distances between PKAc residues shown 
as sticks are measured for 3AGM only. (C) Interactions developed between the 
Fragment 2 of ARC-670 and PKAc; ARC-670 is shown as lines, the residues of the 
protein substrate-site of PKAc interacting with ARC-670 are shown as sticks and 
numbered. 
 
 
Overall, the crystal structure of the PKAc – ARC-670 complex clearly in-
dicated the bisubstrate nature of binding of longer ARC-II conjugates, revealing 
interactions between the Fragment 2 and the amino acid moieties of PKAc 
responsible for the protein/peptide substrate recognition (Glu127, Glu170, etc.). 126 
Moreover, this co-crystal might provide an insight into the interactions 
underlying the binding of those PKAc substrates and PCIs that contain Arg 
residues in different positions than -2 and -3 prescribed by the consensus 
sequence of PKAc substrates Arg-Arg-Xaa-Ser-Hyd (Figure 42). The latter 
application of the ARC-670 co-crystal is possible even despite the fact that 
ARC-IIs contain D-amino acid moieties, not L-amino acid moieties as in natural 
PKAc substrates; in fact, ARC-IIs may be considered as retro-inverso variants 
of PKAc substrate peptides comprised of L-amino acids. Namely, as the latter 
compounds bind with their N-terminus spatially close to the end of helix F and 
their C-terminus close to the phosphorylated Thr197 of PKAc, while the 
Fragment 2 of ARC-670 bound with its N-terminus near the pThr197 and its 
C-terminus near the end of helix F. 
A more practical possibility for application of the data obtained from the 
ARC-670 co-crystal would be the replacement of non-interacting D-Arg 
residues #2 and #5 with structural fragments bearing additional functionality 
(i.e., fluorescent dyes, biotin, myristoyl, etc.) without risks to lose the affinity of 
the conjugate. Moreover, as the overlay of ARC-670 and ARC-1034 co-
crystals showed that the positioning of the linker end closer to the Fragment 2 
practically coincided for both ARC-670 and ARC-1034, the information about 
binding of Fragment 2 obtained from ARC-670 co-crystal may be extrapolated 
to ARC-II compounds that contain Adc as Fragment 1 and Ahx as the linker 
(i.e., ARC-902).  
At the same time, it should be kept in mind that the conformational flexi-
bility of ARC-II compounds might result in development of alternate strong 
interactions with the PK upon change of ARC-II structure, i.e., preservation of 
high affinity after derivatization could still “mask” profound changes in mode 
of binding. For instance, when ARC-902 [Adc-Ahx-(D-Arg)6-NH2] was sub-
jected to Ala-scan where D-Arg residues of Fragment 2 were one-by-one 
replaced with D-Ala, the obtained compounds inhibited PKAc with IC50 values 
very similar to that of ARC-902 itself [J. Rogozina, unpublished data]. This 
observation most likely indicates that the oligo-(D-arginine) serves to a certain 
limit as a “blanket” which might be shifted if necessary to “cover” all or most of 
the crucial binding partners (i.e., Glu127, Glu170, Glu203, Glu230). Inte-
restingly, the largest difference (3-fold higher IC50 than that of ARC-902) was 
exhibited by a compound where D-Ala was substituted for Arg#1, indicating the 
importance of the latter residue as an “anchor” which stabilizes the PKAc 
conformation suitable for binding of Fragment 1 and linker, and at the same 
time directs Fragment 2 to the protein/peptide substrate-site of PK. 
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Figure 42. Overlay of co-crystals PKAc – ARC-670 (3AGM, the backbone of 
Fragment 2 of ARC-670 shown as green lines), PKAc – AMPPNP – PKI(5-24) 
(1ATP, residues 15-22 of PKI shown as cyan ribbon), PKAc – AMPPNP – PKArI(91-
244) (1U7E, residues 92-98 of PKArI shown as yellow ribbon), and PKAc – 
AMPPNP – PKArII(102-265) (3IDC, residues 106-113 of PKArII shown as pink 
ribbon). PKAc residues involved in recognition of arginine moieties of the compounds 
targeting the protein substrate-site of PKAc shown as black lines and numbered; near 
each PKAc residue, the Arg residues of binding partners interacting with the given 
residue are indicated (the number of Arg residue corresponds to the position of the latter 
in the consensus sequence). In the corners, an approximate position of N- and C-termini 
of the compounds targeting the protein substrate-site of PKAc is shown. 
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4. Development of ARC-III conjugates [Paper 2: Lavogina 
et al., 2009, Paper 3: Lavogina et al., 2010a] 
 
The crystal structure of the PKAc – ARC-1034 complex pointed to several 
tendencies and structural features that could further be exploited for the design 
of two sets of compounds. The first set was designed to control the hypothesis 
that elimination of Fragment 2 of ARC-1034 should not influence the affinity 
of compound, as the most strong interactions contributing to the binding energy 
of  ARC-1034 originated from binding of Fragment 1 and a linker. Con-
sequently, the first set comprised “short” compounds that consisted just of 
Fragment 1 and a linker, whereas in some cases one additional moiety (an 
amino acid or a diamine residue) at the C-terminus of the conjugate. The 
compounds were evaluated on the basis of their ability to displace an ARC-
Photo fluorescent probe (ARC-583) from its complex with PKAc in an assay 
with fluorescence anisotropy detection, and the following structure-affinity 
relationship aspects were established (please refer to Table 2 from Paper 2): 
  according to expectations, elimination of the Arg#2 residue from the 
structure of ARC-1034 resulted in slight improvement of affinity, whereas 
the elimination of Arg#2 in combination with an additional replacement of 
Arg#1 with shorter an achiral diamine chain or a hydrophobic D-amino acid 
was not well tolerated by PKAc, which revealed the importance of the 
interaction between Arg#1 of ARC-1034 and Asp166 of PKAc;  
  the steepest drop of affinity (over 300-fold as compared to ARC-1034) was 
observed after elimination of Arg#2 and the replacement of Arg#1 by a 
hydrophobic L-amino acid, which also pointed to the importance of stereo-
configuration of the chiral centre at the C-terminus of the linker; 
  elimination of both, Arg#1 and Arg#2, resulted in a 7-fold decrease in 
affinity as compared to ARC-1034, whereas the introduction of a negative 
charge at the C-terminus of the resulting compound caused an additional 25-
fold reduction in affinity. 
Additionally, it was demonstrated that shifting of the carbonyl group of 
Fragment 1 two bonds towards the C-terminus of the compound (further away 
from the ribose moiety as compared to Adc) resulted in an over 100-fold 
decrease in affinity as compared to ARC-1034. The latter observation thus 
indicated the importance of the hydrogen bond between this carbonyl in Adc 
and the water molecule in ATP-cleft of PKAc. 
The idea behind the design of the second set of compounds originated from 
the fact that D-Arg moieites in Fragment 2 of ARC-1034 did not protrude to 
the region of PKAc responsible for binding of protein/peptide substrates; it was 
therefore decided to “elongate” ARC-1034 by introduction of an additional 
linker moiety (so-called second linker). The structure-affinity relationship 
aspects were summarized in Table 3 from Paper 2; while the addition of another 
Ahx moiety to the Ahx linker of ARC-1034 resulted in only 4-fold increase of 
affinity as compared to ARC-1034, whereas variation of the length of the 129 
second linker did not improve the affinity. Next, it was decided to introduce not 
only the second linker, but also a “chiral spacer” between the two linkers in 
order to maintain the D-configuration of the Arg#1 of ARC-1034, which had 
previously shown its importance for directing the Fragment 2 of ARC-II 
conjugates to the protein/peptide substrate site of PKAc. When D-Lys was used 
as a chiral spacer and Ahx as the second linker, the affinity of the resulting 
compound (ARC-1012, (Figure 43A) increased over 40-fold compared to 
ARC-1034 (by contrast, the analogical compound with L-Lys as the chiral 
linker had lower affinity than ARC-1034). Interestingly, PKAc tolerated D-Ala 
as the chiral spacer equally well, as indicated by the affinity of the ARC-1012 
analogue incorporating D-Ala instead of D-Lys (ARC-1039, Figure 43B). 
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Figure 43. Examples of ARC-III. (A) ARC-1012 with arginine residues numbered. (B) 
ARC-1039 with arginine residues numbered. (C) ARC-1074. (D) ARC-1028. 
 
 
Moreover, the ARC-1012 analogue with H-9 moiety as Fragment 1 and Hex as 
the first linker (ARC-1074, (Figure 43C) also had a higher affinity towards 
PKAc than the corresponding H-9-containing compound without the second 
linker or the chiral spacer [J. Rogozina, unpublished data]. The latter result was 
unexpected, as from the studies of ARC-II inhibitors it had been concluded that 
the mode of binding of H-9-containing compounds was different from that of 
Adc-containing compounds; hence, it was supposed that H-9 containing 
compounds would not profit from introduction of the second linker or the chiral 
spacer. However, it is possible that only the combination of H-9 moiety as 
Fragment 1 and oligo-(L-arginine), not oligo-(D-arginine) as Fragment 2 
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yields conjugates with altered binding mode as compared to Adc-containing 
analogues. Furthermore, despite 10-fold difference in affinity of compounds 
with H9 and Adc used as Fragment 1 in ARC-1074 and ARC-1012, 
respectively, the IC50 values of ARC-1074 and ARC-1012 towards PKAc were 
nearly the same (10 nM and 7.6 nM, respectively). The latter fact indicated that 
the introduction of the second linker and the chiral spacer could still not hit the 
optimal geometry in case of H-9-containing compounds.   
The substitution of an amidated (D-Arg)6-peptide for the amidated (D-Arg)2 
of ARC-1012 yielded compound ARC-1028 (Figure 43D), which possessed a 
subnanomolar Kd value towards PKAc. The achievement of such a high affinity 
allowed the definition of the next generation of ARC-s, ARC-III (Figure 44) 
consisting of Fragment 1 (ATP-mimics) and Fragment 2 [oligo-arginine] 
joined by the sequence comprising two linker moieties and a chiral spacer (i.e., 
amino acid moiety).  
 
Figure 44. General scheme of ARC-III inhibitors. Below are shown examples of 
structures of Fragment 1, Fragment 2, linkers, and chiral moiety. 
 
 
The profiling of ARC-1028 towards a panel of 50 PKs (please refer to Table 5 
from Paper 2) indicated that the general selectivity pattern of ARC-1028 was 
similar to that of ARC-II representative ARC-902, whereas ARC-1028 
inhibited representatives of the AGC-group of kinome slightly better and the 
PKs of CAMK-group slightly worse than ARC-902. The PKs most efficiently 
inhibited by ARC-1028 were PKAc, PKC isoforms (except atypical , , and ), 
ROCK isoforms, and ribosomal S6-kinases. A more detailed characterization of 
ARC-III representatives in the displacement assay towards ROCK-II and in the 
kinetic inhibition assay towards PKB (please refer to Table 4 from Paper 2) 
indicated that ARC-1012 had an even better affinity towards ROCK-II than 
towards PKAc, but was a 7-fold less potent inhibitor of PKB  compared to 
PKAc.  ARC-1028 had subnanomolar Kd values towards both PKAc and 
ROCK-II, and was also a potent inhibitor of PKB with IC50 value of 14.6 nM; 
all in all, the increase in the number of D-Arg moieties of Fragment 2 evened 
out the differences in affinity and inhibitory potency towards different PKs.  
  Still, the most interesting result was the selectivity of ARC-1039 towards 
PKAc, as the former displayed  a 20-fold higher Kd towards ROCK-II and 
nearly 40-fold higher IC50 towards PKB compared to PKAc; in comparison to 
ARC-1012, ARC-1039 bound to ROCK-II with an 85-fold lower affinity and 131 
inhibited PKB with a 5-fold lower potency. This phenomenon could not be 
explained at that point of time, but it was utilized for the design of compound 
ARC-1044 (Figure 45A) that was developed as an example of a highly selective 
ARC-III.  ARC-1044 incorporated the carbocyclic analogue of 3’-deoxyade-
nosine as Fragment 1 (this moiety had previously demonstrated an increase of 
selectivity of ARC-II conjugates towards PKAc; [Enkvist et al., 2007]) and the 
amidated (D-Arg)2-peptide as Fragment 2 joined by the sequence comprising 
two Ahx moieties as both the first and the second linker, and D-Ala as the chiral 
spacer. According to expectations, ARC-1044 had an over 100-fold better 
affinity as well as nearly am 100-fold better inhibitory potency towards PKAc 
versus ROCK-II and PKB, thus expressing the best selectivity towards its 
target PK of all ARCs developed so far. More importantly, the success of ARC-
1044 pinpointed two structural features (Fragment 1 and the chiral spacer) that 
might strongly influence the selectivity of ARC-III compounds, suggesting that 
the right choice of this features might “tune” the affinity profile of conjugates 
according to the requirements of field of application (ideally from highly 
selective to generic). Indeed, the further variations of Fragment 1 of ARC-III 
compounds have recently yielded ARC-668 (Figure 45B), a generic inhibitor of 
the AGC-group of kinome as demonstrated by profiling towards a panel of 50 
PKs [Enkvist et al., 2009]. A few AGC-kinases inhibited to extent less than 
90% by 100 nM concentration of ARC-668 were PKB (80%), PKGII (78%), 
PKC (38%), and PKC (24%).  
 Based  on  ARC-1028, a fluorescent probe ARC-1042 was developed [Adc-
Ahx-(D-Arg)-Ahx-(D-Arg)6(D-Lys{TAMRA})-NH2] (Figure 45C) with a KD 
value below 0.3 nM towards PKAc as determined in the direct binding FA-
assay. ARC-1042 could be successfully displaced from its complex with PKAc 
by compounds targeted to the ATP-site (i.e., H-89) as well as to the protein/ 
peptide substrate-site (i.e., PKArI, PKArII, PKI) of the kinase, and thus 
confirmed the bisubstrate character of ARC-III compounds incorporating 
amidated (D-Arg)6-peptide as Fragment 2. Later on, the bisubstrate character 
of analogical ARC-III compounds possessing amidated (D-Arg)2-peptide as 
Fragment 2 was confirmed by co-crystal structures of ARC-1012 and ARC-
1039 with PKAc [Pflug et al., 2010]. 
  132 
 
 
A  B
 
C 
 
Figure 45. Illustration of tunable selectivity and derivatization potential of ARC-III. (A) 
ARC-1044. (B) ARC-668. (C) ARC-1042; red rounded rectangle surrounds the 
fluorescent dye TAMRA. 
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5. Crystallographic studies of ARC-III conjugates  
[Paper 5: Pflug et al., 2010] 
 
5.1. PKAc – ARC-1012 complex (PDB 3AG9) 
 
The crystal structure of the PKAc – ARC-1012  complex  was  resolved  at  a     
2.0 Å resolution, but lacked electronic density for a part of the C-tail of PKAc 
(residues 317...332) and the second linker of ARC-1012. An asymmetric unit of 
crystal lattice included two PKAc molecules, of which only one was bound to 
ARC-1012; the latter observation could probably be attributed to the random 
effects of crystal packing, as no evidence from binding or inhibition studies had 
suggested a dimeric mechanism of inhibition of PKAc by ARC-1012. 
  As compared to the crystal structure of the PKAc – ARC-1034 complex 
[Lavogina  et al., 2009], several changes in the interactions between PKAc and 
Fragment 1 as well as first linker of ARC-1012 were observed (Figure 46A). The 
Adc moiety in Fragment 1 was buried deeper into the ATP-site and closer to the 
hinge, developing strong interactions with Glu121 and Val123, but only a weak 
hydrogen bond with Thr183. The most drastic difference was a change in 
conformation of ribose moiety of Fragment 1, which was tilted up and towards the 
C-tail of PKAc, losing the “classical” interaction between the 3’ hydroxyl and 
Glu170 of PKAc (but probably gaining interaction with one of C-tail residues, 
which are not visible in the given crystal structure). Such movement of ribose also 
caused lifted position of the Gly-rich loop as compared to the ARC-1034 co-
crystal, as also indicated by distances Ser53...Asp166 (12.3 Å) and His87... 
phosphorylated Thr197 (4.55 Å) in the ARC-1012 co-crystal. Still, the carbonyl 
group at the end of the first linker of ARC-1012 made nearly the same interactions 
with the PKAc residues at the top of the Gly-rich loop as developed by the C-
terminal carbonyl of the linker of ARC-1034; the only difference in the ARC-1012 
co-crystal was the weakened hydrogen bond with Gly55 of PKAc (Figure 46B). 
  The chiral moiety of ARC-1012 adopted a position similar to that of Arg#1 
in the ARC-1034 co-crystal, developing hydrogen bonds with Asp166 (Figure 
47A). However, in case of ARC-1012 the hydrogen bond with Thr201 was 
absent due to the outward movement of the activation loop of PKAc, and the 
interaction with the aromatic ring of Phe187 of PKAc was also missing due to 
the absence of the guanidine group in the side-chain of chiral spacer. Similar to 
ARC-670 and different from ARC-1034 co-crystal, the carbonyl of the chiral 
spacer of ARC-1012 pointed towards the catalytic cleft, but the electronic 
density for the following second linker as well as Arg#1 of ARC-1012 was 
unfortunately ambiguous. However, the Arg#2 of ARC-1012 developed 
multiple strong hydrogen bonds with Glu170 and Glu230, and an additional in-
plane interaction of the guanidinium-group with Phe129, indicating that the 
major gain in affinity of ARC-1012 compared to ARC-1034 resulted from 
interactions of Arg#2 (Figure 47B). Importantly, the overlay of ARC-1012 and 
ARC-670 co-crystals showed that the side-chain of Arg#2 of ARC-1012 
aligned exactly with the side-chain of Arg#6 in ARC-670. 134 
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Figure 46. 3AG9. (A) Interactions developed between the Fragment 1 of ARC-1012 
and the ATP-site of PKAc from 3AG9 (magenta) overlaid with the co-crystal PKAc – 
ARC-1034 (3BWJ, blue). Ligands are shown as sticks, PKAc as cartoon; the residues 
of ATP-site of PKAc interacting with ARC-1012 are shown as lines and numbered. (B) 
Interactions developed between the linker of ARC-1012 and PKAc from 3AG9 
(magenta) overlaid with co-crystal PKAc – ARC-1034 (3BWJ, blue). Ligands are 
shown as sticks, PKAc as cartoon; the residues of Gly-rich loop of PKAc interacting 
with ARC-1012 are shown as lines and numbered. 
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Figure 47. Comparison of 3AG9 and 3BWJ. (A) Interactions developed between the 
chiral moiety of ARC-1012 and PKAc from 3AG9 (magenta) overlaid with the co-crystal 
PKAc – ARC-1034 (3BWJ, blue). Ligands are shown as sticks, PKAc as cartoon; the 
residues of PKAc interacting with the chiral moiety of ARC-1012 are shown as lines and 
numbered. (B) Interactions developed between the Fragment 2 of ARC-1012 and PKAc 
from 3AG9 (magenta) overlaid with co-crystal PKAc – ARC-1034 (3BWJ, blue). Ligands 
are shown as sticks, PKAc as cartoon; the residues of protein substrate-site of PKAc 
interacting with ARC-1012 are shown as lines and numbered. 135 
Overall, the ARC-1012 co-crystal allowed definition of the four major hot-spot 
fragments in ARC-1012 developing strong interactions with PKAc:  
  the purine moiety of Fragment 1 binding to the ATP-site of PKAc,  
  the carbonyl group of the first linker interacting with the residues of PKAc 
constituting the top of the Gly-rich loop,  
  the side-chain of the chiral spacer (D-Lys) developing interactions with 
Asp166 of PKAc; 
  Arg#2 binding Glu170 and Glu230 of PKAc responsible for recognition of 
protein/peptide substrate.  
Most likely, the rest of the ARC-1012 molecule was plainly arranged in a way 
that enabled exact pinpointing the aforementioned crucial contacts with the lo-
west entropic penalty; such hypothesis provides explanation for the tilted con-
formation of the ribose moiety, the poor fixation of Arg#1 and the second linker 
of  ARC-1012,  etc. Indeed, calorimetric studies [Rogozina and Pflug, un-
published] indicated rather entropy-driven mode of binding of ARC-1012 as 
compared to ARC-1034 (Table 6). Moreover, the recent thermodynamic ana-
lysis of multivalent interactions indicated that the use of flexible linkers in 
multi-ligand compounds is an effective strategy, and the loss of conformational 
entropy associated with the flexibility of linker may in several cases be only 
marginal [Kane, 2010].  
 
 
Table 6. Data from calorimetric measurements of binding of ARCs to PKAc 
 
Compound  Kd, nM* ΔHB, kJ/mol
ARC-1012  7.6            –60,7
ARC-1028  <0.1          –78,6
ARC-1034  250           –68,2 
*proportional to ΔGB 
 
 
Possibly, in ARC-III conjugates incorporating the amidated (D-Arg)6-peptide as 
Fragment 2 (i.e., ARC-1028), the hot-spot nature of Arg#2 is lowered, as there 
are other D-Arg residues in positions #3...#6 able to develop interactions with 
Glu203, Glu230, and other PKAc residues spatially closer to the end of helix F. 
In this context, the Pro-scan data of ARC-1028 where D-Arg residues of Frag-
ment 2 were one-by-one replaced with D-Pro was of especial interest, 
indicating that the only modification resulting in an over 20-fold decrease in 
affinity (as compared to ARC-1028) was the replacement of Arg#1, whereas 
replacement of Arg#2 caused only a 3-fold loss of affinity [D. Lavogina, 
unpublished data]. These results indicate that the major importance of Arg#1 
lies in its ability to direct the rest of Fragment 2 of ARC-1028 to the 
protein/peptide substrate-site of PKAc. Additionally, Pro-scan results may 
imply that lowering of hot-spot nature of Arg#2 allows rearrangement of 
conformation of ARC-1028 as compared to ARC-1012 so that Arg#1 is not 
exposed to solvent and may also develop interactions with PKAc. The indirect 136 
confirmation for the latter statement is offered by the crystal structure of 
PKAc – ARC-1039 complex, where elimination of another hot-spot fragment of 
ARC-III is possible due to substitution of D-Ala for D-Lys in the chiral spacer. 
 
 
5.2. PKAc – ARC-1039 complex (PDB 3AGL) 
 
The PKAc – ARC-1039 complex crystallized with two PKAc molecules in the 
asymmetric unit, whereas both PKAc molecules were bound to ARC-1039 (in 
contrast to ARC-1012 co-crystal); the electron density was well defined for the 
whole ARC-1039.  
  The conformation of the Fragment 1 of ARC-1039 was nearly identical to 
that of ARC-1034 (Figure 48A; [Lavogina et al., 2009]), thus interactions with 
residues Glu121, Val123, Glu127, and Glu170 of PKAc were conserved, 
although the interaction between ARC-1039 and Thr183 was weaker. The first 
linker of ARC-1039 also adopted nearly the same shape as the linker of ARC-
1034 and hence also developed contacts with Ser53, Phe54, and Gly55 of 
PKAc, although the carbonyl group of the first linker of ARC-1039 was 
positioned slightly closer to the end of the loop (Figure 48B). The conformation 
of the Gly-rich loop itself was again almost identical to that in the ARC-1034 
co-crystal, with similar distances Tyr330...Glu127 (5.0 Å), Ser53...Asp166 
(10.2 Å), and His87...phosphorylated Thr197 (2.8 Å).  
  Analogically to Arg#1 of ARC-1034 and differently from the chiral spacer 
of ARC-1012, the carbonyl group of the chiral spacer D-Ala in ARC-1039 co-
crystal pointed away from the catalytic cleft, and accepted hydrogen bond 
donated by the side-chain of Ser53 of PKAc (Figure 48C-D); the latter contact 
was the only direct interaction formed by D-Ala and PKAc. Importantly, due to 
an absent interaction of the chiral spacer with Asp166 of PKAc in the ARC-
1039 co-crystal, a strong hydrogen bond was formed between Asp166 and 
Thr201 (with length of 2.2 Å). The latter fact further confirms that ARC-1039 
served as bisubstrate inhibitor of PKAc, as the evidence from the literature has 
so far demonstrated that such hydrogen bond is present only in PKAc co-
crystals with protein/peptide substrates or PCIs [Yang L. et al., 2004]. 
 Similar  to  ARC-1012, no interactions between the second linker of ARC-
1039 and PKAc were observed, although the electronic density was surprisingly 
well defined (in contrast with the second linker of ARC-1012); the latter fact 
might be attributed to good fixation of Fragment 2 of ARC-1039. Differently 
from the ARC-1012 co-crystal, Arg#1 of ARC-1039 pointed towards the 
catalytic cleft and developed strong hydrogen bonds with Glu127 of PKAc, and 
an intramolecular hydrogen bond with the ribose residue from Fragment 1. The 
side-chain of Arg#2 of ARC-1039 protruded to the same pocket as Arg#2 of 
ARC-1012, being involved in multiple polar contacts with Glu170 and Glu230 
of PKAc, and an in-plane interaction of the guanidinium-group with Phe129.  
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Figure 48. Comparison of 3AGL, 3BWJ and 3AG9. (A) Interactions developed 
between the Fragment 1 of ARC-1039 and ATP-site of PKAc from 3AGL (orange) 
overlaid with co-crystal PKAc – ARC-1034 (3BWJ, blue). Ligands are shown as sticks, 
PKAc as cartoon; the residues of ATP-site of PKAc interacting with ARC-1039 are 
shown as lines and numbered. (B) Interactions developed between the linker of ARC-
1039 and PKAc from 3AGL (orange) overlaid with the co-crystal PKAc – ARC-1034 
(3BWJ, blue). Ligands are shown as sticks, PKAc as cartoon; the residues of Gly-rich 
loop of PKAc interacting with ARC-1039 are shown as lines and numbered. (C) 
Interactions developed between the Fragment 2 of ARC-1039 and PKAc from 3AGL 
(orange) overlaid with co-crystal PKAc – ARC-1034 (3BWJ, blue). Ligands are shown 
as sticks, PKAc as cartoon; the residues of PKAc interacting with ARC-1039 are shown 
as lines and numbered. (D) Interactions developed between the Fragment 2 of ARC-
1039 and PKAc from 3AGL (orange) overlaid with co-crystal PKAc – ARC-1012 
(3AG9, magenta). Ligands are shown as sticks, PKAc as cartoon; the residues of PKAc 
interacting with ARC-1039 are shown as lines and numbered. 138 
  Apart from revealing the multiplicity of binding modes of ARC-III com-
pounds, the crystal structure of PKAc – ARC-1039 complex provided an 
explanation for the enhanced affinity of ARC-1039 towards PKAc versus 
ROCK-II. The hydrogen bond between Arg#1 of ARC-1039 and Glu127 of 
PKAc is most likely lost in case of ROCK-II – ARC-1039 complex, as the resi-
due corresponding to Glu127 in ROCK-II is Asp176 with a shorter side-chain. 
In the PKAc – ARC-1012 complex, Arg#1 pointed to solution and did not 
develop any interactions with Glu127, thus no interaction was lost in case of 
ROCK-II. 
  Overall, the change of one residue, the chiral spacer from D-Lys in ARC-
1012 to D-Ala in ARC-1039 induced multiple differences in the ARC-1039 co-
crystal as compared to the ARC-1012 co-crystal, which demonstrated once 
again the conformational flexibility of ARCs. In addition, the concept of 
mutual-induced fit [Williamson, 2000; Huang Z. and Wong, 2008] was clearly 
observable, where not only inhibitor adapted to the tertiary structure of enzyme, 
but the latter also showed local conformational flexibility (i.e., illustrated by 
Gly-rich loop of PKAc). This evidence clearly points to limitations of structure-
aided design performed by computational methods where the structure of an 
enzyme is considered as a fixed entity.  
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6. Application of ARC-II and ARC-III conjugates as 
inhibitors and fluorescent probes of PKGI [Paper 4: 
Lavogina et al., 2010b] 
 
6.1. Development of assays 
 
Having established the selectivity and affinity determinants of ARC-II and 
ARC-III conjugates towards PKAc [Enkvist et al., 2006; Lavogina et al., 2009], 
it was decided to test the affinity and inhibitory potency of ARCs towards a 
closely related kinase, PKGI. Both PKA and PKG belong to family of cyclic 
nucleotide-dependent PKs, and possess high sequence homology of catalytic 
cores as well as cyclic nucleotide-binding domains (Figure 3) from the Section 
1.2.2. PKG; [Hofmann et al., 2009]); however, the structure-aided rational 
design of inhibitors for PKG is aggravated, as the latter has yielded no crystal 
structures so far. Therefore, PKA might be envisaged as a template for the 
design of PKG inhibitors, which may subsequently be optimized from the 
aspect of affinity and selectivity towards PKG in ligand-based design.  
The first step for the screening of ARCs and reference compounds towards 
PKGI was the establishment of a quick homogeneous assay enabling assess-
ment of inhibitors within a wide range of inhibition/binding characteristics with 
sufficient accuracy. The most convenient way to accomplish this task was the 
adaptation of the previously reported ARC-Photo-based binding/displacement 
assay with fluorescence anisotropy/polarization detection (FA-assay), which 
had shown reliable results in experiments with PKAc and ROCK-II [Vaasa et 
al., 2009]. The binding of four ARC-Photo probes representing generations 
ARC-II and ARC-III (ARC-583,  ARC-1042,  ARC-669  [Figure 49A], and 
ARC-1059  [Figure 49B]) was monitored in a direct binding FA-assay by 
titration with PKGI (please refer to Table 1 from Paper 4); the lowest KD value 
of 3.18 nM was obtained for the probe ARC-1059 derived from the inhibitor 
ARC-903. In the presence of cGMP, the affinity of ARC-1059 increased 8-
fold, which was in good agreement with the fact that the catalytic activity of 
PKGIa increases 8...10-fold upon stimulation with cGMP; however, in the 
presence of both, cGMP and Mg
2+, the increase in affinity of ARC-1059 was 
only 3-fold. 140 
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Figure 49. Examples of ARC-Photo. (A) ARC-669. (B) ARC-1059; red rounded 
rectangle surrounds the fluorescent dye TAMRA. 
 
 
Interestingly, from the titration curves of ARC-1059 it could be seen that the 
association of the latter into the complex with PKGI not only caused an 
increase in fluorescence anisotropy of solution, but also led to a 3.5-fold 
enhancement of fluorescence intensity (FI). The change of FI of solution upon 
binding of ARC-Photo to the kinase had been previously reported for ARC-
583, although in the latter case, the decrease in FI had been observed upon 
binding of ARC-583 to PKAc [Vaasa et al., 2009]. For this reason, the 
mathematical model of the FA-assay had been amended with a constant Q 
representing the ratio of FI for the bound and non-bound forms of ARC-Photo 
[Vaasa et al., 2009]. The physical phenomenon behind the change of FI has not 
been unequivocally established. Most probably, Q values smaller than 1 may 
reflect the quenching of the ARC-bound fluorophore by an unfavourable 
environment in the complex with PK, and Q values larger than 1 may be caused 
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by partial intramolecular quenching of fluorophore in solution of free ARC-
Photo (i.e., by neighbouring aromatic systems) relieved upon binding of probe 
to a PK. 
When the titration of ARC-1059 by PKGI in the presence of cGMP was 
monitored by the parallel measurement of FA and FI with microplate reader, the 
yielded curves were highly similar, and the KD value of ARC-1059 measured 
by FI detection was 0.44 nM. When the same titration was performed in a 
cuvette and FI was measured with a fluorescence spectrometer, the obtained KD 
value of ARC-1059 towards PKGI in the presence of cGMP was 0.63 nM. 
The good correlation of results obtained from FA and FI read-outs (either with 
microplate reader or with spectrometer) demonstrated that in case of a 
sufficiently large Q value associated with binding of an ARC-Photo to a PK, the 
FA-assay might be converted to its analogue with FI-detection (FI-assay) that 
requires neither complicated equipment for FA measurement nor microplate 
format. 
The concurrency of results measured by FA- and FI-assays was further 
confirmed by experiments where competitive displacement of ARC-1059 from 
its complex with PKGI i n  t h e  p r e s e n c e  o f  c G M P  b y  A R C s  o r  r e f e r e n c e  
inhibitors was monitored (please refer to Table 2 from Paper 4). The reliability of 
FA- and FI-assays was verified by the “classical” radioactive kinetic assay, where 
the retarding effect of ARCs and reference compounds on the PKGI-catalyzed 
phosphorylation of the peptide substrate TQAKRKKSLAMA was measured in 
the presence of cGMP. The compounds with the best displacement as well as 
inhibition characteristics (i.e., subnanomolar to low nanomolar displacement/ 
inhibition IC50 values) were represented by ARC-II compounds containing H-9 as 
Fragment 1 (i.e., ARC-349, ARC-903), and ARC-III conjugates possessing an 
aminopyrimidine derivative as Fragment 1 ( i.e.,  ARC-663,  ARC-664,  ARC-
668). Similarly to the results of direct binding studies, ARCs containing Adc as 
Fragment 1 exhibited a considerably poorer displacement and inhibition 
characteristics, indicating their poor affinity towards PKGI.  
Another binding/displacement assay format tested with the fluorescent probe 
ARC-1059 was an assay with FRET detection; such assays are endowed with 
great potential from the point of view of intracellular application of ARCs. The 
FRET phenomenon has been widely applied for intracellular monitoring by 
virtue of ratiometric character of measurements and lower susceptibility to 
development of background signals. Previously, ARCs had been successfully 
applied in a biochemical assay where FRET had developed between a donor 
fluorophore FITC used for chemical labelling of PKAc, and the acceptor 
fluorophore TAMRA incorporated in the structure of ARC-1042 [Vaasa et al., 
2010]. This time, fusion protein Cygnet 2.1 [Honda et al., 2005] representing a 
construct of PKGI fused via its C-terminus with fluorescent protein Citrine 
was used as a donor, and TAMRA of ARC-1059 as an acceptor (please refer to 
Figure 4 from Paper 4). The FRET developed as a result of binding could be 
successfully disrupted by the non-fluorescent compound ARC-903, whereas 
both increase in the emission of donor (530 nm) and decrease in emission of 142 
acceptor (580 nm) could be monitored either in the absence or in the presence 
of cGMP. 
Overall, these experiments demonstrated the universal nature of ARC 
inhibitors from the aspect of applicability in assays with multiple fluorescence 
measurement techniques available for detection. Despite the fact that the 
structure-affinity relationship studies identified only generic ARCs as potent 
probes and inhibitors of PKGI, this promiscuous nature of ARCs may prove 
advantageous for applications necessitating fluorescent detection or concomi-
tant inhibition of several basophilic PKs; an example of such application is 
presented in Section 7. Measurement of physiological effects of ARC-903 in 
isolated rat arteries. 
 
 
6.2. Studies of binding and inhibition mechanism  
 
Before proceeding from in vitro bioanalytical methods with PKGI to the 
experiments in living cells and tissues, the mechanism of PKGI inhibition by 
most potent ARCs needed to be established. In FA- and FI-assays, ARC-1059 
could be successfully displaced from its complex with PKGI by ATP and 
ACIs (i.e., H9, H-89, staurosporine). However, the displacement of ARC-1059 
by the PKGI peptide substrate TQAKRKKSLAMA and its non-phosphoryla-
table analogue TQAKRKKALAMA occurred only at high concentrations of 
displacing compounds, and could not be completed; moreover, ARC-1059 
could not be displaced by D-DT-2, a PKGI-selective high-affinity PCI [Nickl 
et al., 2010].  
The kinetic studies of inhibition mechanism of PKGI by ARCs revealed 
that ARC-903 (used as an example of ARC) was competitive versus ATP, but 
clearly not competitive versus substrate peptide; moreover, in contrast to PKAc 
studies, the mechanism of inhibition versus substrate peptide of PKGI 
resembled rather an uncompetitive than a non-competitive pattern (please refer 
to Figure 3 from Paper 4). The latter fact might indicate that ARCs are not 
bisubstrate inhibitors of PKGI, but represent the group of biligand inhibitors 
with Fragment 1 binding to the ATP-site of the PK, and Fragment 2 binding 
to another distant site (i.e., the Glu-rich C-tail of PKGI; Figure 3 from the 
Section 1.2.2. PKG). The biligand nature of ARCs is indirectly supported by the 
fact that these conjugates possess a higher affinity than the fragments 
composing those conjugates (i.e., the Ki value of H9 towards PKGI is 900 nM; 
[Ono-Saito et al., 1999]). 
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7. Measurement of physiological effects of ARC-903 in 
isolated rat arteries [Paper 4: Lavogina et al., 2010b] 
 
The final step in progression from the rational design to assessment of proper-
ties of ARC-type inhibitors was confirmation of the ability of the latters to 
implement their high affinity and inhibition potential towards target PKs in bio-
logically complex systems such as tissues and organs. As an example system, 
the smooth muscle tissue of rat cerebellum isolated intact arteries was chosen, 
due to the high content of PKAc and PKGI, and a wealth of information in 
literature about effects resulting from inhibition of these PKs in this tissue. 
First of all, the ability of ARC-Photos (ARC-583, ARC-669, and ARC-
1059) to penetrate plasma membrane of smooth muscle cells in isolated arteries 
was tested. In accordance with the previously reported experiments in HEK-293 
and CHO cell cultures [Uri et al., 2002; Vaasa et al., 2010], all compounds 
demonstrated cellular uptake after 1 h incubation of arteries in 10 M solution 
of ARCs at room temperature (Figure 50). The staining was characteristically 
pronounced in some regions of the arteries, and both, nuclear staining and 
diffused distribution in the cytoplasm could be indicated, whereas the pro-
portion of distribution between the cytoplasm and the nucleus was dependent on 
the structure of the tested ARC (i.e., ARC-669 accumulated to nucleus, but 
ARC-583 localization was more diffused, although still demonstrating nuclear 
inclusion). The studies of time- and concentration-dependent uptake of ARC-
1059 revealed that at a concentration of 10 M, the internalization of ARC was 
already observable after 20 min of incubation, although the nucleus was not yet 
stained (please refer to Figure 6 from Paper 4). By contrast, at 1 M or lower 
concentrations of ARC-1059, only minor extent of internalization was observed 
even after 60 min of incubation. The latter observation is also in good accor-
dance with experiments in cell cultures [Vaasa et al., 2010], which also 
indicated that a “critical” threshold of the ARC-Photo concentration had to be 
crossed in order to obtain effective internalization of conjugates into the cells. 
Figure 50. Staining of isolated rat cerebellum arteries by (A) 10 M ARC-583, (B)     
10 M ARC-669, or (C) 10 M ARC-1059 (in all cases, incubation time one hour at 
room temperature). 
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Next, measurement of the ability of ARC-903 to inhibit PKGI and PKAc at 
physiological conditions was performed by a pressure myography assay in the 
arteries isolated from rat cerebellum. Both PKGI and PKAc trigger vasodilation 
via several mechanisms, with the net outcome in all cases represented by 
dephosphorylation of MLC20; the inhibition of PKGI or PKAc should therefore 
induce vasoconstriction (Scheme 1, Scheme 2 from the Section 1.2.2. PKG). 
Previously, vasoconstrictive effects had been demonstrated for the PKGI-selective 
potent PCI D-DT-2 (concentration of 1...2 M in the superfusate; [Nickl et al., 
2010]), which relieved PKG- but not PKAc-induced vasodilation. The experimental 
set had comprised an isolated artery cannulised on glass pipettes and developing 
sustained myogenic tone upon pressurization to 80 mmHg. The change of the 
arterial diameter had been monitored in response to selective activators of PKG or 
PKAc (in order to discriminate the components of vasodilation triggered by either 
PK) and inhibitors applied via the superfusate. This time, the same technique was 
applied in tests with ARC-903 (concentration of 4 M in the superfusate). ARC-
903 successfully abolished vasodilation induced by activators of both, PKGI (i.e., 
8-Br-cGMP, MAHMA-NONOate) and PKAc (i.e., Forskolin, 8-CPT-cAMP), 
confirming the ability of potent ARCs to inhibit PKs in physiological conditions 
(please refer to Figure 7 from Paper 4). Furthermore, the vasoconstriction of arteries 
induced by ARC-903 occurred to an extent below the initial (basal) diameter, 
indicating that the basal activity of PKs was also inhibited; the latter result could 
also be repeated when ARC-903 was applied to non-dilated artery.  
Prior to the pressure myography experiments, ARC-903 had revealed in 
bioanalytical in vitro assays highly potent inhibition of not only PKAc and PKG, 
but also ROCK [Enkvist et al., 2006]. The promiscuous nature of ARC-903 was 
therefore considered problematic, as in smooth muscle tissue, the pathways of 
cyclic-nucleotide dependent PKs oppose pathways of ROCK; it was therefore 
relieving to witness that ARC-903 could still implement its high potency via 
inhibiting PKAc and PKGI pathways in tissue. The reason why effects of 
inhibition of PKA and PKGI on the one hand, and ROCK on the other hand did 
not mutually even out, probably lies in the fact that PKAc and PKG serve 
themselves as deactivators of ROCK, and therefore the latter was “switched off” 
during the whole course the experiment. In turn, the latter fact means that the 
constriction of artery upon application of ARC-903 was achieved via ROCK-
independent mechanisms, which might involve downregulation of telokin-
induced MYPT activity and re-gain of function of Ca
2+-pathways.  
The application of a group-selective inhibitor with high affinity towards 
PKAc and PKGI but not ROCK would probably yield more drastic and 
sustained effects in the given assay; still, this final set of pressure myography 
experiments convincingly demonstrated the wide field of application possi-
bilities for the promiscuous nature of ARC-conjugates. Moreover, the ability of 
ARC-903 to inhibit PKGI- and PKAc-induced vasodilation in the arteries 
isolated from rat cerebellum represented the first clearly pronounced physiolo-
gical effect of BSIs reported so far. 145 
CONCLUSIONS 
 
The present thesis focussed on design, synthesis and in vitro characterization of 
new conjugates of an adenosine analogue and an arginine-rich peptide as inhi-
bitors of basophilic protein kinases. The progress within the given work comes 
to the fore by step-by-step evolution of ARCs from submicromolar to sub-
nanomolar inhibitors of PKAc, PKG, ROCK and several other representatives 
of the AGC-group. Importantly, by virtue of enhanced proteolytic stability and 
relatively good cell membrane-penetrative properties, the most efficient ARCs 
are applicable both in biochemical assays and in living cells or tissues. Depen-
dent on the character of application, different ARCs may be used as generic 
probes of basophilic PKs or as remarkably selective modulators of PK activity. 
The main results of the thesis can be summarized as follows:  
  Two new sets of ARCs (subsequently termed as ARC-II and ARC-III) 
have been designed and synthesized. The main modifications in the 
structure of new compounds as compared to the set of the initial ARCs 
(ARC-I) were as follows:  
o  In case of ARC-II, the C-terminus of the compounds was amidated, 
D-Arg residues in the peptidic fragment were substituted for L-Arg 
residues, and H-9 moiety was incorporated as nucleosidic fragment. 
The most efficient representative of ARC-II was ARC-903 with 
inhibition IC50 value of 5.3 nM towards PKAc. 
o  In case of ARC-III, a second linker and the chiral moiety (amino 
acid) were introduced. The most efficient representative of ARC-III 
was  ARC-1028 with competitive displacement IC50 value of less 
than 0.5 nM towards PKAc. 
  The bisubstrate character of ARCs was confirmed in displacement stu-
dies with PKAc (where the fluorescent ARC-probe could be success-
fully displaced from its complex with the kinase by compounds targeted 
to the ATP-site as well as the protein substrate site of PKAc), and by 
co-crystals of PKAc with representatives of ARC-III. 
  The profiling of representatives of ARC-II and ARC-III towards a panel 
of PKs indicated that the novel ARCs were group-selective inhibitors 
possessing high affinity towards several PKs of the AGC-group; the 
more detailed studies with PKAc, PKGI, PKB and ROCK-II revealed 
several structural elements (e.g., nucleosidic fragment or chiral moiety) 
which influence the inhibitory potency and enable tuning the selectivity 
of ARCs. 
  The wide applicability of novel ARCs was confirmed by development 
of ARC-based biochemical in vitro assays for PKGI with detection of 
change of fluorescence anisotropy (FA), fluorescence intensity (FI), or 
FRET. While the FA-assay was adapted from the previous PKAc 
studies, the FI- and FRET-assays were originally designed. 146 
  The potential of novel ARCs as physiological modulators was de-
monstrated in the internalization studies with the isolated smooth musc-
le tissue, and in vasoconstriction experiments with isolated rat arteries 
(via targeting cAMP/PKA and cGMP/PKG pathways).  147 
SUMMARY IN ESTONIAN 
 
Adenosiini analoogi ja oligoarginiini konjugaatidel  
põhinevad proteiinkinaaside inhibiitorid 
 
Valkude fosforüleerimisreaktsioon elusorganismides ning seda katalüüsivad 
valgud – proteiinkinaasid – on olnud loodusteaduste tähelepanu keskpunktis 
alates 1950-test aastatest, kui E. P. Kennedy, E. H. Fischer’i, E. G. Krebs’i, E. 
W. Sutherland’i ja W. D. Wosilait’i tööd avasid kinaaside ajastu [Cohen P., 
2002]. Proteiinkinaasid osalevad enamikes raku elutegevuseks olulistes protses-
sides, seetõttu on häired nende ensüümide funktsioneerimises (eriti kõrgendatud 
aktiivsus) seotud mitmete haigustega (sealhulgas vähkkasvajad, diabeedid ja 
astma). Sellest tulenevalt keskenduvad nii akadeemiliste teadlaste kui ka far-
maatsiafirmade ravimiarendajate huvid üha enam kinaaside toimemehhanismide 
uurimisele ja võimaluste selgitamisele rakusiseste valkude fosforüleerimistasa-
kaalude mõjutamiseks. Viimase ülesande lahendamisel on üheks perspektiiv-
semaks teeks proteiinkinaaside inhibiitorite arendus. 
Käesolev töö kirjeldab adenosiini analoogi ja arginiinirikka peptiidi konju-
gaatide (ARC-de) arendamist proteiinkinaaside bisubstraatseteks kõrge 
inhibeerimispotentsiaaliga ligandideks, nende disaini ja sünteesi. Uudsete ARC-
de arendamisel lähtuti tulemustest, mis saadi inhibiitorite struktuuri mõju uuri-
misel nende sidumis- või inhibeerimisomadustele cAMP-sõltuva proteiinkinaa-
siga (PKA) ning sama proteiinkinaasi ARC-dega kooskristalliseerimisel saadud 
struktuuride röntgenanalüüsil. Töö tulemusena õnnestus valmistada kaks uut 
ARC-tüüpi inhibiitorite põlvkonda (ARC-II ja ARC-III), mille esindajatel on 
võrreldes lähteühenditega (ARC-I) järgmised erinevused: 
  ARC-II puhul amideeriti konjugaadi C-terminaalne karboksüülrühm ning 
peptiidses fragmendis asendati L-arginiinid D-arginiinidega; lisaks asendati 
mõnede ühendite nukleosiidses fragmendis adenosiini derivaat Hidaka inhi-
biitori H-9 jäägiga. ARC-II kõige efektiivsema esindaja (ARC-903) IC50 
väärtus PKAc inhibeerimiskatsetes oli 5,3 nM. 
  ARC-III puhul lisati konjugaatide struktuuri kiraalne element (aminohape) ja 
teine linker. ARC-III kõige efektiivsem esindaja oli ARC-1028, mille IC50 
väärtus väljatõrjumiskatsetes PKAc-ga oli alla 0,5 nM. 
Järgmise sammuna määrati ARC-II ja ARC-III kõige efektiivsemate ühendite 
selektiivsusprofiilid; ühendid osutusid rühm-selektiivseteks inhibiitoriteks mit-
mete basofiilsete proteiinkinaaside, eriti AGC-rühma esindajate suhtes. De-
tailsemates uuringutes proteiinkinaasidega PKGI, PKB ja ROCK-II tehti 
kindlaks ka uute ARC-de struktuurifragmendid, mis mõjutavad inhibiitorite 
selektiivsust ühe või teise kinaasi suhtes.  
Edasistes uuringutes tehti kindlaks, et tulenevalt uute ARC-de suhteliselt 
laiast selektiivsusprofiilist oli võimalik rakendada ARC-del põhinevat sidumis-
meetodit (FA-meetod) kinaasiaktiivsuse hindamiseks ning proteiinkinaasi-
inhibiitorite iseloomustamiseks mitte ainult eelnevalt mudelkinaasina kasutatud 148 
PKA jaoks, vaid ka viimasega struktuurselt sarnase PKGI jaoks. Lisaks eelne-
vale arendati uute ARC-de põhjal PKGI jaoks veel kaks sidumismeetodit, 
milles inhibiitorite afiinsuse või kinaasi aktiivsuse määramiseks mõõdeti fluo-
restsentsi või FRET-i intensiivsuse muutust. Kõiki eespoolmainitud meetodeid 
on suure tõenäosusega võimalik kohandada ka mitme teise basofiilse proteiin-
kinaasi jaoks. 
Töö viimases etapis demonstreeriti, et uute ARC-de rakendusala ei piirdu 
biokeemiliste  in vitro mõõtmismeetoditega, vaid see on laiendatav in vitro 
katsetele elusrakkudes ja -kudedes. ARC-II ja ARC-III efektiivsemate esin-
dajate proteolüütiline stabiilsus ja võime läbida raku plasmamembraani võimal-
dasid uurida uusi inhibiitoreid roti isoleeritud ajuarterite silelihaskoes. Nende 
katsetuste tulemusena selgus, et ARC-d suudavad inhibeerida cAMP/PKA ja 
cGMP/PKG radu füsioloogilistes tingimustes.  
 149 
REFERENCES 
 
Adelstein R. S., Conti M. A., Hathaway D. R., Klee C. B., JBC (1978), 253, 8347–8350 
Adrian F. J., Ding Q., Sim T., Velentza A., Sloan C., Liu Y., Zhang G., Hur W., Ding 
S., Manley P., Mestan J., Fabbro D., Gray N. S., Nat. Chem. Biol. (2006), 2, 95–102 
Ahn D.-R., Han K.-C., Kwon H. S., Yang E. G., Bioorg. Med. Chem. Lett. (2007), 17, 
147–151 
Airhart N., Yang Y.-F., Roberts C. T. Jr., Silberbach M., JBC (2003), 278, 38693–
38698 
Akamine P., Madhusudan, Wu J., Xuong N.-H., Ten Eyck L. F., Taylor S. S., J. Mol. 
Biol. (2003), 327, 159–171 
Akritopoulou-Zanze I., Hajduk P. J., Drug Disc. Today (2009), 14, 291–297 
Allen M. D., Zhang J., Biochem. Biophys. Res. Comm. (2006), 348, 716–721 
Alverdi V., Mazon H., Versluis C., Hemrika W., Esposito G., van den Heuvel R., 
Scholten A., Heck A. J. R., J. Mol. Biol. (2008), 375, 1380–1393 
Amano M., Chihara K., Nakamura N., Kaneko T., Matsuura Y., Kaibuchi K., JBC 
(1999), 274, 32418–32424 
Anand G. S., Krishnamurthy S., Bishnoi T., Kornev A., Taylor S. S., Johnson D. A., 
Mol. Cell. Proteomics (2010), doi: 10.1074/mcp.M900388-MCP200 
Argiriadi M. A., Sousa S., Banach D., Marcotte D., Xiang T., Tomlinson M. J., Demers 
M., Harris C., Kwak S., Hardman J., Pietras M., Quinn L., DiMauro J., Ni B., 
Mankovich J., Borhani D. W., Talanian R. V., Sadhukhan R., BMC Struct. Biol. 
(2009), 9, 16 
Bain J., McLauchlan H., Elliott M., Cohen P., Biochem. J. (2003), 371, 199–204 
Baird G. S., Zacharias D. A., Tsien R. Y., PNAS USA (1999), 96, 11241–11246 
Beene D. L., Scott J. D., Curr. Opin. Cell Biol. (2007), 19, 192–198 
Benoiton N. L., Chemistry of peptide synthesis, CRC Press Taylor and Francis Group 
(2006) 
Bishop A. C., Buzko O., Shokat K. M., Trends Cell. Biol. (2001), 11, 167–172 
Bissantz C., Kuhn B., Stahl M., J. Med. Chem. (2010), 53, 5061–5084 
Bogoyevitch M. A., Barr R. K., Ketterman A. J., Biochim. Biophys. Acta (2005), 1754, 
79–99 
Bogoyevitch M. A., Fairlie D. P., Drug Disc. Today (2007), 12, 622–633 
Bonke G., Vedel L., Witt M., Jaroszewski J. W., Olsen C. A., Franzyk H., Synthesis 
(2008), 15, 2381–2390 
Bonn S., Herrero S., Breitenlechner C. B., Erlbruch A., Lehmann W., Engh R. A., 
Gassel M., Bossemeyer D., JBC (2006), 281, 24818–24830 
Bonny C., Oberson A., Negri S., Sauser C., Schorderet D. F., Diabetes (2001), 50, 77–
82 
Borsi V., Calderone V., Fragai M., Luchinat C., Sarti N., J. Med. Chem. (2010), 53, 
4285–4289 
Bostrom S. L., Dore J., Griffith L. C., Biochem. Biophys. Res. Commun. (2009), 390, 
1154–1159 
Bragg, W. L., Proc. Cambridge Philosoph.Soc.  (1913), 17, 43–57 
Breitenlechner C. B., Bossemeyer D., Engh R. A., Bioch. et Bioph. Acta (2005), 1754, 
38–49 
Brown M. J., Novel fluorescent kinase ligands and assays employing the same, 
WO2008071937 (2008) 150 
Brown S. H. J., Wu J., Kim C., Alberto K., Taylor S. S., J. Mol. Biol. (2009) 393, 1070–
1082 
Burkhardt M., Glazova M., Gambaryan S., Vollkommer T., Butt E., Bader B., 
Heermeieri K., Lincoln T. M., Walter U., Palmetshofer A., JBC (2000), 275, 33536–
33541 
Butt E., Pdhler D., Genieser H.-G., Huggins J. P., Bucher B., Br. J. Pharmacol. (1995), 
116, 3110–3116 
Caldwell J. J., Davies T. G., Donald A., McHardy T., Rowlands M. G., Aherne G. W., 
Hunter L. K., Taylor K., Ruddle R., Raynaud F. I., Verdonk M., Workman P., 
Garrett M. D., Collins I., J. Med. Chem. (2008), 51, 2147–2157 
Calleja V., Alcor D., Laguerre M., Park J., Vojnovic B., Hemmings B. A., Downward 
J., Parker P. J., Larijani B., PLoS Biol. (2007), 5, 780–791 
Carlson C. B., Robers M. B., Vogel K. W., Machleidt T., J. Biomol. Screen. (2009), 14, 
121–132 
Cary S. P. L., Winger J. A., Marletta M. A., PNAS USA (2005), 102 , 13064–13069 
Casteel D. E., Zhang T., Zhuang S., Pilz R. B., Cell. Signal. (2008), 20, 1392–1399 
Chan W. C., White P. D., Fmoc Solid Phase Peptide Synthesis, Oxford University Press 
(2000) 
Chang L., Karin M., Nature (2001), 410, 37–40 
Charter N. W., Kauffman L., Singh R., Eglen R. M., J. Biomol. Screen. (200), 11, 390–
339 
Chen Y. T., Bannister T. D., Weiser A., Griffin E., Lin L., Ruiz C., Cameron M. D., 
Schürer S., Duckett D., Schröter T., LoGrasso P., Feng Y., Bioorg. Med. Chem. 
Lett. (2008), 18, 6406–6409 
Cheng J. Q., Lindsley C. W., Cheng G. Z., Yang H., Nicosia S. V., Oncogene (2005), 
24, 7482–7492 
Cheng K.-Y., Noble M. E. M., Skamnaki V., Brown N. R., Lowe E. D., Kontogiannis 
L., Shen K., Cole P. A., Siligardi G., Johnson L. N., JBC (2006), 281, 23167–23179 
Cheng X., Ji Z., Tsalkova T., Mei F., Acta Biochim. Biophys. Sin. (Shanghai) (2008), 
40, 651–662 
Cheng Y., Prusoff W. H., Biochem. Pharmacol. (1973), 22, 3099–3108 
Cheng Y., Zhang Y., McCammon J. A., JACS (2005), 127, 1553–1562 
Chico L. K., Van Eldik L. J., Watterson D. M., Nat. Rev. Drug Discov. (2009), 8, 892–
909  
Chuan H., Lin J., Wang J. H., JBC (1989), 264, 7981–7988 
Clardy J., Walsh C. , Nature (2004), 432, 829–837 
Cohen M. S., Zhang C., Shokat K. M., Taunton J., Science (2005), 308, 1318–1321 
Cohen P., Nat. Cell. Biol. (2002), 4, E127-E130 
Cohen P., Biochem. J. (2010), 425, 53–54 
Collins I., Caldwell J., Fonseca T., Donald A., Bavetsias V., Hunter L.-J. K., Garrett M. 
D., Rowlands M. G., Aherne G. W., Davies T. G., Berdini V., Woodhead S. J., 
Davis D., Seavers L. C. A., Wyatt P. G., Workman P., McDonald E., Bioorg. Med. 
Chem. (2006), 14, 1255–1273 
Collins I., Anti-Cancer Agents Med. Chem. (2009), 9, 32–50 
Cox G., Matz M., Salih A., Microscopy Res. Tech. (2007), 70, 243–251 
Craggs T. D., Chem. Soc. Rev. (2009), 38, 2865–2875 
Cross D. A. E., Alessi D. R., Cohen P., Andjelkovich M., Hemmings B. A., Nature 
(1995), 378, 785–789 
Currie R. A., Walker K. S., Gray A., Deak M., Casamayor A., Downes C. P., Cohen P., 
Alessi D. R., Lucocq J., Biochem. J. (1999), 337, 575–583 151 
Dalziel K., Dickinson F. M., Biochem. J. (1966), 100, 34–46 
Dalton G. D., Dewey W. L., Neuropeptides (2006), 40, 23–34 
Davidson W., Frego L., Peet G. W., Kroe R. R., Labadia M. E., Lukas S. M., Snow R. 
J., Jakes S., Grygon C. A., Pargellis C., Werneburg B. G., Biochemistry (2004), 43, 
11658–11671 
Davies T. G., Verdonk M. L., Graham B., Saalau-Bethell S., Hamlett C.C. F., McHardy 
T., Collins I., Garrett M. D., Workman P., Woodhead S. J., Jhoti H., Barford D., J. 
Mol. Biol. (2007), 367, 882–894 
Davis A. M., St-Gallay S. A., Kleywegt G. J., Drug Discovery Today (2008), 13, 831–
841 
De Barry J., Liégeois C. M., Janoshazi A., Experim. Gerontology (2010), 45, 64–69 
Degorce F., Card A., Soh S., Trinquet E., Knapik G. P., Xie B., Curr. Chem. Genomics 
(2009), 3, 22–32 
Desai M. C., Zuckermann R. N., Moos W. H., Drug Dev. Res. (1994), 33, 174–188 
Desch M., Sigl K., Hieke B., Salb K., Kees F., Bernhard D., Jochim A., Spiessberger B., 
Hocherl K., Feil R., Feil S., Lukowski R., Wegener J. W., Hofmann F., Schlossmann 
J., Cardiovasc. Res. Adv. Acc. (2010), 86, 496–505 
Di Benedetto G., Zoccarato A., Lissandron V., Terrin A., Li X., Houslay M. D., Baillie 
G. S., Zaccolo M., Circ. Res. (2008), 103, 836–844 
Dilly A. K., Rajala R. V. S., IOVS (2008), 49, 4765–4773 
Diskar M., Zenn H.-M., Kaupisch A., Prinz A., Herberg F. W., Cell. Signal. (2007), 19, 
2024–2034 
Doe C., Bentley R., Behm D. J., Lafferty R., Stavenger R., Jung D., Bamford M., 
Panchal T., Grygielko E., Wright L. L., Smith G. K., Chen Z., Webb C., Khandekar 
S., Yi T., Kirkpatrick R., Dul E., Jolivette L., Marino J. P. Jr., Willette R., Lee D., 
Hu E., J. Pharmacol. Exp. Ther. (2007), 320, 89–98 
Doerig C., Abdi A., Bland N., Eschenlauer S., Dorin-Semblat D., Fennell C., Halbert J., 
Holland Z., Nivez M.-P., Semblat J.-P., Sicard A., Reininger L., Biochim. Biophys. 
Acta (2010), 1804, 604–612 
Dominguez I., Diaz-Meco M. T., Municio M. M., Berra E., de Herreros A. G., Cornet 
M. E., Sanz L., Moscat J., Mol. Cell. Biol. (1992), 12, 3776–3783 
Dostmann W. R. G., Nickl C., Thiel S., Tsigelny I., Frank R., Tegge W. J., Pharmacol. 
Ther. (1999), 82, 373–387 
Dostmann W. R. G., Taylor M. S., Nickl C. K., Brayden J. E., Frank R., Tegge W. J., 
PNAS USA (2000), 97, 14772–14777 
Dostmann W. R. G., Tegge W., Frank R., Nickl C. K., Taylor M. S., Brayden J. E., 
Pharmacol. Ther. (2002), 93, 203–215 
Druker B. J., Lydon N. B., J. Clin. Invest. (2000), 105, 3–7 
Du K., Montminy M., JBC (1998), 273, 32377–32379 
Duchardt F., Fotin-Mleczek M., Schwarz H., Fischer R., Brock R., Traffic (2007), 8, 
848–866 
Dulin N. O., Niu J., Browning D. D., Ye R. D., Voyno-Yasenetskaya T., JBC (2001), 
276, 20827–20830 
Eichholtz T., de Bont D. B., de Widt J., Liskamp R. M., Ploegh H. L., JBC (1993), 268, 
1982–986 
Ekokoski E., Aitio O., Törnquist K., Yli-Kauhaluomae J., Tuominena R. K., Eur. J. 
Pharmaceutical Sci. (2010), 40, 404–411 
Elphick L. M., Lee S. E., Gouverneur V., Mann D. J., ACS Chem. Biol. (2007), 2, 299–
314  
Engh R. A., Bossemeyer D., Pharmacol Ther. (2002), 93, 99–111 152 
Enkvist E., Lavogina D., Raidaru G., Vaasa A., Viil I., Lust M., Viht K., Uri A., J. Med. 
Chem. (2006), 49, 7150–7159 
Enkvist E., Raidaru G., Vaasa A., Pehk T., Lavogina D., Uri A., Bioorg. Med. Chem. 
Lett. (2007), 17, 5336–5339 
Enkvist E., Kriisa M., Roben M., Kadak G., Raidaru G., Uri A., Bioorg. Med. Chem. 
Lett. (2009), 19, 6098–6101 
Facchinetti V., Ouyang W., Wei H., Soto N., Lazorchak A., Gould C., Lowry C., 
Newton A. C., Mao Y., Miao R. Q., Sessa W. C., Qin J., Zhang P., Su B., Jacinto E., 
EMBO J. (2008), 27, 1932–1943 
Fan Q. W., Weiss WA. Cell Cycle (2006), 5, 2301–2305 
Fedorov O., Müller S., Knapp S., Nat. Chem. Biol. (2010), 6, 166–169 
Feng Y., Cameron M. D., Frackowiak B., Griffin E., Lin L., Ruiz C., Schröter T., 
LoGrasso P., Bioorg. Med. Chem. Lett. (2007), 17, 2355–2360 
Fischer J. R., Lessel U., Rarey M., J. Chem. Inf. Model. (2010), 50, 1–21 
Fischer P. M., Curr. Prot. Pept. Sci. (2003), 4, 339–356 
Fischer P. M., Curr. Med.Chem. (2004), 11, 1563–1583 
Fischer R., Waizenegger T., Köhler K., Brock R., Biochim. Biophys. Acta (2002), 
1564, 365–374 
Frame S., Cohen P., Biochem. J. (2001), 359, 1–16 
Freeman-Cook K. D., Autry C., Borzillo G., Gordon D., Barbacci-Tobin E., Bernardo 
V., Briere D., Clark T., Corbett M., Jakubczak J., Kakar S., Knauth E., Lippa B., 
Luzzio M. J., Mansour M., Martinelli G., Marx M., Nelson K., Pandit J., Rajamohan 
F., Robinson S., Subramanyam C., Wei L., Wythes M., Morris J., J. Med. Chem. 
(2010), 53, 4615–4622 
Frei E., Huster M., Smital P., Schlossmann J., Hofmann F., Wegener J. W., Am. J. 
Physiol. Gastrointest. Liver Physiol. (2009), 297, G834-G839 
Fry D. W., Pharmacol. Ther. (1999), 82, 207–218 
Fuerst, M. L., Onc. Times (2010), 32, 5–7 
Fujiwara D., Ye Z., Gouda M., Yokota K., Tsumuraya T., Fujii I., Bioorg. Med. Chem. 
Lett. (2010), 20, 1776–1778 
Fukami Y., Tokmakov A. A., Konaka K., Sato K.-I., Pharmacol. Ther. (1999), 82, 399–
407 
Fukata Y., Amano M., Kaibuchi K., Trends Pharmacol. Sciences (2001), 22, 32–39 
Fuse E., Kuwabara T., Sparreboom A., Sausville E. A., Figg W. D., J. Clin. Pharmacol. 
(2005), 45, 394–403 
Futer O., Saadat A. R., Doran J. D., Raybuck S. A., Pazhanisamy S., Biochemistry 
(2006), 45, 7913–7923 
Gadella T. W. J. (Editor), FRET and FLIM techniques , Laboratory Techniques in 
Biochemistry and Molecular Biology (2009), 33 
Gani O. A. B. S. M., Engh R. A., Nat. Prod. Rep. (2010), 27, 489–498 
Garcia-Echeverria C., Traxler P., Evans D. B., Med. Res. Rev. (2000), 20, 28–57 
Garcia-Echeverria C., Sellers W. R., Oncogene (2008), 27, 5511–5526 
Gayani B., Perera K., Maly D. J., Mol. Bio. Syst. (2008), 4, 542–550 
Giacovazzo C., Monaco H. L., Artioli G., Viterbo D., Ferraris G., Gilli G., Zanotti G., 
Catti M., Fundamentals of crystallography. Oxford University Press (2005) 
Gill A., Mini Rev. Med. Chem. (2004), 4, 301–311  
Goldenberg-Furmanov M., Stein I., Pikarsky E., Rubin H., Kasem S., Wygoda M., 
Weinstein I., Reuveni H., Ben-Sasson S. A., Cancer Res. (2004), 64, 1058–1066 
Goodman K. B., Cui H., Dowdell S. E., Gaitanopoulos D. E., Ivy R. L., Sehon C. A., 
Stavenger R. A., Wang G. Z., Viet A. Q., Xu W., Ye G., Semus S. F., Evans C., 153 
Fries H. E., Jolivette L. J., Kirkpatrick R. B., Dul E., Khandekar S. S., Yi T., Jung D. 
K., Wright L. L., Smith G. K., Behm D. J., Bentley R., Doe C. P., Hu E., Lee D., J. 
Med. Chem. (2007), 50, 6–9 
Grant S. K., Cell. Mol. Life Sci. (2009), 66, 1163–1177 
Grauer A., König B., Eur. J. Org. Chem. (2009), 2009, 5099–5111 
Green K. D., Kay M., Pflum H., JACS (2007), 129, 10–11 
Greene T. W., Wuts P. G. M., Protective Groups in Organic Synthesis, John Wiley & 
Sons, Inc. (1999), 3rd edition 
Gridelli C., Maione P., Del Gaizo F., Colantuoni G., Guerriero C., Ferrara C., Nicolella 
D., Comunale D., De Vita A., Rossi A., Oncologist (2007), 12, 191–200 
Grodsky N., Li Y., Bouzida D., Love R., Jensen J., Nodes B., Nonomiya J., Grant S., 
Biochemistry (2006), 45, 13970–13981 
Gumireddy K., Baker S. J., Cosenza S. C., John P., Kang A. D., Robell K. A., Reddy M. 
V. R., Reddy E. P., PNAS USA (2005), 102, 1992–1997  
Hahmann C., Schroeter T., Cell. Mol. Life Sci. (2010), 67, 171–177 
Hajduk P. J., Huth J. R., Tse C., Drug Disc. Targets (2005), 10, 1675–1682 
Han S., Zhou V., Pan S., Liu Y., Hornsby M., McMullan D., Klock H. E., Haugen J., 
Lesley S. A., Gray N., Caldwell J., Gu X. J., Bioorg. Med. Chem. Lett. (2005), 15, 
5467–5473 
Handa A. K., Johri M. M., Plant Physiol. (1977), 59, 490–496 
Hanks S. K., Hunter T., FASEB J. (1995), 9, 576–596 
Hanks S. K., Genome Biol. (2003), 4, 111 
Hanoune J., Defer N., Annu. Rev. Pharmacol. Toxicol. (2001), 41, 145–174 
Harootunian A. T., Adams S. R., Wen W., Meinkoth J. L., Taylor S. S., Tsien R. Y., 
Mol. Biol. Cell. (1993), 4, 993–1002 
Harris T. E., Persaud S. J., Jones P. M., Mol. Cell. Endocrinology (1999), 155, 61–68 
Hastie C. J., McLauchlan H. J., Cohen P., Nat. Protoc. (2006), 1, 968–971 
Hauptman H. A., Rep. Prog. Phys. (1991), 54, 1427–1454 
Heerding D. A., Rhodes N., Leber J. D., Clark T. J., Keenan R. M., Lafrance L. V., Li 
M., Safonov I. G., Takata D. T., Venslavsky J. W., Yamashita D. S., Choudhry A. 
E., Copeland R. A., Lai Z., Schaber M. D., Tummino P. J., Strum S. L., Wood E. R., 
Duckett D. R., Eberwein D., Knick V. B., Lansing T. J., McConnell R. T., Zhang S., 
Minthorn E. A., Concha N. O., Warren G. L., Kumar R., J. Med. Chem. (2008), 51, 
5663–5679 
Herberg F. W., Taylor S. S., Biochemistry (1993), 32, 14015–14022 
Herberg F. W., Doyle M. L., Cox S., Taylor S. S., Biochemistry (1999), 38, 6352–6360 
Heymach J. V., Nilsson M., Blumenschein G., Papadimitrakopoulou V., Herbst R., 
Clin. Cancer Res. (2006), 12, 4441s-4445s 
Hidaka H., Inagaki M., Kawamoto S., Sasaki Y., Biochemistry (1984), 23, 5036–5041 
Hines A. C., Cole P. A., Bioorg. Med. Chem. Lett., (2004), 14, 2951–2954 
Hofmann F., Bechtel P. J., Krebs E. G., JBC (1977), 252, 1441–1447 
Hofmann F., Ammendola A., Schlossmann J., J. Cell Science (2000), 113, 1671–1676 
Hofmann F., Bernhard D., Lukowski R., Weinmeister P., cGMP: Generators, Effectors 
and Therapeutic Implications (Handbook of Experimental Pharmacology), Springer 
(2009), 137–162 
Honda A., Sawyer C. L., Cawley S. M., Dostmann W. R., Methods Mol. Biol. (2005), 
307, 27–43 
Hopkins A. L., Groom C. R., Nature Rev. Drug Discov. (2002), 1, 727–730 
House C., Kemp B. E., Science (1987), 238, 1726–1728 
Huang J., Manning B. D., Biochem. Soc. Trans. (2009), 37, 217–222 154 
Huang L. J., Durick K., Weiner J. A., Chun J., Taylor S. S., JBC (1997), 272, 8057–
8064 
Huang Z., Wong C. F., J. Comput. Chem. (2008), 30, 631–644 
Huang X., J. Biomol. Screen. (2003), 8, 34–38 
Huse M., Kuriyan J., Cell Volume 109, Issue 3, 3 May 2002, Pages 275–282 
Invitrogen
TM Human Kinome Map, 
http://www.invitrogen.com/site/us/en/home/LINNEA-Online-Guides/human-
kinome-map/Search-The-Human-Kinome.html, last viewed August 7, 2010 
Invitrogen
TM Product Spectra 5-TAMRA/pH 7.0, 
http://www.invitrogen.com/site/us/en/home/support/Product-Technical-
Resources/Product-Spectra.6121ph7.html, last viewed August 16, 2010 
Iwakubo M., Takami A., Okada Y., Kawata T., Tagami Y., Sato M., Sugiyama T., 
Fukushima K., Taya S., Amano M., Kaibuchi K., Iijima H., Bioorg. Med. Chem. 
(2007a), 15, 1022–1033 
Iwakubo M., Takami A., Okada Y., Kawata T., Tagami Y., Ohashi H., Sato M., 
Sugiyama T., Fukushima K., Iijima H., Bioorg. Med. Chem. (2007b), 15, 350–364 
Jacobs M., Hayakawa K., Swenson L., Bellon S., Fleming M., Taslimi P., Doran J., JBC 
(2006), 281, 260–268 
Jameson D. M., Ross J. A., Chem Rev. (2010), 110, 2685–2708 
Joachimiak A., Curr. Opin. Struct. Biol. (2009), 19, 573–584 
Johannessen M., Moens U.,Front. Bioscience (2007), 12, 1814–1832 
Johnson D. A., Akamine P., Radzio-Andzelm E., Madhusudan, Taylor S. S., Chem. 
Rev. (2001), 101, 2243–2270 
Johnson L. N., Quarterly Rev. Biophys. (2009), 42, 1–40 
Kaláb P., Soderholm J.,  (2010), 51, 220–232 
Kalesh K. A., Sim D. S. B., Wang J., Liu K., Lin Q., Yao S. Q., Chem. Commun. 
(2010), 46, 1118–1120 
Kane R. S., Langmuir (2010), 26, 8636–8640 
Kang J.-H., Asai D., Toita R., Kitazaki H., Katayama Y., Carcinogenesis (2009), 30, 
1927–1931 
Karaman M. W., Herrgard S., Treiber D. K., Gallant P., Atteridge C. E., Campbell B. 
T., Chan K. W., Ciceri P., Davis M. I., Edeen P. T., Faraoni R., Floyd M., Hunt J. P., 
Lockhart D. J., Milanov Z. V., Morrison M. J., Pallares G., Patel H. K., Pritchard S., 
Wodicka L. M., Zarrinkar P. P., Nat. Biotechnol. (2008), 26, 127–132 
Kase H., Iwahashi K., Nakanishi S., Matsuda Y., Yamada K., Takahashi M., Murakata 
C., Sato A., Kaneko M., Biochem. Biophys. Res. Commun. (1987), 142, 436–440 
Kawai Y., Sato M., Umezawa Y., Anal. Chem. (2004), 76, 6144–6149 
Kayser K. J., Glenn M. P., Sebti S. M., Cheng J. Q., Hamilton A. D., Bioorg. Med. 
Chem. Lett. (2007), 17, 2068–2073 
Keller T. H., Pichota A., Yin Z., Curr. Opin. Chem. Biol. (2006), 10, 357–361 
Kéri G., Orfi L., Eros D., Hegymegi-Barakonyi B., Szintai-Kis C., Horvith Z., Wjczek 
F., Marosfalvi J., Szabadkai I., Pato J., Greff Z., Hafenbradl D., Daub H., Müller G., 
Klebl B., Ullrich A., Curr. Signal Transduction Therapy (2006), 1, 67–95 
Kerlavage A. R., Taylor S. S., JBC (1980), 255, 8483–8486 
Kim C., Cheng C. Y., Saldanha S. A., Taylor S. S., Cell (2007), 130, 1032–1043 
Kim D., Sun M., He L., Zhou Q.-H., Chen J., Sun X.-M., Bepler G., Sebti S. M., Cheng 
J. Q., JBC (2010), 285, 8383–8394 
Kim K., Cole P.A., JACS (1998), 120, 6851–6858  
Kinderman F. S., Kim C., von Daake S., Ma Y., Pham B. Q., Spraggon G., Xuong N.-
H., Jennings P. A., Taylor S. S., Molecular Cell 24, 397–408, November 3, 2006 155 
Kinnings S. L., Jackson R. M., J Chem. Inf. Model. (2009), 49, 318–329 
Kittel, C. Introduction to Solid State Physics, John Wiley & Sons (1986), 2nd edition 
Knight Z. A., Lin H., Shokat K. M., Nature Rev. Cancer (2010), 10, 130–137 
Knighton D. R., Zheng J. H., Ten Eyck L. F., Ashford V. A., Xuong N. H., Taylor S. S., 
Sowadski J. M., Science (1991), 253, 407–414 
Komander D., Kular G. S., Bain J., Elliott M., Alessi D. R., van Aalten D. M. F., 
Biochem. J. (2003), 375, 255–262 
Komander D., Kular G. S., Schüttelkopf A. W., Deak M., Prakash K. R. C., Bain J., 
Elliott M., Garrido-Franco M., Kozikowski A. P., Alessi D. R., van Aalten D. M. F., 
Structure (2004), 12, 215–226 
Kong C.-T., Cook P. F., Biochemistry (1988), 27, 4795–4799 
Kornev A. P., Haste N. M., Taylor S. S., Ten Eyck L. F., PNAS USA (2006), 103, 
17783–17788 
Kornev A. P., Taylor S. S., Biochim. Biophys. Acta (2010), 1804, 440–444 
Krishnamurty R., Maly D. J., ACS Chem. Biol. (2010), 5, 121–138 
Kumar P., Walsh D. A., Biochem. J. (2002), 362, 533–537 
Kuroki H., Imai A., Nashida T., Shimomura H., Arch. Oral. Biol. (2007), 52, 905–610 
Kwan J., Ling A., Papp E., Shaw D., Bradshaw J. M., Anal. Biochem. (2009), 395, 
256–262 
Lackey, K. E., Curr. Top. Med. Chem. (2006), 6, 435–460 
Lakowicz J. R., Principles of fluorescence spectroscopy, Springer (2006), 3rd edition 
Lam K. S., Wu J., Lou Q., Int. J. Pept. Protein Res. (1995), 45, 587–592 
Lam K. S., Lebl M., Krchnak V., Chem. Rev. (1997), 97, 411–448 
Lam K. S., Liu R., Miyamoto S., Lehman A. L., Tuscano J. M., Acc. Chem. Res. 
(2003), 36, 370–377 
Landgraf W., Hofmann F., Eur. J. Biochem. (1989), 181, 643–650 
Landry Y., Gies J.-P., Fundamental Clin. Pharmacol. (2008), 22, 1–18 
Lavogina D., Lust M., Viil I., König N., Raidaru G., Rogozina J., Enkvist E., Uri A., 
Bossemeyer D., J. Med. Chem. (2009), 52, 308–321 
Lavogina D., Enkvist E., Uri A., Chem. Med. Chem. (2010a), 5, 23–34 
Lavogina D., Nickl C. K., Enkvist E., Raidaru G., Lust M., Vaasa A., Uri A., Dostmann 
W. R., Biochim. Biophys. Acta (2010b), 1804, 1857–1868 
Lawrence D. S., Niu J., Pharmacol. Ther. (1998), 77, 81–114 
Lawrence D. S., Inhibitors of Protein Kinases and Protein Phosphatases, Handbook of 
Experimental Pharmacology, Springer (2005), 167 
Lebakken C. S., Kang H. C., Vogel K. W., J. Biomol. Screen. (2007), 12, 828–841 
Lee G. M., Craik C. S., Science (2009), 324, 213–215 
Lee H.-M., Larson D. R., Lawrence D. S., ACS Chem. Biol. (2009), 4, 409–427  
Lee J.,  Rudd J. J., Trends Plant Sc. (2002), 7, 97–98 
Lee J. H., Nandy S. K., Lawrence D. S., JACS (2004), 126, 3394–3395 
Leonard C. J., Aravind L., Koonin E. V., Genome Res. (1998), 8, 1038–1047 
Levinson N. M., Kuchment O., Shen K., Young M. A., Koldobskiy M., Karplus M., 
Cole P. A., Kuriyan J., PLoS Biol. (2006), 4, e144 
Lew J., Coruh N., Tsigelny I., Garrod S., Taylor S. S., JBC (1997a), 272, 1507–1513 
Lew J., Taylor S. S., Adams J. A., Biochemistry (1997b), 36, 6717–6724 
Lewis J. A., Lebois E. P., Lindsley C. W., Curr. Opin. Chem. Biol. (2008), 12, 269–280 
Levitzki A., Mishani E., Annu. Rev. Biochem. (2006), 75, 93–109 
Li H., Hah J.-M., Lawrence D. S., JACS (2008), 130, 10474–10475 
Li Q., Woods K. W., Thomas S., Zhu G.-D., Packard G., Fisher J., Li T., Gong J., 
Dinges J., Song X., Abrams J., Luo Y., Johnson E. F., Shi Y., Liu X., Klinghofer V., 156 
Jong R. D., Oltersdorf T., Stoll V. S., Jakob C. G., Rosenberg S. H., Giranda V. L., 
Bioorg. Med. Chem. Lett. (2006), 16, 2000–2007 
Li S., WenFang X., Sci. China Series B: Chem. (2009), 52, 535–548 
Li Y. J., Xie W. H., Fang G. J., Anal. Bioanal. Chem. (2008), 390, 2049–2057 
Lienhard G. E., Secemski I. I., JBC (1973), 248, 1121–1123 
Lin H., Yamashita D. S., Zeng J., Xie R., Wang W., Nidarmarthy S., Luengo J. I., 
Rhodes N., Knick V. B., Choudhry A. E., Lai Z., Minthorn E. A., Strum S. L., Wood 
E. R., Elkins P. A., Concha N. O., Heerding D. A., Bioorg. Med. Chem. Lett. 
(2010), 20, 673–678 
Lin X., Ayrapetov M. K., Sun G., BMC Biochem. (2005), 6, 25 
Lin X., Murray J. M., Rico A. C., Wang M. X., Chu D. T., Zhou Y., Del Rosario M., 
Kaufman S., Ma S., Fang E., Crawford K., Jefferson A. B., Bioorg. Med. Chem. 
Lett. (2006), 16, 4163–4168 
Lindsley C. W., Zhao Z., Leister W. H., Robinson R. G., Barnett S. F., Defeo-Jones D., 
Jones R. E., Hartman G. D., Huff J. R., Huberb H. E., Duggan M. E., Bioorg. Med. 
Chem. Lett. (2005), 15, 761–764 
Lipinski C. A., Lombardo F., Dominy B. W., Feeney P., J. Adv. Drug Deliv. Rev. 
(2001), 46, 3–26 
Liu K., Kalesh K. A., Ong L. B., Yao S. Q., Chem. Bio. Chem (2008), 9, 1883–1888 
Liu P., Cheng H., Roberts T. M., Zhao J. J., Nat. Rev. Drug Disc. (2009), 8, 627–644 
Liu Y., Bishop A., Witucki L., Kraybill B., Shimizu E., Tsien J., Ubersax J., Blethrow 
J., Morgan D. O., Shokat K. M. Chem. Biol. (1999), 6, 671–678 
Livnah N., Yechezkel T., Salitra Y., Perlmutter B., Ohne O., Cohen I., Litman P., 
Senderovitz H., Protein kinase inhibitors comprising ATP mimetics conjugated to 
peptides or peptidomimetics,  WO2003010281, 2003 
Livnah N., Levitzki A., Senderovitz H., Yechezkel T., Salitra Y., Litman P., Ohne O., 
Cell permeable conjugates of peptides for inhibition of protein kinases, 
WO2004110337, 2004 
LoGrasso P. V., Feng Y., Curr. Topics Med. Chem. (2009), 9, 704–723 
London N., Movshovitz-Attias D., Schueler-Furman O., Structure (2010), 18, 188–199  
Loog M., Uri A., Raidaru G., Järv J., Ek P., Bioorg. Med. Chem. Lett. (1999), 9, 1447–
1452 
Loog M., Uri A., Raidaru G., Järv J., Ek P., FEBS Lett. (2000), 480, 244–248 
Luo R., David L., Hung H., Devaney J., Gilson M. K., J. Phys. Chem. B (1999), 103, 
727–736 
Luo Y., Smith R. A., Guan R., Liu X., Klinghofer V., Shen J., Hutchins C., Richardson 
P., Holzman T., Rosenberg S. H., Giranda V. L., Biochemistry (2004), 43, 1254–
1263 
Ma H., Deacon S., Horiuchi K., Expert Opin. Drug Discov. (2008), 3, 607–621 
Ma Y., Pitson S., Hercus T., Murphy J., Lopez A., Woodcock J., JBC (2005), 280, 
26011–26017 
Madhusudan, Akamine P., Xuong N. H., Taylor S. S., Nat. Struct. Biol. (2002), 9, 273–
277 
Maekawa M., Ishizaki T., Boku S., Watanabe N., Fujita A., Iwamatsu A., Obinata T., 
Ohashi K., Mizuno K., Narumiya S., Science (1999), 285, 895–898 
Magalhaes M. L. B., Vetting M. W., Gao F., Freiburger L., Auclair K., Blanchard J. S., 
Biochemistry (2008), 47, 579–584 
Maillard N., Clouet A., Darbre T., Reymond J.-L ., Nat. Protoc. (2009), 4, 132–142 
Maly D. J., Allen J. A., Shokat K. M., JACS (2004), 126, 9160–9161 
Manning B. D., Cantley L. C., Cell (2007), 129, 1261–1274 157 
Manning G., Whyte D. B., Martinez R., Hunter T., Sudarsanam S., Science (2002), 298, 
1912–1934 
Martinez A., Alonso M., Castro A., Pérez C., Moreno F. J., J. Med. Chem. (2002) ,45, 
1292–1299 
Martinez A., Alonso M., Castro A., Dorronsoro I., Gelpí J. L., Luque F. J., Pérez C., 
Moreno F. J., J. Med. Chem. (2005), 48, 7103–7112 
Masterson L. R., Mascioni A., Traaseth N. J., Taylor S. S., Veglia G., PNAS USA 
(2008), 105, 506–511  
Matheson R. R., Jr., Van Wart H. E., Burgess A. W., Weinstein L. I., Scheraga H. A., 
Biochemistry (1977), 16, 396–403 
Matthews B. W., J. Mol. Biol. (1968), 33, 491–497 
Medzihradszky D., Chen S.L., Kenyon G.L., Gibson B.W., JACS (1994), 116, 9413–
9419  
Merrifield R. B., JACS (1963), 85, 2149–2154 
Millward M. J., House C., Bowtell D., Webster L., Olver I. N., Gore M., Copeman M., 
Lynch K., Yap A., Wang Y., Cohen P. S., Zalcberg J., Br. J. Cancer (2006), 95, 
829–834 
Miranda-Saavedra D., Stark M. J. R., Packer J. C., Vivares C. P., Doerig C., Barton G. 
J., BMC Genomics (2007), 8, 309 
Moore E. G., Samuel A. P. S., Raymond K. N., Acc. Chem. Res. (2009), 42, 542–552 
Morphy R., J. Med. Chem. (2010), 53, 1413–1437 
Mulder J., Ariaens A., van den Boomen D., Moolenaar W. H., Mol. Biol. Cell (2004), 
15, 5516–5527 
Murray A. J., Sci. Signal. (2008), 1, re4 
Murray A. W., Cell (2004), 116, 221–234 
Murthy K. S., Zhou H., Grider J. R., Makhlouf G. M., Am. J. Physiol. Gastrointest. 
Liver. Physiol. (2003), 284, G1006-G1016 
Murthy K. S., Annu. Rev. Physiol. (2006), 68, 345–374 
Muzaffar S., Jeremy J. Y., Sparatore A., Del Soldato P., Angelini G. D., Shukla N., Br. 
J. Pharmacol. (2008), 155, 984–994 
Nakayama M., Amano M., Katsumi A., Kaneko T., Kawabata S., Takefuji M., Kaibuchi 
K., Genes to Cells (2005), 10, 107–117 
Narayana N., Cox S., Xuong N.-H., Ten Eyck L. F., Taylor S. S., Structure (1997), 5, 
921–935 
Nelson D. L., Lehninger A. L., Cox M. M., Lehninger principles of biochemistry, 
Worth Publishers (2000) 
Nesterova M. V., Johnson N., Cheadle C., Bates S. E., Mani S., Stratakis C. A., Kahn I., 
Gupta R. K., Cho-Chung Y. S., Cancer Res. (2006), 66, 8971–8974 
Nickl C. K., Raidas S. K., Zhao H., Sausbier M., Ruth P., Tegge W., Brayden J. E., 
Dostmann W. R., Biochim. Biophys. Acta (2010), 1804, 524–532 
Niv M. Y., Rubin H., Cohen J., Tsirulnikov L., Licht T., Peretzman-Shemer A., Cnaan 
E., Tartakovsky A., Stein I., Albeck S., Weinstein I., Goldenberg-Furmanov M., 
Tobi D., Cohen E., Laster M., Ben-Sasson S. A., Reuveni H., JBC (2004), 279, 
1242–1255 
Noble M. E. M., Endicott J. A., Johnson L. N., Science (2004), 303, 1800–1805  
Nolen B., Taylor S., Ghosh G., Mol Cell., Volume 15, Issue 5, 10 September 2004, 
Pages 661–675 
Obrecht D., Villalgordo J. M., Solid-Supported Combinatorial and Parallel Synthesis of 
Small-Molecular-Weight Compound Libraries, Elsevier Science (1998) 158 
Ohren J. F., Chen H., Pavlovsky A., Whitehead C., Zhang E., Kuffa P., Yan C., 
McConnell P., Spessard C., Banotai C., Mueller W. T., Delaney A., Omer C., 
Sebolt-Leopold J., Dudley D. T., Leung I. K., Flamme C., Warmus J., Kaufman M., 
Barrett S., Tecle H., Hasemann C. A., Nat. Struct. Mol. Biol. (2004), 11, 1192–1197 
Olson M. F., Curr. Opin. Cell Biol. (2008), 20, 242–248 
Ono-Saito N., Niki I., Hidaka H., Pharmacol. Ther. (1999), 82, 123–131 
Oswald C., Smits S. H. J., Bremer E., Schmitt L., Int. J. Mol. Sci. (2008), 9, 1131–1141 
Pande V., Ramos M. J., Gago F., Anti-Cancer Agents Med. Chem. (2008), 8, 638–645 
Parang K., Till J. H., Ablooglu A. J., Kohanski R. A., Hubbard S. R., Cole P. A., Nat. 
Struct. Biol. (2001), 8, 37–41 
Parang K., Cole P. A., Pharmacol. Ther. (2002a), 93, 145–157 
Parang K., Kohn J. A., Saldanha S. A., Cole P. A., FEBS Lett. (2002b), 520, 156–160 
Parang K., Sun G., Curr. Opin. Drug Discovery Devel. (2004), 7, 617–629 
Parsons M., Worthey E. A., Ward P. N., Mottram J. C. BMC Genomics (2005), 6, 127 
Patricelli M. P., Szardenings A. K., Liyanage M., Nomanbhoy T. K., Wu M., Weissig 
H., Aban A., Chun D., Tanner S., Kozarich J. W., Biochemistry (2007), 46, 350–358 
Paul B. Z. S.,  Daniel J. L.,  Kunapuli S. P., JBC (1999), 274, 28293–28300 
Pearce L. R., Komander D., Alessi D. R., Nat. Rev. Mol. Cell. Biol. (2010), 11, 9–22 
Perea S. E., Reyes O., Puchades Y., Mendoza O., Vispo N. S., Torrens I., Santos A., 
Silva R., Acevedo B., Lopez E., Falcon V., Alonso D. F., Cancer Res. (2004), 64, 
7127–7129 
PerkinElmer Scintillation Proximity Assay (SPA), 
http://las.perkinelmer.com/Catalog/CategoryPage.htm?CategoryID=Scintillation+Pr
oximity+Assay+%5bSPA%5d, last viewed August 7, 2010 
Pflug A., Rogozina J., Lavogina D., Enkvist E., Uri A., Engh R. A., Bossemeyer D., J. 
Med. Chem. (2010), doi: 10.1016/j.jmb.2010.08.028 
Phipps J., Terreux R. Targeted protein kinase C inhibitors and uses thereof, 
WO2007016777 (2007) 
Pidoux G., Taskén K., J. Mol. Endocrinol. (2010), 44, 271–284 
Pinkse M. W. H., Rijkers D. T. S., Dostmann W. R., Heck A. J. R., JBC (2009), 284, 
16354–16368 
Pinna L. A., Ruzzene M., Biochim. Biophys. Acta (1996), 1314, 191–225 
Polshakov D., Rai S., Wilson R. M., Mack E. T., Vogel M., Krause J. A., Burdzinski G., 
Platz M. S., Biochemistry (2005), 44, 11241–11253 
Poppe H., Rybalkin S. D., Rehmann H., Hinds T. R., Tang X.-B., Christensen A. E., 
Schwede F., Genieser H.-G., Bos J. L., Doskeland S. O., Beavo J. A., Butt E., Nat. 
Methods (2008), 5, 277–278  
Pratt D. J., Endicott J. A., Noble M. E., Curr. Opin. Drug Discov. Devel. (2004), 7, 
428–436 
Priestman M. A., Lawrence D. S., Biochim. Biophys. Acta (2010), 1804, 547–558 
Profirovic J., Gorovoy M., Niu J., Pavlovic S., Voyno-Yasenetskaya T., JBC (2005), 
32866–32876 
Promega ProFluor® PKA Assay, 
http://www.promega.com/catalog/catalogproducts.aspx?categoryname=productleaf_
1566, last viewed August 13, 2010 
Prudent R., Cochet C., Chem. Biol. (2009), 16, 112–120 
Puetz S., Lubomirov L. T., Pfitzer G., Physiology (2009), 24, 342–356 
Rabiller M., Getlik M., Klüter S., Richters A., Tückmantel S., Simard J. R., Rauh D., 
Arch. Pharm. Chem. Life Sci. (2010), 343, 193–206 
Ratcliffe S. J., Yi T., Khandekar S. S., J. Biomol. Screen. (2007), 12, 126–132 159 
Resch-Genger U., Grabolle M., Cavaliere-Jaricot S., Nitschke R., Nann T., Nat. Meth. 
(2008), 5, 763–775 
Rhodes N., Heerding D. A., Duckett D. R., Eberwein D. J., Knick V. B., Lansing T. J., 
McConnell R. T., Gilmer T. M., Zhang S.-Y., Robell K., Kahana J. A., Geske R. S., 
Kleymenova E. V., Choudhry A. E., Lai Z., Leber J. D., Minthorn E. A., Strum S. 
L., Wood E. R., Huang P. S., Copeland R. A., Kumar R., Cancer Res. (2008), 68, 
2366–2374 
Ricouart A., Tartar A., Sergheraert C., Inhibition of protein kinase C by retro-inverso 
pseudosubstrate analogues, Biochem. Biophys. Res. Commun. (1989), 165, 1382–
1390 
Ricouart A., Gesquiere J. C., Tartar A., Sergheraert C.,  J. Med. Chem. (1991), 34, 73–
78 
Rininsland F., Xia W., Wittenburg S., Shi X., Stankewicz C., Achyuthan K., McBranch 
D., Whitten D., PNAS USA (2004), 101, 15295–15300 
Rix U., Superti-Furga G., Nat. Chem. Biol. (2009), 5, 616–624 
Rodgers D.W., Structure (1994), 2, 1135–1140 
Romano R. A., Kannan N., Kornev A. P., Allison C. J., Taylor S. S., Prot. Science 
(2009), 18, 1486–1497 
Rosenberg D., Groussin L., Jullian E., Perlemoine K., Bertagna X., Bertherat J., Ann. 
N.Y. Acad. Sci. (2002), 968, 65–74 
Rosse G., Sequin U., Mett H., Furet P., Traxler P., Fretz H., Helvetica Chim. Acta 
(1997), 80, 653–670 
Ruggeri B. A., Miknyoczki S. J., Singh J., Hudkins R. L., Curr. Med. Chem. (1999), 6, 
845–857 
Räägel H., Säälik P., Hansen M., Langel U., Pooga M., J. Control Release (2009), 139, 
108–117 
Rybalkin S. D., Rybalkina I. G., Feil R., Hofmann F., Beavo J. A., JBC (2002), 277, 
3310–3317 
Rybalkin S. D., Rybalkina I. G., Shimizu-Albergine M.,. Tang X.-B, Beavo J. A., 
EMBO J. (2003), 23, 469–478 
Saghatelian A., Cravatt B. F., Nat. Chem. Biol. (2005), 1, 130–142 
Sánchez A., Villalba N., Martínez A. C., García-Sacristán A., Hernández M., Prieto D., 
Eur. J. Pharmacol. (2008), 586, 283–287 
Sarbassov D. D., Guertin D. A., Ali S. M., Sabatini D. M., Science (2005), 307, 1098–
1101 
Sarma G. N., Kinderman F. S., Kim C., von Daake S., Chen L., Wang B.-C., Taylor S. 
S., Structure 18, 155–166, February 10, 2010 
Saxty G., Woodhead S. J., Berdini V., Davies T. G., Verdonk M. L., Wyatt P. G., Boyle 
R. G., Barford D., Downham R., Garrett M. D., Carr R. A., J. Med. Chem. (2007), 
50, 2293–2296 
Schirok H., Kast R., Figueroa-Pérez S., Bennabi S., Gnoth M. J., Feurer A., Heckroth 
H., Thutewohl M., Paulsen H., Knorr A., Hütter J., Lobell M., Münter K., Geiss V., 
Ehmke H., Lang D., Radtke M., Mittendorf J., Stasch J. P., Chem. Med. Chem. 
(2008), 3, 1893–1904 
Schlossmann J., Ammendola A., Ashman K., Zong X., Huber A., Neubauer G., Wang 
G.-X., Allescher H.-D., Korth M., Wilm M., Hofmann F., Ruth P., Nature (2000), 
404, 197–201 
Schneider T. L., Mathew R. S., Rice K. P., Tamaki K., Wood J. L., Schepartz A., Org. 
Lett. (2005), 7, 1695–1698 
Scholten A., Aye T.-T., Heck A. J.R., Mass Spectr. Rev. (2008), 27, 331–353 160 
Schulz S., Chinkers M., Garbers D. L., FASEB J. (1989), 3, 2026–2035 
Segel I. H., Enzyme kinetics: behavior and analysis of rapid equilibrium and steady 
state enzyme systems, John Wiley & Sons, Inc. (1993) 
Sehon C. A., Wang G. Z., Viet A. Q., Goodman K. B., Dowdell S. E., Elkins P. A., 
Semus S. F., Evans C., Jolivette L. J., Kirkpatrick R. B., Dul E., Khandekar S. S., Yi 
T., Wright L. L., Smith G. K., Behm D. J., Bentley R., Doe C. P., Hu E., Lee D., J. 
Med. Chem. (2008), 51, 6631–6634 
Senderowicz A. M., Investig. New Drugs (1999), 17, 313–320 
Sessions E. H., Yin Y., Bannister T. D., Weiser A., Griffin E., Pocas J., Cameron M. D., 
Ruiz C., Lin L., Schürer S. C., Schröter T., LoGrasso P., Feng Y., Bioorg. Med. 
Chem. Lett. (2008), 18, 6390–6393 
Seydack M., Biosensors and Bioelectronics (2005), 20, 2454–2469 
Shabb J. B., Corbin J. D., JBC (1992), 267, 5723–5726  
Shabb J. B., Chem. Rev. (2001), 101, 2381–2411 
Shah B. H., Neithardt A., Chu D. B., Shah F. B., Catt K. J., J. Cell. Physiol. (2006), 206, 
47–57 
Shah N. P., Skaggs B. J., Branford S., Hughes T. P., Nicoll J. M., Paquette R. L., 
Sawyers C. L., J. Clin. Invest. (2007), 117, 2562–2569 
Sharma V., Wang Q., Lawrence D. S., Biochim. Biophys. Acta (2008), 1784, 94–99 
Shen K., Cole P. A., JACS (2003), 125, 16172–16173 
Shen K., Hines A. C., Schwarzer D., Pickin K. A., Cole P. A., Biochim. Biophys. Acta 
(2005), 1754, 65–78 
Shin D.-S., Kim D.-H., Chung W.-J., Lee Y.-S., J. Biochem. Mol. Biol. (2005), 38, 
517–525 
Shomin C. D., Meyer S. C., Ghosh I., Bioorg. Med. Chem. (2009), 17, 6196–6202 
Shu Y.-Z., J. Nat. Prod. (1998), 61, 1053–1071 
Shugar D., Acta Biochim. Pol. (1996), 43, 9–24 
Sigma-Aldrich
 Resin Explorer, http://www.sigmaaldrich.com/chemistry/drug-
discovery/resin-explorer/solid-phase-resin.html , last viewed August 7, 2010 
Simard J. R., Getlik M., Grütter C., Schneider R., Wulfert S., Rauh D., JACS (2010), 
132, 4152–4160 
Skalhegg B. S., Johansen A. K., Levy F. O., Andersson K. B., Aandahl E. M., Blomhoff 
H. K., Hansson V., Tasken K., J. Cell. Physiol. (1998), 177, 85–93 
Skålhegg B. S., Funderud A., Henanger H. H., Hafte T. T., Larsen A. C., Kvissel A.-K., 
Eikvar S., Ørstavik S., Current Drug Targets (2005), 6, 655–664 
Smaill J. B., Palmer B. D., Rewcastle G. W., Denny W. A., McNamara D. J., Dobrusin 
E. M., Bridges A. J., Zhou H., Showalter H. D. H., Winters R. T., Leopold W. R., 
Fry D. W., Nelson J. M., Slintak V., Elliot W. L., Roberts B. J., Vincent P. W., 
Patmore S. J., J. Med. Chem. (1999), 42, 1803–1815 
Smith C. M., Radzio-Andzelm E., Madhusudan, Akamine P., Taylor S. S., Progress 
Biophys. Mol. Biol. (1999), 71, 313–341 
Smith J. A., Francis S. H., Walsh K. A., Kumar S., Corbin J. D., JBC (1996),271, 
20756–20762 
Smith J. A., Reed R. B., Francis S. H., Grimes K., Corbin J. D., JBC (2000), 275, 154–
158 
Smolenski A., Burkhardt A. M., Eigenthaler M., Butt E., Gambaryan S., Lohmann S. 
M., Walter U., Naunyn-Schmiedeberg’s Arch. Pharmacol. (1998), 358, 134–139 
Somlyo A. P., Somlyo A. V., J. Physiol. (2000), 522, 177–185 
Souslova E. A., Chudakov D. M., Biochemistry (Mosc). (2007), 72, 683–697 161 
Southall, N. T., Dill, K. A., Haymet, A. D. J., J. Phys. Chem. B (2002), 106, 521–533 
Speers A. E., Cravatt B. F., Chem. Bio. Chem (2004), 5, 41–47 
Sriwai W., Zhou H., Murthy K. S., Biochem. J. (2008), 411, 543–551 
Statsuk A. V., Maly D. J., Seeliger M. A., Fabian M. A., Biggs III. W. H., Lockhart D. 
J., Zarrinkar P. P., Kuriyan J., Shokat K. M., JACS (2008), 130, 17568–17574 
Stavenger R. A., Cui H., Dowdell S. E., Franz R. G., Gaitanopoulos D. E., Goodman K. 
B., Hilfiker M. A., Ivy R. L., Leber J. D., Marino J. P. Jr., Oh H.-J., Viet A. Q., Xu 
W., Ye G., Zhang D., Zhao Y., Jolivette L. J., Head M. S., Semus S. F., Elkins P. A., 
Kirkpatrick R. B., Dul E., Khandekar S. S., Yi T., Jung D. K., Wright L. L., Smith 
G. K., Behm D. J., Doe C. P., Bentley R., Chen Z. X., Hu E., Lee D., J. Med. Chem. 
(2007), 50, 2–5 
Steichen J. M., Iyer G. H., Li S., Saldanha S. A., Deal M. S., Woods V. L. Jr, Taylor S. 
S., JBC (2010), 285, 3825–3832 
Tal-Gan Y., Freeman N. S., Klein S., Levitzki A., Gilon C., Bioorg. Med. Chem. 
(2010), 18, 2976–2985 
Tamura M., Nakao H., Yoshizaki H., Shiratsuchi M., Shigyo H., Yamada H., Ozawa T., 
Totsuka J., Hidaka H., Biochim. Biophys. Acta (2005), 1754, 245–252 
Tasken K., Aandahl E. M., Physiol. Rev. (2004), 84, 137–167 
Taylor M. S., Okwuchukwuasanya C., Nickl C. K., Tegge W., Brayden J. E., Dostmann 
W. R. G., Mol. Pharmacol. (2004), 65, 1111–1119 
Taylor S. S., Yang J., Wu J., Haste N. M., Radzio-Andzelm E., Anand G., Biochim. 
Biophys. Acta (2004), 1697, 259–269 
Taylor S. S., Kim C., Cheng C. Y., Brown S. H. J., Wu J., Kannan N., Biochim. 
Biophys. Acta (2008), 1784, 16–26 
Technikova-Dobrova Z., Sardanelli A. M., Papa S., FEBS (1991), 292, 69–72 
Tegge W., Frank R., Hofmann F., Dostmann W. R. G., Biochemistry (1995), 34, 
10569–10577 
Toker A., Mol. Cell (2008), 31, 6–8 
Tokushige H., Inatani M., Nemoto S., Sakaki H., Katayama K., Uehata M., Tanihara H., 
Invest. Ophthalmol. Vis. Sci. (2007), 48, 3216–3222 
Toral-Barza L., Zhang W. G., Huang X., McDonald L. A., Salaski E. J., Barbieri L. R., 
Ding W. D., Krishnamurthy G., Hu Y. B., Lucas J., Bernan V. S., Cai P., Levin J. I., 
Mansour T. S., Gibbons J. J., Abraham R. T., Yu K., Mol. Cancer Ther. (2007), 6, 
3028–3038 
Tsien R. Y., Baird G., Circularly permuted fluorescent protein indicators, United States 
Patent 7060793 (2006) 
Tsien R. Y., Angew. Chem. Int. Ed. (2009), 48, 5612–5626 
Uehata M., Ishizaki T., Satoh H., Ono T., Kawahara T., Morishita T., Tamakawa H., 
Yamagami K., Inui J., Maekawa M., Narumiya S., Nature (1997), 389, 990–994 
Uri A., Raidaru G., Subbi J., Padari K., Pooga M., Bioorg. Med. Chem. Lett. (2002), 12, 
2117–2120 
Uri A., Lust M., Vaasa A., Lavogina D., Viht K., Enkvist E., Biochim. Biophys. Acta. 
(2010), 1804, 541–546 
Vaandrager A. B., Hogema B. M., de Jonge H. R., Front. Biosci. (2005), 10, 2150–2164 
Vaasa A., Viil I., Enkvist E., Viht K., Raidaru G., Lavogina D., Uri A., Anal. Biochem. 
(2009), 385, 85–93 
Vaasa A., Lust M., Terrin A., Uri A., Zaccolo M., Biochem. Biophys. Res. Commun. 
(2010), 397, 750–775 
Vallone B., Miele A. E., Vecchini P., Chiancone E., Brunori M., PNAS USA (1998), 
95, 6103–6107 162 
Walsh D. A., Perkins J. P., Krebs E. G., J. Biol. Chem. (1968), 243, 3763–3765 
Wang H., Shimizu E., Tang Y. P., Cho M., Kyin M., Zuo W., Robinson D. A., Alaimo 
P. J., Zhang C., Morimoto H., Zhuo M., Feng R., Shokat K. M., Tsien J. Z. PNAS 
USA (2003), 100, 4287–4292 
Wang H., Li M., Lin W., Wang W., Zhang Z., Rayburn E. R., Lu J., Chen D., Yue X., 
Shen F., Jiang F., He J., Wei W., Zeng X., Zhang R., Cancer Epidemiol. Biomarkers 
Prev. (2007), 16, 789–795 
Wang H., Nakata E., Hamachi I., Chem. Bio. Chem. (2009), 10, 2560–2577 
Wang Q., Lawrence D. S., JACS (2005), 127, 7684–7685 
Ward N. E., O’Brian C. A., Biochemistry (1993), 32, 11903- 11909 
Warmuth, M., Kim, S., Gu, X. J., Xia, G. Adrian, F., Curr. Opin. Oncol. (2007), 19, 55–
60 
Watkins C. L., Schmaljohann D., Futaki S., Jones A. T., Biochem. J. (2009), 420, 179–
189 
Wei J.-Y., Cohen I. E. D., Genieser H.-G., Barnstable C.  J., J. Mol. Neurosci. (1998), 
10, 53–64  
Weisberg E., Manley P. W., Breitenstein W., Brüggen J., Cowan-Jacob S. W., Ray A., 
Huntly B., Fabbro D., Fendrich G., Hall-Meyers E., Kung A. L., Mestan J., Daley G. 
Q., Callahan L., Catley L., Cavazza C., Azam M., Neuberg D., Wright R. D., 
Gilliland D. G., Griffin J. D., Cancer Cell. (2005), 7, 129–141 
Wen W., Taylor S.S., Meinkoth J. L., JBC (1995), 270, 2041–2046 
Wen W., Liu W., Yan J., Zhang M., JBC (2008), 283, 26263–26273 
Vieth M., Erickson J., Wang J., Webster Y., Mader M., Higgs R., Watson I., J. Med. 
Chem. (2009), 52, 6456–6466 
Viht K., Padari K., Raidaru G., Subbi J., Tammiste I., Pooga M., Uri A., Bioorg. Med. 
Chem. Lett.  (2003), 13, 3035–3039 
Viht K., Vaasa A., Raidaru G., Enkvist E., Uri A., Anal. Biochem. (2005), 340, 165–
170 
Viht K., Schweinsberg S., Lust M., Vaasa A., Raidaru G., Lavogina D., Uri A., Herberg 
F. W., Anal. Biochem. (2007), 362, 268–277 
Virdee K., Yoshida H., Peak-Chew S., Goedert M., FEBS Lett. (2007), 581, 2657–2662 
Williamson J. R., Nat. Struct. Biol. (2000), 7, 834–837 
Wilson E. M., Chinkers M., Biochemistry (1995), 34, 4696–4701 
Wilson L. S., Elbatarny H. S., Crawley S. W., Bennett B. M., Maurice D. H., PNAS 
USA (2008), 105, 13650–13655 
Wissner A., Fraser H. L., Ingalls C. L., Dushin R. G., Floyd M. B., Cheung K., Nittoli 
T., Ravi M. R., Tan X., Loganzo F., Bioorg. Med. Chem. (2007), 15, 3635–3648 
Wlodarczyk J., Woehler A., Kobe F., Ponimaskin E., Zeug A., Neher E., Biophys. J. 
(2008), 94, 986–1000 
Wlodawer A., Minor W., Dauter Z., Jaskolski M., FEBS J. (2008), 275, 1–21 
Wolfenden R., Accounts Chem. Res. (1972), 5, 10–18 
Wood E. R., Truesdale A. T., McDonald O. B., Yuan D., Hassell A., Dickerson S. H., 
Ellis B., Pennisi C., Horne E., Lackey K., Alligood K. J., Rusnak D. W., Gilmer T. 
M., Shewchuk L., Cancer Res. (2004), 64, 6652–6659 
Wood J. S., Yan X., Mendelow M., Corbin J. D., Francis S. H., Lawrence D. S., JBC 
(1996), 271, 174–179 
Wooldridge A. A., MacDonald J. A., Erdodi F., Ma C., Borman M. A., Hartshorne D. 
J., Haystead T. A. J., JBC (2004), 279, 34496–34504 
Wu J., Brown S. H. J., von Daake S., Taylor S. S., 2007 VOL 318 Science, 274–279 
Wu Y., Xu J. C., Chin. Chem. Lett. (2000), 11, 771–774 163 
Xu Z., Nagashima K., Sun D., Rush T., Northrup A., Andersen J. N., Kariv I., Bobkova 
E. V., J. Biomol. Screen. (2009), 14, 1257–1262 
Yamaguchi H., Kasa M., Amano M., Kaibuchi K., Hakoshima T., Structure (2006a), 14, 
589–600 
Yamaguchi H., Miwa Y., Kasa M., Kitano K., Amano M., Kaibuchi K., Hakoshima T., 
J. Biochem. (2006b), 140, 305–311 
Yan B., Acc. Chem. Res. (1998), 31, 621–630 
Yang J., Cron P., Good V. M., Thompson V., Hemmings B. A., Barford D., Nat. Struct. 
Biol. (2002), 9, 940–944 
Yang J., Ten Eyck L. F., Xuong N.-H., Taylor S. S., J. Mol. Biol. (2004), 336, 473–487 
Yang J., Kennedy E. J., Wu J., Deal M. S., Pennypacker J., Ghosh G., Taylor S. S., JBC 
(2009), 284, 6241–6248. 
Yang L., Dan H. C., Sun M., Liu Q., Sun X.-M., Feldman R. I., Hamilton A. D., 
Polokoff M., Nicosia S. V., Herlyn M., Sebti S. M., Cheng J. Q., Cancer Res. 
(2004), 64, 4394–4399 
Zaccolo M., Magalhães P., Pozzan T., Curr. Opin. Cell Biol. (2002), 14, 160–166 
Zhang H. H., Lipovsky A. I., Dibble C. C., Sahin M., Manning B. D., Mol. Cell. (2006), 
24, 185–197 
Zhang J., Yang P. L., Gray N. S., Nature Rev. Cancer (2009), 9, 28–39 
Zhang X., Crespo A., Fernández A., Trends Biotechnol. (2008), 26, 295–301 
Zhao Z., Leister W. H., Robinson R. G., Barnett S. F., Defeo-Jones D., Jones R. E., 
Hartman G. D., Huff J. R., Huber H. E., Duggan M. E., Lindsley C. W., Bioorg. 
Med. Chem. Lett. (2005), 15, 905–909 
Zhong H., SuYang H., Erdjument-Bromage H., Tempst P., Ghosh S., Cell (1997), 89, 
413–424 
Zhou J., Adams J. A., Biochemistry (1997), 36, 15733–15738 
Zhou W., Ercan D., Chen L., Yun C.-H., Li D., Capelletti M., Cortot A. B., Chirieac L., 
Iacob R. E., Padera R., Engen J. R., Wong K.-K., Eck M. J., Gray N. S., Jänne P. A., 
Nature (2009), 462, 1070–1074 
Zhu G.-D., Gong J., Gandhi V. B., Woods K., Luo Y., Liu X., Guan R., Klinghofer V., 
Johnson E. F., Stoll V. S., Mamo M., Li Q., Rosenberg S. H., Giranda V. L., Bioorg. 
Med. Chem. (2007), 15, 2441–2452 
Zoller M. J., Nelson N. C., Taylor S. S., JBC (1981), 256, 10837–10842 164 
APPENDICES 
Appendix 1. Selectivity profiling of ARC-902, ARC-903, ARC-1028 
and ARC-664 
 
 
 
Data integrated from Enkvist et al., 2006; Enkvist et al., 2009; Lavogina et al., 
2009 165 
ACKNOWLEDGEMENTS 
 
The support from the following institutions and organizations is gratefully 
acknowledged: 
  Research group of Dr. Asko Uri, Chair of Bioorganic Chemistry, Institute of 
Chemistry, University of Tartu, Tartu, Estonia; 
  Research group of Dr. Ago Rinken, Chair of Bioorganic Chemistry, Institute 
of Chemistry, University of Tartu, Tartu, Estonia; 
  Research group of Dr. Dirk Bossemeyer, Research Group Structural Bio-
chemistry, DKFZ, Heidelberg, Germany; 
  Research group of Dr. Wolfgang R. Dostmann, Department of Pharma-
cology, College of Medicine, University of Vermont, Burlington VT, USA; 
  Research group of Dr. Richard Engh, Department of Chemistry, Faculty of 
Science, University of Tromsø, Tromsø, Norway 
  Graduate school “Functional materials and processes” recieving funding 
from the European Social Fund under project 1.2.0401.09-0079 in Estonia; 
  Kristjan Jaagu stipendiumid, Sihtasutus Archimedes, Tallinn, Estonia; 
  Programme “DoRa”, Sihtasutus Archimedes, Tallinn, Estonia. 
  
42 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
PUBLICATIONS CURRICULUM VITAE 
 
General data 
 
Name:   Darja Lavõgina 
Born:  May 31, 1986, Tartu, Estonia 
Citizenship: Estonian 
Address:   University of Tartu, Institute of Chemistry, 14A Ravila St., 
50411 Tartu, Estonia  
E-mail: darja.lavogina@ut.ee 
 
 
Education 
 
2007–...   University of Tartu, Institute of Chemistry, PhD student   
2006–2007   University of Tartu, Faculty of Physics and Chemistry,  
MSc student   
2003–2006   University of Tartu, Faculty of Physics and Chemistry,  
BSc student   
 
Professional employment 
 
2007–2009   University of Tartu, Faculty of Science and Technology, Institute 
of Chemistry, Tartu University, Chair of Bioorganic Chemistry; 
Extraordinary Researcher (0.20)   
2008–2008   University of Tartu, Faculty of Science and Technology, Dean’s 
Office, Materjaliteaduse ja materjalide tehnoloogia doktorikool; 
Extraordinary Researcher (0.08) 
 
 
Professional self-improvement 
 
2006–2007  Research Group Structural Biochemistry, DKFZ, Heidelberg, 
Germany (4 months) 
2009  Department of Pharmacology, College of Medicine,  
University of Vermont, Burlington VT, USA (3 months) 
2010   Sexual Medicine and Andrology Unit, Department of Clinical 
Physiopathology, University of Florence, Florence, Italy  
(2 weeks) 
2010   Institute of Bioscience, Department of Physiology,  
University of São Paulo, São Paulo, Brazil (2 months)   
  
   
 
 
239  
Scientific publications 
 
Pflug A., Rogozina J., Lavogina D., Enkvist E., Uri A., Engh R. A., Bosse-
meyer D., Diversity of bisubstrate binding modes of adenosine analogue-
oligoarginine conjugates in protein kinase A and implications for protein 
substrate interactions. Journal of Molecular Biology (2010), doi: 10.1016/ 
j.jmb.2010.08.028 
Lavogina D., Nickl C. K., Enkvist E., Raidaru G., Lust M., Vaasa A., Uri A., 
Dostmann W. R., Adenosine analogue-oligo-arginine conjugates (ARCs) 
serve as high-affinity inhibitors and fluorescence probes of type I cGMP-
dependent protein kinase (PKGIalpha). Biochimica et Biophysica Acta-
Proteins and Proteomics (2010), 1804, 1857–1868 
Uri A., Lust M., Vaasa A., Lavogina D., Viht K., Enkvist E., Bisubstrate 
fluorescent probes and biosensors in binding assays for HTS of protein 
kinase inhibitors. Biochimica et Biophysica Acta (2010), 1804, 541–546 
Lavogina D., Enkvist E., Uri A., Bisubstrate Inhibitors of Protein Kinases: from 
Principle to Practical Applications. ChemMedChem (2010), 5, 23–34 
Lavogina D., Lust M., Viil I., König N., Raidaru G., Rogozina J., Enkvist E., 
Uri A., Bossemeyer D., Structural Analysis of ARC-Type Inhibitor (ARC-
1034) Binding to Protein Kinase A Catalytic Subunit and Rational Design of 
Bisubstrate Analogue Inhibitors of Basophilic Protein Kinases. Journal of 
Medicinal Chemistry (2009), 52, 308–321 
Vaasa A., Viil I., Enkvist E., Viht K., Raidaru G., Lavogina D., Uri A., High-
affinity bisubstrate probe for fluorescence anisotropy binding/displacement 
assays with protein kinases PKA and ROCK. Analytical Biochemistry 
(2009), 385, 85–93 
Enkvist E., Raidaru G., Vaasa A., Pehk T., Lavogina D., Uri A., Carbocyclic 
3′-deoxyadenosine-based highly potent bisubstrate-analog inhibitor of ba-
sophilic protein kinases. Bioorganic & Medicinal Chemistry Letters (2007), 
17, 5336–5339 
Viht K., Schweinsberg S., Lust M., Vaasa A., Raidaru G., Lavogina D., Uri A., 
Herberg F., Surface-plasmon-resonance-based biosensor with immobilized 
bisubstrate analog inhibitor for the determination of affinities of ATP- and 
protein-competitive ligands of cAMP-dependent protein kinase. Analytical 
Biochemistry (2007), 362, 268–277 
Enkvist E., Lavogina D., Raidaru G., Vaasa A., Viil I., Lust M., Viht K., Uri 
A., Conjugation of adenosine and hexa-(D-arginine) leads to a nanomolar 
bisubstrate-analog inhibitor of basophilic protein kinases. Journal of Medi-
cinal Chemistry (2006), 49, 7150–7159 
 
 
240 
ELULOOKIRJELDUS 
 
Üldandmed 
 
Nimi:   Darja Lavõgina 
Sünniaeg ja koht:   31. mai 1986, Tartu, Eesti 
Kodakondsus:   Eesti 
Aadress:   Tartu Ülikool, Keemia Instituut, Ravila 14A, Tartu 50411, 
Eesti 
E-mail: darja.lavogina@ut.ee 
 
 
Haridus 
 
2007–...   Tartu Ülikool, Keemia Instituut, Doktoriõpe 
2006–2007   Tartu Ülikool, Füüsika-keemiateaduskond, keemia eriala, 
Magistriõpe 
2003–2006   Tartu Ülikool, Füüsika-keemiateaduskond, keemia eriala, 
Bakalaureuseõpe 
 
 
Teenistuskäik 
 
2007–2009   Tartu Ülikool, Loodus- ja tehnoloogiateaduskond, Tartu 
Ülikooli Keemia Instituut, Bioorgaanilise keemia õppetool; 
Erakorraline teadur (0.20) 
2008–2008   Tartu Ülikool, Loodus- ja tehnoloogiateaduskond, Loodus- ja 
tehnoloogiateaduskonna dekanaat, Materjaliteaduse ja 
materjalide tehnoloogia doktorikool; Erakorraline teadur (0.08) 
 
 
Erialane enesetäiendus 
 
2006–2007  Research Group Structural Biochemistry, DKFZ, Heidelberg, 
Saksamaa (4 kuud) 
2009  Department of Pharmacology, College of Medicine, University 
of Vermont, Burlington VT, USA (3 kuud) 
2010   Sexual Medicine and Andrology Unit, Department of Clinical 
Physiopathology, University of Florence, Firenze, Itaalia  
(2 nädalat) 
2010   Institute of Bioscience, Department of Physiology, University 
of São Paulo, São Paulo, Brasiilia (2 kuud)       
 
 
241
61 
Teaduspublikatsioonid 
 
Pflug A., Rogozina J., Lavogina D., Enkvist E., Uri A., Engh R. A., Bosse-
meyer D., Diversity of bisubstrate binding modes of adenosine analogue-
oligoarginine conjugates in protein kinase A and implications for protein 
substrate interactions. Journal of Molecular Biology (2010), doi: 10.1016/ 
j.jmb.2010.08.028 
Lavogina D., Nickl C. K., Enkvist E., Raidaru G., Lust M., Vaasa A., Uri A., 
Dostmann W. R., Adenosine analogue-oligo-arginine conjugates (ARCs) 
serve as high-affinity inhibitors and fluorescence probes of type I cGMP-
dependent protein kinase (PKGIalpha). Biochimica et Biophysica Acta-
Proteins and Proteomics (2010), 1804, 1857–1868 
Uri A., Lust M., Vaasa A., Lavogina D., Viht K., Enkvist E., Bisubstrate 
fluorescent probes and biosensors in binding assays for HTS of protein 
kinase inhibitors. Biochimica et Biophysica Acta (2010), 1804, 541–546 
Lavogina D., Enkvist E., Uri A., Bisubstrate Inhibitors of Protein Kinases: from 
Principle to Practical Applications. ChemMedChem (2010), 5, 23–34 
Lavogina D., Lust M., Viil I., König N., Raidaru G., Rogozina J., Enkvist E., 
Uri A., Bossemeyer D., Structural Analysis of ARC-Type Inhibitor (ARC-
1034) Binding to Protein Kinase A Catalytic Subunit and Rational Design of 
Bisubstrate Analogue Inhibitors of Basophilic Protein Kinases. Journal of 
Medicinal Chemistry (2009), 52, 308–321 
Vaasa A., Viil I., Enkvist E., Viht K., Raidaru G., Lavogina D., Uri A., High-
affinity bisubstrate probe for fluorescence anisotropy binding/displacement 
assays with protein kinases PKA and ROCK. Analytical Biochemistry 
(2009), 385, 85–93 
Enkvist E., Raidaru G., Vaasa A., Pehk T., Lavogina D., Uri A., Carbocyclic 
3′-deoxyadenosine-based highly potent bisubstrate-analog inhibitor of baso-
philic protein kinases. Bioorganic & Medicinal Chemistry Letters (2007), 
17, 5336–5339 
Viht K., Schweinsberg S., Lust M., Vaasa A., Raidaru G., Lavogina D., Uri A., 
Herberg F., Surface-plasmon-resonance-based biosensor with immobilized 
bisubstrate analog inhibitor for the determination of affinities of ATP- and 
protein-competitive ligands of cAMP-dependent protein kinase. Analytical 
Biochemistry (2007), 362, 268–277 
Enkvist E., Lavogina D., Raidaru G., Vaasa A., Viil I., Lust M., Viht K., Uri 
A., Conjugation of adenosine and hexa-(D-arginine) leads to a nanomolar 
bisubstrate-analog inhibitor of basophilic protein kinases. Journal of Medi-
cinal Chemistry (2006), 49, 7150–7159 
 
 
242DISSERTATIONES CHIMICAE 
UNIVERSITATIS TARTUENSIS 
 
 
1.  Toomas Tamm. Quantum-chemical simulation of solvent effects. Tartu, 
1993, 110 p. 
2.  Peeter Burk. Theoretical study of gas-phase acid-base equilibria. Tartu, 
1994, 96 p. 
3.  Victor Lobanov. Quantitative structure-property relationships in large 
descriptor spaces. Tartu, 1995, 135 p. 
4.  Vahur Mäemets. The 
17O and 
1H nuclear magnetic resonance study of 
H2O in individual solvents and its charged clusters in aqueous solutions of 
electrolytes. Tartu, 1997, 140 p. 
5.   Andrus Metsala. Microcanonical rate constant in nonequilibrium distribu-
tion of vibrational energy and in restricted intramolecular vibrational 
energy redistribution on the basis of slater’s theory of unimolecular re-
actions. Tartu, 1997, 150 p. 
6.  Uko Maran. Quantum-mechanical study of potential energy surfaces in 
different environments. Tartu, 1997, 137 p. 
7.  Alar Jänes. Adsorption of organic compounds on antimony, bismuth and 
cadmium electrodes. Tartu, 1998, 219 p. 
8.  Kaido Tammeveski. Oxygen electroreduction on thin platinum films and 
the electrochemical detection of superoxide anion. Tartu, 1998, 139 p. 
9.  Ivo Leito. Studies of Brønsted acid-base equilibria in water and non-
aqueous media. Tartu, 1998, 101 p. 
10.  Jaan Leis. Conformational dynamics and equilibria in amides. Tartu, 
1998, 131 p. 
11.  Toonika Rinken. The modelling of amperometric biosensors based on oxi-
doreductases. Tartu, 2000, 108 p. 
12.  Dmitri Panov. Partially solvated Grignard reagents. Tartu, 2000, 64 p.  
13.  Kaja Orupõld. Treatment and analysis of phenolic wastewater with micro-
organisms. Tartu, 2000, 123 p. 
14.  Jüri Ivask. Ion Chromatographic determination of major anions and 
cations in polar ice core. Tartu, 2000, 85 p. 
15.  Lauri Vares.  Stereoselective Synthesis of Tetrahydrofuran and Tetra-
hydropyran Derivatives by Use of Asymmetric Horner-Wadsworth-Em-
mons and Ring Closure Reactions. Tartu, 2000, 184 p.  
16.  Martin Lepiku. Kinetic aspects of dopamine D2 receptor interactions with 
specific ligands. Tartu, 2000, 81 p. 
17.  Katrin Sak. Some aspects of ligand specificity of P2Y receptors. Tartu, 
2000, 106 p. 
18.  Vello Pällin. The role of solvation in the formation of iotsitch complexes. 
Tartu, 2001, 95 p. 
243 19.  Katrin Kollist. Interactions between polycyclic aromatic compounds and 
humic substances. Tartu, 2001, 93 p. 
20.  Ivar Koppel. Quantum chemical study of acidity of strong and superstrong 
Brønsted acids. Tartu, 2001, 104 p. 
21.  Viljar Pihl. The study of the substituent and solvent effects on the acidity 
of OH and CH acids. Tartu, 2001, 132 p. 
22.  Natalia Palm. Specification of the minimum, sufficient and significant set 
of descriptors for general description of solvent effects. Tartu, 2001, 134 p. 
23.  Sulev Sild. QSPR/QSAR approaches for complex molecular systems. 
Tartu, 2001, 134 p. 
24.  Ruslan Petrukhin. Industrial applications of the quantitative structure-
property relationships. Tartu, 2001, 162 p. 
25.  Boris V. Rogovoy. Synthesis of (benzotriazolyl)carboximidamides and their 
application in relations with N- and S-nucleophyles. Tartu, 2002, 84 p. 
26.  Koit Herodes. Solvent effects on UV-vis absorption spectra of some 
solvatochromic substances in binary solvent mixtures: the preferential 
solvation model. Tartu, 2002, 102 p. 
27.  Anti Perkson. Synthesis and characterisation of nanostructured carbon. 
Tartu, 2002, 152 p. 
28.  Ivari Kaljurand. Self-consistent acidity scales of neutral and cationic 
Brønsted acids in acetonitrile and tetrahydrofuran. Tartu, 2003, 108 p. 
29.  Karmen Lust. Adsorption of anions on bismuth single crystal electrodes. 
Tartu, 2003, 128 p. 
30.  Mare Piirsalu. Substituent, temperature and solvent effects on the alkaline 
hydrolysis of substituted phenyl and alkyl esters of benzoic acid. Tartu, 
2003, 156 p. 
31.  Meeri Sassian. Reactions of partially solvated Grignard reagents. Tartu, 
2003, 78 p. 
32.  Tarmo Tamm. Quantum chemical modelling of polypyrrole. Tartu, 2003. 
100 p. 
33.  Erik Teinemaa. The environmental fate of the particulate matter and 
organic pollutants from an oil shale power plant. Tartu, 2003. 102 p. 
34.  Jaana Tammiku-Taul. Quantum chemical study of the properties of 
Grignard reagents. Tartu, 2003. 120 p. 
35.  Andre Lomaka. Biomedical applications of predictive computational   
chemistry. Tartu, 2003. 132 p. 
36.  Kostyantyn Kirichenko. Benzotriazole — Mediated Carbon–Carbon 
Bond Formation. Tartu, 2003. 132 p. 
37.  Gunnar Nurk. Adsorption kinetics of some organic compounds on bis-
muth single crystal electrodes. Tartu, 2003, 170 p. 
38.  Mati Arulepp. Electrochemical characteristics of porous carbon materials 
and electrical double layer capacitors. Tartu, 2003, 196 p. 
244 39.  Dan Cornel Fara. QSPR modeling of complexation and distribution of 
organic compounds. Tartu, 2004, 126 p. 
40.  Riina Mahlapuu. Signalling of galanin and amyloid precursor protein 
through adenylate cyclase. Tartu, 2004, 124 p. 
41.  Mihkel Kerikmäe. Some luminescent materials for dosimetric applications 
and physical research. Tartu, 2004, 143 p. 
42.  Jaanus Kruusma. Determination of some important trace metal ions in 
human blood. Tartu, 2004, 115 p. 
43.  Urmas Johanson. Investigations of the electrochemical properties of poly-
pyrrole modified electrodes. Tartu, 2004, 91 p. 
44.  Kaido Sillar. Computational study of the acid sites in zeolite ZSM-5. 
Tartu, 2004, 80 p. 
45.  Aldo Oras. Kinetic aspects of dATPS interaction with P2Y1 receptor. 
Tartu, 2004, 75 p. 
46.  Erik Mölder. Measurement of the oxygen mass transfer through the air-
water interface. Tartu, 2005, 73 p.  
47.  Thomas Thomberg. The kinetics of electroreduction of peroxodisulfate 
anion on cadmium (0001) single crystal electrode. Tartu, 2005, 95 p. 
48.  Olavi Loog. Aspects of condensations of carbonyl compounds and their 
imine analogues. Tartu, 2005, 83 p.  
49.  Siim Salmar. Effect of ultrasound on ester hydrolysis in aqueous ethanol. 
Tartu, 2006, 73 p.  
50.  Ain Uustare. Modulation of signal transduction of heptahelical receptors 
by other receptors and G proteins. Tartu, 2006, 121 p. 
51.  Sergei Yurchenko. Determination of some carcinogenic contaminants in 
food. Tartu, 2006, 143 p.  
52.  Kaido Tämm. QSPR modeling of some properties of organic compounds. 
Tartu, 2006, 67 p.  
53.  Olga Tšubrik. New methods in the synthesis of multisubstituted hydra-
zines. Tartu. 2006, 183 p.  
54.  Lilli Sooväli. Spectrophotometric measurements and their uncertainty in 
chemical analysis and dissociation constant measurements. Tartu, 2006,   
125 p. 
55.  Eve Koort. Uncertainty estimation of potentiometrically measured ph and 
pKa values. Tartu, 2006, 139 p.  
56.  Sergei Kopanchuk. Regulation of ligand binding to melanocortin receptor 
subtypes. Tartu, 2006, 119 p.  
57.  Silvar Kallip. Surface structure of some bismuth and antimony single 
crystal electrodes. Tartu, 2006, 107 p. 
58.  Kristjan Saal. Surface silanization and its application in biomolecule 
coupling. Tartu, 2006, 77 p. 
59.  Tanel Tätte. High viscosity Sn(OBu)4 oligomeric concentrates and their 
applications in technology. Tartu, 2006, 91 p. 
245 
6260.  Dimitar Atanasov Dobchev. Robust QSAR methods for the prediction of 
properties from molecular structure. Tartu, 2006, 118 p.  
61.  Hannes Hagu. Impact of ultrasound on hydrophobic interactions in 
solutions. Tartu, 2007, 81 p. 
62.  Rutha Jäger. Electroreduction of peroxodisulfate anion on bismuth 
electrodes. Tartu, 2007, 142 p. 
63.  Kaido Viht. Immobilizable bisubstrate-analogue inhibitors of basophilic 
protein kinases: development and application in biosensors. Tartu, 2007, 
88 p. 
64.  Eva-Ingrid Rõõm. Acid-base equilibria in nonpolar media. Tartu, 2007, 
156 p. 
65.  Sven Tamp. DFT study of the cesium cation containing complexes relevant 
to the cesium cation binding by the humic acids. Tartu, 2007, 102 p. 
66.  Jaak Nerut. Electroreduction of hexacyanoferrate(III) anion on Cadmium 
(0001) single crystal electrode. Tartu, 2007, 180 p.  
67.  Lauri Jalukse. Measurement uncertainty estimation in amperometric 
dissolved oxygen concentration measurement. Tartu, 2007, 112 p. 
68.  Aime Lust. Charge state of dopants and ordered clusters formation in 
CaF2:Mn and CaF2:Eu luminophors. Tartu, 2007, 100 p. 
69.  Iiris Kahn. Quantitative Structure-Activity Relationships of environ-
mentally relevant properties. Tartu, 2007, 98 p. 
70.  Mari Reinik. Nitrates, nitrites, N-nitrosamines and polycyclic aromatic 
hydrocarbons in food: analytical methods, occurrence and dietary intake. 
Tartu, 2007, 172 p. 
71.  Heili Kasuk. Thermodynamic parameters and adsorption kinetics of orga-
nic compounds forming the compact adsorption layer at Bi single crystal 
electrodes. Tartu, 2007, 212 p. 
72.  Erki Enkvist. Synthesis of adenosine-peptide conjugates for biological 
applications. Tartu, 2007, 114 p.  
73.  Svetoslav Hristov Slavov. Biomedical applications of the QSAR ap-
proach. Tartu, 2007, 146 p. 
74.  Eneli Härk. Electroreduction of complex cations on electrochemically 
polished Bi(hkl) single crystal electrodes. Tartu, 2008, 158 p.  
75.  Priit Möller. Electrochemical characteristics of some cathodes for medium 
temperature solid oxide fuel cells, synthesized by solid state reaction 
technique. Tartu, 2008, 90 p.  
76.  Signe Viggor. Impact of biochemical parameters of genetically different 
pseudomonads at the degradation of phenolic compounds. Tartu, 2008, 122 p. 
77.  Ave Sarapuu. Electrochemical reduction of oxygen on quinone-modified 
carbon electrodes and on thin films of platinum and gold. Tartu, 2008,  
134 p.  
78.  Agnes Kütt. Studies of acid-base equilibria in non-aqueous media. Tartu, 
2008, 198 p.  
246 79.  Rouvim Kadis. Evaluation of measurement uncertainty in analytical che-
mistry: related concepts and some points of misinterpretation. Tartu, 2008, 
118 p. 
80.  Valter Reedo. Elaboration of IVB group metal oxide structures and their 
possible applications. Tartu, 2008, 98 p. 
81.  Aleksei Kuznetsov. Allosteric effects in reactions catalyzed by the cAMP-
dependent protein kinase catalytic subunit. Tartu, 2009, 133 p. 
82.  Aleksei Bredihhin. Use of mono- and polyanions in the synthesis of 
multisubstituted hydrazine derivatives. Tartu, 2009, 105 p. 
83.  Anu Ploom. Quantitative structure-reactivity analysis in organosilicon 
chemistry. Tartu, 2009, 99 p.  
84. Argo  Vonk.  Determination of adenosine A2A- and dopamine D1 receptor-
specific modulation of adenylate cyclase activity in rat striatum. Tartu, 
2009, 129 p. 
85.  Indrek Kivi. Synthesis and electrochemical characterization of porous 
cathode materials for intermediate temperature solid oxide fuel cells. Tartu, 
2009, 177 p.  
86.  Jaanus Eskusson. Synthesis and characterisation of diamond-like carbon 
thin films prepared by pulsed laser deposition method. Tartu, 2009, 117 p. 
87.  Margo Lätt. Carbide derived microporous carbon and electrical double 
layer capacitors. Tartu, 2009, 107 p. 
88.   Vladimir Stepanov. Slow conformational changes in dopamine transporter 
interaction with its ligands. Tartu, 2009, 103 p.  
89.  Aleksander Trummal. Computational Study of Structural and Solvent 
Effects on Acidities of Some Brønsted Acids. Tartu, 2009, 103 p. 
90.  Eerold Vellemäe. Applications of mischmetal in organic synthesis. Tartu, 
2009, 93 p. 
91.  Sven Parkel. Ligand binding to 5-HT1A receptors and its regulation by 
Mg
2+ and Mn
2+. Tartu, 2010, 99 p. 
92. Signe Vahur. Expanding the possibilities of ATR-FT-IR spectroscopy in 
determination of inorganic pigments. Tartu, 2010, 184 p. 
93.   Tavo Romann. Preparation and surface modification of bismuth thin film, 
porous, and microelectrodes. Tartu, 2010, 155 p. 
94.  Nadežda Aleksejeva. Electrocatalytic reduction of oxygen on carbon 
nanotube-based nanocomposite materials. Tartu, 2010, 147 p.  
95.  Marko Kullapere. Electrochemical properties of glassy carbon, nickel and 
gold electrodes modified with aryl groups. Tartu, 2010,  233 p. 
96.  Liis Siinor. Adsorption kinetics of ions at Bi single crystal planes from 
aqueous electrolyte solutions and room-temperature ionic liquids. Tartu, 
2010, 101 p. 
97.   Angela Vaasa. Development of fluorescence-based kinetic and binding 
assays for characterization of protein kinases and their inhibitors. Tartu 
2010, 101 p. 
247  
98.  Indrek Tulp. Multivariate analysis of chemical and biological properties. 
Tartu 2010, 105 p. 
99.  Evaluation of environmental quality in Northern Estonia by 
the analysis of leachate. Tartu 2010, 117 p. 
 
 
 
 
 
 
 
 
 
 
 Aare Selberg. 
248